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Head and neck squamous - cell carcinoma (HNSCC) is a disease marked by its aggressiveness 
and likelihood of recurrence. The most prominent risk factors include longstanding alcohol 
and tobacco consumption and chronic infection with human papilloma virus (HPV). 
Radiotherapy, often combined with platinum - based chemotherapeutics, is considered 
to be the standard care for treating HNSCC. Primary care for HNSCC includes radiotherapy, 
as it has been shown to have a high efficacy as well as being a preferable option for 
organ conservation [1]. Unfortunately, the efficacy of radiotherapy is strongly attenuated 
by the presence of low oxygen (hypoxia) within tumour tissue. Hypoxia can arise due 
to an imbalance between oxygen supply and demand, caused by an altered tumour 
metabolism, as well as aberrant tumour vasculature or poor vessel perfusion [2]. Tumour 
hypoxia contributes to radioresistance, primarily due to decreased radiation - induced 
DNA damage in the absence of oxygen [3 - 5]. HPV positive tumours, which represent an 
increasing subset of HNSCC, display marked radiosensitivity compared to HPV negative 
tumours. This is reflected in the patient population, as HPV positive HNSCC patients have 
a 3 - year survival rate of 82.4% as compared to 57.1% in HPV negative patients [6].
Hypoxia detection and patient stratification
In order to therapeutically exploit tumour hypoxia, overcome hypoxia - related radiation 
resistance, or select patients for hypoxia - modifying therapy, feasible and reliable methods 
of detection of clinically relevant tumour hypoxia are required. Approaches to detect 
tumour hypoxia in the clinic have historically included methods such as polarographic 
needle electrodes, measurement of endogenous or exogenous hypoxia tissue markers, 
and hypoxia imaging [7]. Needle electrode measurements using oxygen probes provide 
a direct approach to detect oxygen partial pressure within the tumour, and have been 
shown to be prognostic in HNSCC [8]. However, as the use of needle electrodes is an 
invasive procedure, they are limited to accessible tumours [9]. In the clinical setting, this 
approach is also limited by methodological issues such as poor spatial resolution, oxygen 
consumption by the microelectrodes and biological heterogeneity of oxygenation 
within tumours. A solution to this is the use of hypoxia markers in biopsies or surgical 
material, obtained from the primary tumour or distant metastases. The most commonly 
investigated endogenous hypoxia markers include hypoxia inducible factor 1α (HIF - 1α), 
glucose transporter 1 (GLUT - 1), carbonic anhydrase IX (CAIX), vascular endothelial growth 
factor (VEGF), and the serological marker, osteopontin (OPN). HIF - 1α overexpression has 
been associated with poor prognosis, advanced disease, an aggressive cancer phenotype 
and poor response to radiotherapy in a number of malignancies, including HNSCC [10]. 
There is clear clinical utility to using hypoxia - related proteins such as CAIX or HIF - 1α as 
surrogate markers of tumour hypoxia as they can be easily detected in tissue samples, 
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have low assay costs, offer the potential of marker co - detection and the possibility of 
repeatedly detecting and monitoring biomarkers when samples are available. Extrinsic 
markers of hypoxia such as EF5 and pimonidazole are non - physiologic substances that 
are injected into the body where they accumulate under hypoxic conditions as a result of 
chemical reduction and covalent binding to macromolecules. EF5 and pimonidazole offer 
high spatial resolution, delineating hypoxia from anoxia/necrotic areas in which exogenous 
hypoxia markers do not accumulate, and were shown to be of prognostic value in patients 
with HNSCC [11, 12]. While these hypoxia tissue markers, with the exception of serological 
OPN, provide an excellent spatial resolution as well as information on the chronic or acute 
state of hypoxia, markers such as OPN and CAIX are not entirely hypoxia - specific and are 
subject to the influence of other components of the tumour microenvironment including 
local acidity and the immune infiltrate [13]. Hypoxia - related gene signatures have also 
been developed, which consist of a number of genes that are significantly up - regulated 
in response to hypoxia. Evidence for the prognostic and predictive value of specific 
hypoxic gene signatures is increasing [14 - 16]. These data demonstrated inferior clinical 
outcome in 323 HNSCC patients whose tumours were classified hypoxic according to 
a 15 - gene hypoxia classifier previously determined in human squamous cell carcinoma 
xenograft tumours [17]. This was later evaluated using alternative gene signatures in an 
independent HNSCC patient cohort (n=302) and showed a prognostic impact of all three of 
the signatures tested and a successful discrimination of patients with low and high tumour 
hypoxia [18]. Interestingly, the clinical outcome of patients with hypoxic tumours could 
be improved by the addition of the hypoxia modifier, nimorazole, in patients classified 
according to hypoxic gene signatures [17]. As both oxygen electrode measurements and 
tissue/blood - based hypoxia markers only inform on tumour oxygenation at a specific 
time point, they require repeated readings or biopsies in order to monitor tumour 
oxygenation throughout treatment. Thus, non - invasive approaches such as PET imaging 
with exogenous or endogenous hypoxia tracers are more realistic methods for clinical 
practice [19]. PET, using the hypoxic tracer 18fluoromisonidazole (18F - MISO), has been shown 
to be a feasible and reproducible approach for visualising tumour hypoxia, offering a high 
correlation with tumour oxygenation in many types of human cancers including HNSCC 
[20 - 23]. Moreover, 18F - MISO - PET was able to identify HNSCC patients who benefitted 
from additional treatment with the hypoxia - activated cytotoxin, tirapazamine (TPZ), and 
successfully predicted the risk for tumour recurrence after radiotherapy [24]. Recently, 
18F - MISO - PET was used to detect tumour hypoxia during radiotherapy of HNSCC and this 
subsequently identified patients at high risk for local recurrence [25]. Other imaging - based 
methods for hypoxia detection include visualisation through SPECT - CT with the use of 
radioactive tracers, consisting of a 111In/89Zr labelled antibody directed against endogenous 
hypoxic markers such as CAIX [26]. While showing promising in vitro and in vivo data, the 




Advances in modifying and targeting tumour hypoxia in HNSCC
Through technological advances in radiation oncology, specifically the implementation of 
new treatment strategies for HNSCC such as intensity - modulated or volumetric - modulated 
arc radiotherapy, treatment - related toxicity has been significantly reduced and further 
reduction may come from the introduction of proton therapy [27 - 29]. Treatment 
modification such as addition of concomitant chemotherapy and the use of altered 
fractionation regimes (i.e. hyperfractionation), has improved clinical outcome and tumour 
control significantly in patients with locally advanced HNSCC [30]. Moreover, the integration 
of biological targeted therapy such as EGFR - inhibition (cetuximab) and the use of hypoxic 
cell radiosensitisers in selected patients further increased overall survival and locoregional 
tumour control [17, 31]. Strategies to target and modify hypoxia - mediated radiation 
resistance include hyperbaric oxygenation, the use of bioreductive compounds such 
as TPZ and accelerated radiotherapy with carbogen and nicotinamide [24, 32]. Evidence 
shows a clinical impact of hypoxic modification on therapeutic outcome, pre - dominantly 
on (loco-) regional tumour control and disease - free survival [33, 34]. Hypoxia offers an 
opportunity to target and exploit tumour biology in the treatment of cancer. The principle 
behind hypoxia - activated prodrugs (HAP), which include N - oxides, metal complexes, nitro 
compounds and quinones, is that these inactive prodrugs undergo enzymatic reduction 
at low oxygen concentrations leading to the generation of cytotoxic species selectively in 
hypoxic cells [35 - 37]. TPZ, which is an aromatic N - oxide HAP, showed favourable tumour 
control and increased failure - free overall survival when added to primary radiotherapy 
of locally advanced HNSCC, although there was evidence of augmented hematologic 
toxicity in hypoxic tumours [24, 38, 39]. Late phase clinical trials failed to demonstrate a 
significant survival benefit when TPZ was combined with radiotherapy and cisplatin for 
HNSCC thereby highlighting the necessity of patient stratification for hypoxia modulating 
therapies [40]. Among the nitro - based HAPs, nimorazole can be regarded as the only 
hypoxic radiosensitiser that has been translated into clinical practice. The results of a 
large phase III clinical trial of the Danish Head - And - Neck Cancer Study Group (DAHANCA) 
demonstrated significantly improved loco - regional tumour control at 4 years (49% with 
vs 33% without nimorazole, p=0.002) and reduced cancer - related deaths (52% vs 41%, 
p=0.002), and lead to the implementation of nimorazole as the standard of care in Danish 
HNSCC cases [41]. Currently, a multicentre phase III trial (NIMRAD) is accruing patients to 
confirm the DAHANCA findings (NCT01950689). Related strategies in this field include the 
development of DNA - targeting HAP such as TH - 302 and PR - 104, which induce cell death 
through DNA crosslinking [37, 42, 43]. Despite promising data on TH - 302 in combination 
with radiotherapy in other cancer types, preclinical data using HNSCC cells as tumour 
xenografts showed these cells were resistant to TH - 302 alone and in combination with 
radiation [44]. Recently, it was reported for HNSCC that there is higher expression of 
cytochrome P450 oxidoreductase (POR) in HPV negative tumours. Knockdown of POR 
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results in reduced sensitivity to TH - 302 under hypoxia, suggesting POR as a potential 
predictive biomarker of HAP sensitivity and a possible relationship between human 
papillomavirus status and HAP sensitivity [45]. Importantly, not only do a considerable 
number of HNSCC cases express significant levels of POR, but a subset of these carcinomas 
was classified as hypoxic by 18F - MISO PET, confirming coincidence of the two targets, 
hypoxia and POR [45].
Figure 1 Overview of the key characteristics of HPV positive and HPV negative HNSCC
HNSCC can be divided into HPV positive and HPV negative subgroups, with each having unique characteristics. 
Overall, patients with HPV positive tumours have a better prognosis and are more radiosensitive. The overall 
mutation rate and frequency of p53 mutations is higher in HPV negative tumours. Despite their different 
aetiology, both HPV negative and HPV positive tumours display a similar degree of hypoxia. TME: tumour 
microenvironment.
HPV infection in HNSCC
While both alcohol/tobacco - induced HNSCC and HPV - associated HNSCC are subject to 
the same treatment regimen, it is important to acknowledge the differences between 
the disease types (Figure 1). Patients with HPV - associated HNSCC are younger, more often 
Caucasian and male, and have a higher number of sexual partners [46]. Recently, the rising 
incidence of HPV positive HNSCC has led to an increasing number of reports evaluating the 




which are unencapsulated circular double stranded DNA viruses comprised of 6 to 8 genes. 
Over 200 types of HPV have been identified, only some of which have been identified as 
‘high - risk’, meaning that these types contribute to oncogenesis. Among these, HPV - 16 
and HPV - 18 are the most commonly found types in HNSCC [48]. The HPV16 virus is an 8 
Kb virus that encodes 2 late genes (L1 and L2) and 6 early genes (E1, E2, E4, E5, E6, and E7). 
The early genes facilitate viral genome replication, while the late genes are required for the 
production of viral capsid proteins that are required for effective viral entry into future host 
cells [49, 50]. Of the HPV genes, the E6 and E7 genes are the genes known to contribute 
most significantly to oncogenesis. The E6 protein is able to bind the tumour suppressor 
protein p53 and target it for ubiquitination and subsequent proteasomal degradation [51]. 
Similarly, E7 binds to retinoblastoma protein (RB), also a tumour suppressor, and facilitates 
proteasomal degradation [51]. As a result of proteolysis of p53 and RB, the host cell loses 
the ability to enter into apoptosis or senescence, or to arrest the cell cycle, creating an 
ideal environment for viral production and oncogenesis. Notably, E6 and E7 protein have 
been shown to interact with dozens of other cellular proteins, indicating that there may be 
other contributing pathways [52]. HPV positive tumours are characterised by a mutational 
landscape that is distinct from HPV negative tumours. Overall the mutation rate is lower 
in HPV positive tumours and they are specifically characterised by a lower number of 
p53 mutations. As E6 can effectively abrogate p53 function, there is less evolutionary 
pressure for HPV positive tumour cells to select for p53 mutations [53, 54]. In HNSCC, 
particularly in oropharyngeal squamous cell carcinomas (OPSCC), HPV positivity has both 
prognostic and clinical implications [55 - 57]. Numerous studies have shown a strong 
prognostic effect of HPV positivity with superior loco - regional tumour control and overall/
event - free survival both in the primary and post - operative radiotherapy of HNSCC [58 - 62]. 
Data from DAHANCA demonstrated a significantly superior loco - regional tumour control, 
event - free and overall survival in HPV positive OPSCCs and recently, the results from four 
randomised trials were reported (RTOG9003, DAHANCA6&7, RTOG0129, ARTSCAN), showing 
a significantly better progression - free and overall survival with an absolute survival increase 
at 10 years of 31.2% in HPV positive tumours following radiotherapy [63 - 65]. Taken together, 
there is a significant amount of evidence to support that HPV positive tumours are more 
radiosensitive.
As a result of these clinical observations, several groups have investigated the in vitro 
mechanisms of radiosensitivity in HNSCC and specifically the contribution of HPV. A number 
of studies have now demonstrated that HPV positive HNSCC cell lines are more sensitive to 
irradiation in vitro [66 - 72]. Understanding why HPV positive HNSCC are more susceptible to 
irradiation, or HPV negative more resistant, may lead to improved therapeutic approaches 
for both types. For OPSCCs it has been shown that the cellular mechanism underlying 
the increased radiosensitivity of HPV positive HNSCC cells is, at least in part, due to a 
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reduced capacity for repairing radiation - induced double strand breaks (DSB), as shown by 
a delayed resolution of yH2AX and 53BP1 foci (Figure 2) [73]. Interestingly, key components 
of base excision and single strand repair, including XRCC1, DNA polymerase β, PNKP and 
PARP - 1, were found to be up - regulated in HPV positive OPSCC suggesting an increased 
ability to repair certain DNA lesions [73]. Together, this could indicate that the increased 
basal radiosensitivity in HPV positive HNSCC is specifically due to impaired DSB repair, 
as opposed to the repair of all types of damage. The deficiency in DSB repair combined 
with increased levels of PARP - 1 observed in HPV positive OPSCC cells suggested that 
PARP - 1 inhibition might radiosensitise HPV positive cells. Unexpectedly, olaparib increased 
in vitro radiosensitivity of HPV negative OPSCC cells compared to HPV positive cells where 
the PARP - 1 inhibitor had no significant effect on tumour cell survival [73]. Several other 
studies, which investigated the cause of radiosensitivity in HPV positive HNSCC, found 
altered DNA damage repair pathways as well as differentially regulated cell cycle control 
in HPV positive HNSCC. The viral oncoprotein E7 not only leads to loss of RB, but also the 
degradation of the acetyltransferase Tip60, which is required for ATM activation upon DNA 
damage [74]. In addition, E6 contributes, through an as yet un - described mechanism, to the 
hypermethylation of the SMG - 1 promoter. The consequential reduction of SMG - 1 protein 
expression results in enhanced radiosensitivity, as SMG - 1 is a DNA damage signalling 
transducer. In support of a role for SMG - 1 in radiosensitivity, depletion of SMG - 1 in HPV 
negative HNSCC also increased radiosensitivity [75]. E7 was also found to contribute to 
altered cell cycle regulation and DNA damage response (DDR). E7 - mediated degradation 
of RB leads to accumulation of p16, as it is no longer under transcriptional repression of 
RB/E2F [76]. The overexpression of p16 has been shown to be an important feature in 
HPV - associated radiosensitivity, and is commonly used in clinical practice to determine 
HPV status. Specifically, it was demonstrated that p16 overexpression leads to activation 
of the TRIP12 - RNF168 - 53BP1 axis, and that by repressing TRIP12, an E3 ubiquitin - protein 
ligase, p16 overexpression ultimately leads to a delayed DDR [77]. In another study, p16 
expression was found to impair the homologous recombination pathway, the most 
faithful DSB repair mechanism, by preventing the recruitment of RAD51 [67]. Other studies 
found additional evidence for altered, delayed, or deficient DDR in HPV positive HNSCC, 
and it was shown that expression of E7 correlated with increased yH2AX foci, albeit in 
human keratinocytes [78]. Similarly, it has been demonstrated that HPV positive cell lines 
accumulate more 53BP1 and yH2AX foci and display a marked G2/M arrest in response 
to radiation [69]. This observation was supported by a subsequent study, where it was 
shown that E7 - transgenic mice had retained 53BP1 and yH2AX foci without alterations 
in ATM or ATR levels [79]. A further study observed a deficiency in DNA damage repair as 
shown by a delayed resolution of yH2AX foci, and attributed this to a decreased BRCA2 
and DNA - PK expression, which resulted in aberrant NHEJ and HR signalling. Additionally, it 




sensing mechanisms are still intact [80]. An alternative or complementary explanation for 
the increased radiosensitivity in HPV positive HNSCC could be that, while E6 mediates 
p53 degradation, there is still residual activity of the p53 protein. This hypothesis was 
supported by the observation that further knockdown of p53 was possible in HPV positive 
HNSCC cell lines and that this increased radiation resistance in HPV positive cell lines [72]. 
Taken together, the evidence demonstrates that HPV positive HNSCC have altered DNA 
repair mechanisms, including NHEJ, HR, and mismatch repair, which strongly contributes 
to radiosensitivity. The roles that E6 and E7 play in this process are evident, however it is 
possible that other HPV driven mechanisms may have been overlooked.
HPV and the tumour microenvironment
Aside from the intrinsic cellular radiosensitivity of HPV positive HNSCC, it is important to 
recognise that other factors, such as the tumour microenvironment, contribute to the 
in vivo response to radiation. HPV positive tumours have been found to have striking 
differences in the tumour microenvironment. E6 and E7 specific antibodies were detected 
in sera of HPV positive HNSCC patients, and correlated with improved survival, indicating 
that there is an active immune response against HPV in patients [81, 82]. Multiple studies 
show that in HPV positive HNSCC, a shift towards more CD4+ and CD8+ effector T - cells 
(as opposed to naïve T - cells) could be observed. This HPV - mediated shift in immune 
response was also associated with increased production of proinflammatory cytokines 
TNF - a and IFN - y, and a distinct B - cell signature [83 - 85]. While these studies did not establish 
a causal link for increased radiosensitivity, it has been hypothesized that in HPV positive 
HNSCC, cell injury and local inflammation after irradiation may effectively contribute to 
increased antigen presentation and enhanced recruitment of cytotoxic immune cells [66]. 
Taken together, it is clear that the immune system is involved in the systemic and local 
anti - tumour response in terms of radiotherapy response. While strong causal relationships 
are still lacking, several studies suggest that the immune cell rich tumour microenvironment 
of HPV positive HNSCC may contribute to their increased radiosensitivity.
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Figure 2 Mechanisms contributing to an altered DDR and increased radiosensitivity in HPV positive HNSCC
Infection with HPV, and subsequent expression of E6 and E7, contribute to an altered DDR in HNSCC tumour 
cells. E6, E7, and possibly other undescribed mechanisms, repress DNA damage signalling transducers and 
effectors, such as SMG - 1, p53, and BRCA2. Irradiation of HPV positive tumour cells causes significantly more 
yH2AX and RAD51 foci than in HPV negative tumour cells. Additionally, it is believed that HPV positive tumour 
cells have a delay in DSB repair, as measured by 53BP1 foci clearance, indicating that HPV positive tumour cells 
have impaired DSB repair mechanism(s), contributing to their intrinsic radiosensitivity.
Clinical data suggests there is no significant difference in the level, nor distribution of 
hypoxia in HPV positive and HPV negative tumours, as measured by a 15 - gene hypoxia 
classifier and 18F - MISO PET [17, 86]. To date, the expression of two of the key viral proteins, 
E6 and E7, have been shown to be altered in response to hypoxic conditions. In response 
to hypoxia, the interaction between E6, the ubiquitin ligase E6AP and p53 is abrogated, 
and therefore p53 can be stabilised in response to hypoxia in HPV positive cell lines [87]. 
More recently, exposure to hypoxia was also found to repress the expression of both E6 
and E7 in a range of cervical cell lines [88]. Interestingly, repression of E6 and E7 did not 
induce senescence in these cells, yet rather forced them into a dormant state, which upon 




could provide a mechanism to escape E6/E7 specific therapeutic approaches, such as E6/
E7 vaccines, or perhaps anti - tumour immune cells, as well as that the dormant tumour 
cells may serve as a reservoir for repopulation after reoxygenation [88].
In HPV positive tumours there is evidence for immune - related phenomena, such as 
increased intratumoural immune - cell infiltration, that could further potentiate the 
response to therapy including radiotherapy [89]. However, there are also data suggesting 
that tumour infiltrating lymphocytes may not be limited to HPV positive tumours [90]. 
This underlines the necessity for further studies evaluating the prognostic impact of the 
immune component on the outcome after radiotherapy for HNSCC, specifically in the 
context of HPV infection. Hypoxia can directly affect the immune cells present in the 
tumour and their function. Exposure to hypoxia alters IL - 6, IL - 10 and TGF - β cytokine levels 
and the expression of CD274 (encoding PD - L1), the last of which is mediated by HIF - 1α 
[91]. Yet, there is no evidence that HPV positivity is associated with HIF - 1α expression 
in OPSCC and the prognostic impact of other hypoxia - related parameters such as CAIX 
or microvascular density seems to be independent of HPV status [92, 93]. Additionally, 
hypoxic tumours appear to contain various types of immune cells, such as regulatory 
T - cells, tumour associated macrophages, myeloid- derived suppressor cells, which together, 
exert an immunosuppressive function [94]. While it has not yet directly been investigated, 
it is highly likely that hypoxia will affect the immune - permissive tumour microenvironment 
of HPV positive tumours, and shift its balance towards a more immunosuppressive state.
HPV, hypoxia and radiation response
An in vitro study showed that, as expected, both HPV positive and HPV negative HNSCC 
cell lines display decreased radiosensitivity when irradiated in hypoxic conditions. The 
oxygen enhancement ratios were found to be similar (2.3 – 2.9) when both HPV positive 
and –negative cell lines were irradiated under hypoxia [68]. As previously mentioned, it 
has been confirmed that HPV positive tumours have a similar degree and distribution of 
hypoxia compared to HPV negative tumours [17, 86]. In vivo it has been demonstrated that 
in HPV positive xenograft tumours in nude mice, cell proliferation decreased significantly 
upon irradiation, as opposed to HPV negative tumours. Furthermore, after irradiation, the 
hypoxic fraction was reduced over time in HPV positive tumours [95]. This observation is 
supported by earlier observations that irradiation of HPV positive cell lines induces a G2/M 
arrest, and can thereby effectively repress cell proliferation and thus oxygen consumption 
[69, 72]. Together, this suggests that the higher radiosensitivity of HPV positive tumours 
may be caused by a radiation - induced decrease of the hypoxic fraction and proliferating 
cells [95]. These mechanisms, while not yet fully understood, may prove to be essential 
in determining the optimal use of hypoxia modification therapy in HNSCC. While in vitro, 
hypoxic HPV positive cell lines could be radiosensitised by nimorazole, there is no clinical 
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evidence of its efficacy in patient populations [68]. Indeed, clinical studies have shown that 
patients have improved locoregional control when combining irradiation with nimorazole, 
but that this effect is limited to HPV negative HNSCC patients [17, 57, 96]. This suggests 
hypoxia modification may be a less effective and unnecessary treatment option for HPV 
positive HNSCC. Further studies will be required to determine the added value of hypoxia 
modification in HNSCC and to bring more clarity to the mechanisms involved. Additionally, 
these future studies would require a consistent and well - defined manner of measuring 
tumour hypoxia and detecting HPV status.
Summary
HNSCC can be divided in two distinct tumour types based on HPV infection, and the 
incidence of HPV positive HNSCC has been increasing over the last decades. It has 
been conclusively demonstrated that patients with HPV positive tumours have a better 
overall prognosis, and that these tumours are more sensitive to radiotherapy. However, 
so far there have been no changes in the treatment strategy for either HPV positive or 
HPV negative HNSCC. By investigating the mechanisms causing HPV positive tumours 
to be more sensitive, possible targets for treatment of HPV negative HNSCC could be 
identified. HPV positive tumours express the E6 and E7 oncoproteins, which are a causal 
factor for oncogenesis. In addition, the tumour microenvironment of HPV positive 
tumours contains elevated numbers of immune cells and pro - inflammatory cytokines, 
which may contribute to a more efficient tumour clearance after irradiation. Hypoxia, an 
overall negative prognostic marker, affects HPV positive and HPV negative HNSCC equally, 
reducing the effectiveness of radiotherapy. Several methods to detect and quantify levels 
of hypoxia have been established, and can be used clinically to predict treatment response. 
Concurrently, hypoxia - targeting or -modifying therapies have been developed which can 
effectively radiosensitise hypoxic tumour cells. Despite observations that HPV positive 
tumours have an equal hypoxic fraction as HPV negative tumours, hypoxia - modifying 
strategies such as nimorazole treatment have been shown to be ineffective in HPV positive 
HNSCC. This contributes to the notion that HPV positive and HPV negative HNSCC are 
two distinct disease types, which require individual treatment optimisation. Further, and 
larger, studies are needed in the future to determine mechanisms that contribute to 




Outline of this thesis
In this thesis, the molecular mechanisms that mediate radioresistance and - sensitivity in 
HNSCC are investigated, with a main focus on HPV positive versus HPV negative HNSCC 
cells. The identified pathways are then exploited to enhance radiosensitivity in both HPV 
positive and -negative HNSCC cells. In addition, the applicability of one of the identified 
radioresistance - mediating gene as a clinical biomarker is examined in a set of patient 
cohorts.
Chapter 2 describes the role of ATM interactor (ATMIN), a DNA damage signalling 
protein that is suspected to contribute to ATM stabilisation and signalling under hypoxic 
circumstances. Its role in the DNA damage response and hypoxia are explored, as well as 
the consequences for cellular radiosensitivity after knockdown. In Chapter 3, the role of 
the DNA damage response is further examined using a rationale - based approach. The 
p16 signalling pathway, that leads to a DNA damage repair defect in HPV positive HNSCC, 
is exploited and applied to target HPV negative HNSCC by combining irradiation with 
pharmacological inhibition of cyclin dependent kinases 4 and 6. Chapter 4 deals with 
the role of metabolic gene expression and their relation to radioresistance in HNSCC cells. 
Using targeted RNA sequencing in a panel of 14 HNSCC cell lines, over 200 metabolic genes 
are interrogated for any association between gene expression and radiosensitivity. One of 
the top candidate genes is further examined for its role in the DNA damage response, and 
assessed in three separate patient cohorts to test for any prognostic or predictive value for 
radiotherapy. In Chapter 5, the relationship between hypoxia, radioresistance, and the AKT 
survival pathway is examined in both HPV positive and -negative HNSCC. In addition, the 
applicability of an AKT inhibitor for each subset is tested in an in vitro setting. Chapter 6 
provides an extensive characterisation of 22 HNSCC cell lines, ranging from hypoxia- and 
radiosensitivity, tumour suppressor- and oncogene mutation analysis, morphology, HPV, 
and p16 status. Chapter 7 puts the findings of this thesis in a broader perspective and 
discusses the directions for future research. This thesis concludes with a general summary 
of the findings in Chapter 8.
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Hypoxia - induced replication stress is one of the most physiologically relevant signals known 
to activate ATM in tumours. Recently, the ATM interactor (ATMIN) was identified as critical 
for replication stress - induced activation of ATM in response to aphidicolin and hydroxyurea. 
This suggests an essential role for ATMIN in ATM regulation during hypoxia, which induces 
replication stress. However, ATMIN also has a role in base excision repair, a process that 
has been demonstrated to be repressed and less efficient in hypoxic conditions. Here, we 
demonstrate that ATMIN is dispensable for ATM activation in hypoxia and in contrast to 
ATM, does not affect cell survival and radiosensitivity in hypoxia. Instead, we show that 
in hypoxic conditions ATMIN expression is repressed. Repression of ATMIN in hypoxia 
is mediated by both p53 and HIF - 1α in an oxygen dependent manner. The biological 
consequence of ATMIN repression in hypoxia is decreased expression of the target gene, 
DYNLL1. An expression signature associated with p53 activity was negatively correlated with 
DYNLL1 expression in patient samples further supporting the p53 dependent repression 
of DYNLL1. Together, these data demonstrate multiple mechanisms of ATMIN repression 
in hypoxia with consequences including impaired BER and down regulation of the ATMIN 
transcriptional target, DYNLL1.
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Introduction
Hypoxia (insufficient oxygen levels) occurs in the majority of solid tumours due to aberrant 
and inefficient vasculature and is a negative prognostic factor for patients, irrespective 
of treatment modality [1, 2]. The poor clinical outcome linked to highly hypoxic tumours 
is due to increased aggressiveness and metastatic potential, as well as chemo- and 
radiotherapy - resistance [3, 4]. Hypoxia also potentiates genomic instability in tumours 
through down regulation of the DNA repair pathways, including base excision repair 
(BER), homologous recombination (HR) and mismatch repair (MMR) [5 - 9]. DNA repair has 
been shown to be repressed over a range of oxygen conditions which occur in human 
tumours [10]. The mechanisms of repression of repair are numerous (recently reviewed in 
[11]) but in some cases have been shown to be dependent on the hypoxia inducible factor 
(HIF - 1) [12]. In contrast, hypoxia induced ATM activation is restricted to severely hypoxic 
conditions (<0.1 % O2), which also induce replication stress [13, 14]. Hypoxia - induced ATM 
activation occurs in response to replication stress and in the context of specific chromatin 
modifications and importantly, in the absence of detectable DNA damage [15 - 18]. ATM 
activation in hypoxia occurs independently of the MRE11 - RAD50 - NBS1 complex, however, 
the requirement for alternative specific ATM interacting proteins has not been investigated 
[13]. As a result of ATM/ATR signaling in hypoxia the p53 tumour suppressor gene is 
activated and can lead to hypoxia - induced apoptosis [19].
Recently, the ATM interactor (ATMIN, also known as ASCIZ) was described as having a role 
in the activation of ATM both in the absence of DNA damage (for example in response 
to NaCl and chloroquine induced hypotonic stress) and in response to replication stress 
induced by hydroxyurea (Hu) or aphidicolin (APH) [20 - 25]. These reports concluded that 
ATMIN is crucial for ATM activation in the absence of DNA damage, while NBS1 takes 
over this role when double DNA strand breaks are present e.g. in response to ionizing 
radiation (IR) [21, 23, 24]. It has also been suggested that ATMIN is important for the 
repair of DNA damage induced by agents such as methyl methanesulfonate (MMS) or 
H2O2, and is therefore likely to be involved in the BER pathway [26]. Specifically, ATMIN 
was demonstrated to be necessary for the formation of Rad51 foci in response to MMS 
treatment, and for recruitment of 53BP1 to foci after both MMS and APH treatment [22, 
26 - 29]. A role for ATMIN in maintaining genomic stability was also demonstrated to be 
important in the suppression of B-cell lymphoma [30]. Finally, ATMIN, which includes a 
Zn2+ finger domain, has been shown to act as a transcription factor driving expression of 
a very limited number of target genes including DYNLL1, which plays an important role in 




Here, we demonstrate that ATMIN was not required for ATM activation in hypoxia and was 
instead repressed in hypoxic conditions therefore contributing to the hypoxia - mediated 
repression of DNA repair. The mechanism of repression is complex and is in part dependent 
on both HIF - 1 and p53, demonstrating that repression of ATMIN is critical to the biological 
response to hypoxia. While this may be due to the role of ATMIN in DNA repair, we also 
demonstrate for the first time that expression of the ATMIN target gene DYNLL1 is altered 
in response to hypoxia.
Methods
Cell lines, transfections and drug treatments
RKO, HCT116 (colorectal carcinoma cells), RPE1 - hTERT (retinal epithelial cells), HCT116 
p53+/+ and p53-/- cell lines (Prof Vogelstein, Johns Hopkins [31]), RKO HIF - 1α+/+ and HIF - 1α-/- 
[32] were cultured in DMEM with 10% FBS. For siRNA knockdown, cells were transfected 
using Dharma - FECT 1 reagent (Thermo Fisher Scientific) at 50 nM siRNA and used in 
assays from 24 to 72 h after transfection. Human ATMIN ON - Target SMARTplus siRNA 
targeting sequences used as a pool or separately: si#1 5’-UUUGAAACAGGACCGAAA - 3’; 
si#2 5’-UUACAACACCACCGAGAUA - 3’; si#3 5’-GAUAGAAAGUCCAACGGAU - 3’; si#4 
5’-CCGAACUGGGCACGAGAUA - 3’; were from GE Healthcare Dharmacon (L - 020304 - 01 - 0005). 
pMSCV - ATMIN vector was a kind gift from Prof Axel Behrens (The Francis Crick Institute, 
London) and was transfected using Lipofectamine Ltx reagent (Life Technologies) [24]. 
Drugs were purchased from Sigma unless otherwise stated and were used at the following 
concentrations: 100 µM DFO, 150 μM CoCl2, 1 mM Hu, 1 μM APH, 25 μg/ml cycloheximide, 
5 μM MG - 132 or 10 μM KU - 55933 (Tocris).
Colony survival
RKO cells were transfected with 50 nM ATMIN siRNA and the next day re - plated at a density 
of 250 - 2000 cells/well in a 6 - well plate. After 2 h, cells were exposed to <0.1 % O 2 for 0 - 36 
h and/or drug treatment and then left for 7 - 9 days to form colonies, which were visualized 
by crystal violet staining.
Hypoxia and radiation
Hypoxic treatments at <0.1% O2 were carried out in a Bactron chamber (Shel Lab) and at 
2% O2 in a Don Whitley H35 Hypoxystation. Radiation doses were delivered in a GSM D1 
137 - Cesium gamma irradiator with at 0 - 6 Gy doses as previously described [33].
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Western blotting
Protein lysates were extracted with SDS lysis buffer (10 mM Tris - Cl, pH 7.5, 0.1 mM EDTA, 
0.1 mM EGTA, 0.5% SDS, 0.1 mM β - mercaptoethanol, protease/phosphatase inhibitors) 
and western blotting carried out as described previously [34]. Western blots were imaged 
using the Odyssey infrared system (LI - COR). The following antibodies were used: ATMIN 
(Millipore), HIF - 1α (BD Biosciences), p53 (Santa Cruz), β - actin (Santa Cruz), ATM (Sigma and 
Cell Signaling), pATM - S1981 (Epitomics), Kap1 - S824 (Bethyl), Kap1 (Bethyl), γH2AX (Millipore) 
and H2AX (Calbiochem).
RT - qPCR
Cells were lysed in TRI reagent (Sigma) and mRNA extracted according to manufacturer 
instructions. The RNA was quantified using NanoDrop. cDNA was synthesized using 
500 ng RNA and the Verso cDNA Enzyme kit (Life Technologies). qPCR was carried out 
with SYBR mix using a 7500 Fast Real - time PCR Detection System (Applied Biosystems). 
Primer sequences: ATMIN forward: 5’-AACAGCACTGCAGTCTCACA - 3’; ATMIN reverse: 
5’-CTGGTCTAGGGATTGGTTGGT; 18S forward: 5’-GCCCGAAGCGTTTACTTTGA - 3’; 18S reverse: 
5’-TCCATTATTCCTAGCTGCGGTATC - 3’; DYNLL1 forward: 5’-AGATGCAACAGGACTCGGTG - 3’; 
DYNLL1 reverse: 5’-CCACTTGGCCCAGGTAGAAG - 3’.
Expression analysis in cancer datasets
Raw RNA - sequencing (RNA - seq) data for 1105 Breast invasive carcinoma and 522 Lung 
adenocarcinoma tumours were downloaded from the TCGA project (accessed through 
cBioportal: http://www.cbioportal.org/) on 10th September 2015 and 12th September 2015 
respectively. To examine tumour - associated p53 - activity (referred to as p53 signature in 
the figure), raw data for each sequenced gene were rescaled to set the median equal to 
1, and p53 - activity was quantified by averaging the normalized expression of 6 p53 target 
genes, associated with hypoxia - induced p53 activity (encoding BTG2, CYFIP2, INPP5D, KANK3, 
PHLDA3 and SULF2) [19]. Log10 conversion of the p53 signature was plotted against Log10 
conversion of raw data for DYNLL1 (also rescaled to set the median equal to 1). One - tailed 
p value shown on each graph for each Pearson r (correlation coefficient).
Statistical analysis
Statistical analysis of clonogenic assays, mRNA expression and expression analysis in 
cancer datasets was carried out using Graphpad Prism v6.03 software. For colony survival 
assays the plating efficiency per condition was determined by dividing the total number 
of counted colonies by the total number of plated cells. Surviving fractions (SF) were 
calculated by dividing the plating efficiency of treated cells by the plating efficiency of 
the control cells. Comparison of groups was done using an unpaired t - test with Welch’s 




SF = e-(αD + β(D*D)). Sensitizer enhancement ratio (SER) was calculated as SER37 = D0(without 
sensitizer) / D0(with sensitizer) for the same biological effect at SF=37%. qPCR data was 
analyzed on 7500 Software V.2.0.5 (Applied Biosystems) using the ΔΔCt method. An 
unpaired t - test with Welch’s correction was used. Statistical significance is marked as 
follows: * p<0.05, ** p<0.01, ***p<0.001.
Results
ATMIN is dispensable for ATM activation in hypoxia
To test the hypothesis that ATMIN might be required for hypoxia - induced ATM activation, 
we used ATMIN siRNA to deplete ATMIN levels in RKO cells. The cells were then exposed 
to hypoxia (<0.1 % O2) for 3 h, as we have shown previously that ATM is activated during 
this period [13]. As expected, a robust induction of phosphorylated ATM (ATM - S1981) and 
the ATM target Kap - 1 (Kap1 - S824) was observed in response to hypoxia in the cells treated 
with the control siRNA. Surprisingly, a similar induction of ATM activity was also observed 
in the cells with depleted levels of ATMIN (Figure 1A). To ensure that ATMIN did not have 
role in sustaining hypoxia - induced ATM activation, experiments over a longer time period 
were also carried out and again no dependence on ATMIN was observed (Figure S1). This 
finding was also verified with two single siRNAs to ATMIN (Figure S2). As a control, we also 
tested the previously reported effect of ATMIN on ATM activity in response to other factors 
inducing replication stress. While we were not able to see the effect of ATMIN depletion 
on Hu - induced ATM activation, we saw a clear decrease in APH - induced ATM activity, 
supporting the previous reports showing that ATMIN plays a role in activation of ATM by 
replication stress induced with APH (Figure S3) [22, 35]. Loss of ATM has a dramatic and 
well - characterized effect on radiosensitivity, although this has not been as extensively 
demonstrated under hypoxic conditions [36]. Here, we used an ATM inhibitor (KU - 55933) 
in hypoxic conditions and exposed RKO cells to radiation (0 - 6 Gy). As expected, the cells 
treated with the ATM inhibitor were significantly more sensitive to radiation even in hypoxic 
conditions (SER37 = 2.1) (Figure 1B and S4). We then asked if ATMIN might contribute to 
the role of ATM in radiation response under hypoxic conditions by carrying out the same 
experiment in cells treated with a siRNA against ATMIN. Loss of ATMIN did not affect the 
radiation sensitivity of cells irradiated under hypoxic conditions suggesting that ATM 
function could not have been significantly impacted by ATMIN depletion (Figure 1C). 
Previous studies have shown that loss of ATM activity leads to increased sensitivity to 
hypoxia/reoxygenation [15, 37]. Therefore if ATMIN contributed to ATM activity in hypoxia, 
loss of ATMIN would also be expected to increase sensitivity to hypoxia/reoxygenation. 
Again, ATMIN was depleted using siRNA in RKO cells and a colony survival assay in response 
to hypoxia/reoxygenation was carried out. Depletion of ATMIN had no significant effect on 
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cell viability in response to hypoxia compared to wild type RKO cells, which again suggests 
that ATMIN does not contribute to ATM activity during this hypoxia (Figure 1D). To further 
support this conclusion, we investigated the induction of apoptosis 6 hours after hypoxic 
exposure and found that loss of ATMIN did not significantly affect the fraction of apoptotic 
cells (Figure S5). Altogether, these data demonstrate that ATMIN is not required for the 
activation of ATM in response to hypoxia - induced replication stress.
Figure 1 ATMIN loss does not impair ATM activation in hypoxia
A, RKO cells were transfected with either non - targeting scrambled siRNA or ATMIN - specific siRNA. 24 h post 
transfection, cells were exposed for up to 3 h of hypoxia (<0.1% O2). B, Colony survival assay of RKO cells treated 
with 10 μM KU - 55933, exposed to 6 h hypoxia (<0.1% O2), and irradiated with 0 - 6 Gy. Post treatment, cells were 
allowed to form colonies for 8 days under normal tissue culture conditions. Mean and standard deviation 
(SD) from 3 independent experiments is shown. C, RKO cells transfected with either scrambled (Scr) siRNA or 
ATMIN siRNA were exposed to 6 h of hypoxia treatment (<0.1% O2) or left at normoxia (21% O2), followed by 
irradiation (4 Gy). Post radiation, cells were reoxygenated and kept under normal tissue culture condition to 
allow colony formation. D, Colony survival assay of RKO cells transfected with ATMIN siRNA, exposed for up to 





ATMIN is repressed in an oxygen dependent manner through p53 and HIF - 1α
While investigating the potential role of ATMIN in ATM activation over time in hypoxia we 
noticed that ATMIN levels decreased over time in hypoxia (Figure S1). Both cancer (RKO, 
HCT116) and non - cancerous (RPE1 - hTERT) cell lines were exposed to hypoxia (<0.1% O2) for 
up to 24 h and analyzed for ATMIN expression by western blotting. In each case the levels 
of ATMIN protein were significantly decreased in hypoxia (Figure 2A - C). Next, we tested the 
oxygen dependency of ATMIN decrease by comparing exposure to severe (<0.1% O2) and 
mild hypoxia (2% O2). The levels of ATMIN decreased at both oxygen tensions, although 
more profoundly at <0.1% O2 (27% and 55% decrease at 2% O2 and <0.1% O2, respectively, 
when compared to ATMIN levels at 21% O2) (Figure 2D). In addition, we investigated the 
effect of commonly used hypoxia mimetics, desferoxamine (DFO) and CoCl2, and found 
that DFO treatment partially repressed ATMIN (25% decrease), while CoCl2 had no effect 
on ATMIN protein (Figure 2D). As the levels of ATMIN have not been reported to change in 
response to stress previously, we asked if this also occurred upon exposure to alternative 
sources of replication stress. RKO cells were exposed to Hu or APH for a period of 3 - 6 h and 
the levels of ATMIN protein determined. No apparent decrease in ATMIN was detected in 
response to either treatment suggesting that hypoxia has a unique effect on ATMIN levels 
(Figure 2E). To rule out repression of ATMIN with slower kinetics compared to hypoxia, no 
decrease in ATMIN expression was observed when cells were treated with Hu and APH for 
up to 18 h (Figure S6). Together, this data demonstrate that ATMIN is repressed in response 
to a range of hypoxic conditions (<0.1 - 2% O2) but this effect is more profound at the more 
severe levels of hypoxia.
As HIF - 1 has been demonstrated to play a role in the repression of other DNA repair 
proteins in hypoxia we investigated a potential role for HIF - 1 in ATMIN repression [11]. 
However, as the repression of ATMIN was more significant in severe hypoxia compared 
to milder levels we also included p53 in our analysis, as p53 activity is also restricted to 
severely hypoxic conditions [34]. We used isogenic cell lines HCT116 p53+/+ and p53-/- or RKO 
HIF - 1α+/+ and RKO HIF - 1α-/- to initially investigate this hypothesis. We observed that ATMIN 
repression in hypoxia was partially reversed when either p53 or HIF - 1α were deleted (Figure 
S7A - B). To investigate further the contribution of p53 and HIF - 1 to ATMIN repression, we 
used siRNA to knock down HIF1A in a TP53 null background and compared ATMIN protein 
levels after hypoxia. We observed that the combined depletion of p53 and HIF - 1α had 
the largest effect on rescuing ATMIN protein levels when compared to knock - down or 
deletion of either transcription factor alone (Figure 2F). These results suggest that both 
p53 and HIF - 1α independently contribute to repression of ATMIN in hypoxia.
35
Mechanisms and consequences of ATMIN repression in hypoxic conditions
Figure 2 ATMIN expression decreases in an oxygen dependent manner through HIF - 1α and p53 - dependent 
pathways
A - C, RKO (A), HCT116 (B) and RPE1 - hTERT (C) cells were exposed to hypoxia (<0.1% O2) for the times indicated 
and western blot analysis was carried out using the antibodies indicated (β - actin was used as a loading control). 
D, RKO cells were treated as indicated for a period of 16 h. The hypoxia mimetic drugs were used as follows; 
100 µM DFO and 150 μM CoCl2. Western blots using the antibodies indicated are shown. E, RKO cells were 
exposed to DMSO, 1 mM hydroxyurea or 5 µg/ml APH for the indicated amount of time and western blot 
analysis was carried out for ATMIN, RPA 32 and β - actin (loading control). F, HCT116 p53-/- cells were transfected 
with either HIF - 1α siRNA or Scr siRNA and HCT116 p53+/+ cells were transfected with Scr siRNA. Cells were 
exposed to hypoxia (<0.1% O2) for the times indicated and protein lysates analyzed by western blotting with 
the antibodies shown.
Hypoxia represses ATMIN expression at the protein level without increasing 
degradation rates
As both transcription factors HIF - 1 and p53 play a role in ATMIN repression we investigated 
ATMIN mRNA expression in hypoxia. ATMIN mRNA was measured by qPCR in response 
to hypoxia in 5 cells lines (RKOp53wt, HCT116p53wt, U87p53wt, MCF - 7p53wt and U2OSp53wt) all of 




by hypoxia in the majority of the cell lines tested with the exception of HCT116 cells where 
mRNA decreased initially (after 8 h) and then basal levels were restored. These results 
demonstrate that in the cell lines tested neither p53 nor HIF - 1 directly or indirectly repress 
ATMIN transcription (Figure 3A - C and S8A - B). This was further confirmed by analyzing 
ATMIN mRNA expression in cells lacking either p53 (HCT116 p53-/-) or HIF - 1α (RKO HIF - 1α-/-), 
again no hypoxia - dependent increase in expression was observed (Figure S8C - D).
ATMIN contains a C - terminal PEST domain, which is associated with proteasomal 
degradation [21]. Given the stability of ATMIN mRNA in hypoxia we hypothesized that 
ATMIN could be repressed through increased protein degradation in hypoxia. We 
measured ATMIN in cells exposed to a proteasomal inhibitor (MG - 132) either in normoxia 
or in hypoxia. The hypoxia - mediated repression of ATMIN was abrogated by the addition of 
proteasomal inhibitor MG - 132 confirming that ATMIN levels are regulated by proteasomal 
degradation (Figure 3D). However, ATMIN also accumulated in normoxic conditions (21% 
O2) in the presence of MG - 132, suggesting that ATMIN is not specifically targeted to the 
proteasome in hypoxic conditions. To verify this further we measured the half - life of ATMIN 
in both normoxia and hypoxia by blocking protein translation with cycloheximide. We 
determined that the half - life of ATMIN (approximately 4 hours) was not altered by exposure 
to hypoxia (Figure 3E and S9). Together, these findings suggest that in response to hypoxia 
ATMIN translation is repressed as opposed to altered transcription or degradation rates.
Biological consequences of hypoxia - mediated repression of ATMIN include the 
down regulation of ATMIN target DYNLL1
ATMIN has been described as having a role in BER although this role is somewhat unclear 
[26, 27]. BER is known to be functionally repressed in hypoxic conditions and consequently 
hypoxic cells are less able to repair damage induced by agents such as MMS [5]. To 
determine if the loss of ATMIN expression contributes to the increased sensitivity to MMS 
observed in hypoxic cells we exposed cells treated with ATMIN siRNA to range of hypoxic 
conditions and MMS and carried out a colony survival assay. In agreement with previous 
reports we observed an increased sensitivity of hypoxic cells to MMS [5]. We also found 
a significant decrease in cell survival of cells treated with MMS when ATMIN levels were 
depleted (Figure 4A) [22, 26, 27]. This effect was decreased in cells exposed to 2% O2 and 
completely abolished in cells treated with <0.1% O2 (Figure 4A), where ATMIN was most 
repressed as a result of the hypoxia exposure.
ATMIN directly transactivates DYNLL1, therefore suggesting the novel hypothesis that 
DYNLL1 mRNA levels might be regulated in an oxygen dependent manner [29]. In 
agreement with previous reports, we confirmed that DYNLL1 expression is dependent 
on ATMIN levels in RKO cells (Figure 4B). Next, we exposed cells to hypoxia, and observed 
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an oxygen - dependent down - regulation of DYNLL1 expression, again with a more 
profound decrease at <0.1% O2 (Figure 4C), which correlates with ATMIN levels (Figure 
2D). The hypoxia - mediated decrease in DYNLL1 expression was rescued by over - expression 
of ATMIN in these conditions (Figure 4D and S10). As the decrease of ATMIN in severe 
hypoxia was p53 dependent (Figure 2F and S7A), we asked if DYNLL1 was also regulated in 
a p53 - dependent manner in hypoxia. Therefore we tested the levels of DYNLL1 mRNA in 
RKO cells treated with p53 siRNA. As predicted, hypoxia - mediated repression of DYNLL1 was 
partially but significantly rescued in the absence of p53 (Figure 4E). This study highlights 
an entirely novel link between ATMIN regulation of DYNLL1 and tumour hypoxia.
Figure 3 Hypoxia represses ATMIN without increasing degradation 
A - C, RKO (A), HCT116 (B) and U - 87 (C) cells were exposed to hypoxia (<0.1% O2) for the times indicated and 
ATMIN mRNA expression was analyzed by qPCR in relation to 18S (reference gene). The mean mRNA expression ± 
SD from three independent experiments is shown. D, RKO cells were treated with DMSO or 5 μM MG - 132 under 
normoxic (21% O2) or hypoxic (<0.1% O2) conditions for the times indicated and ATMIN levels were analyzed by 
western blotting. E,. RKO cells were treated with 25 μg/mL cycloheximide under normoxic (21% O2) or hypoxic 
(<0.1% O2) conditions for the times indicated. ATMIN protein expression was measured by western blotting 





Figure 4 Loss of ATMIN contributes to the hypoxia - mediated repression of DNA repair and a decrease in 
DYNLL1 expression
A, RKO cells transfected with either Scr siRNA or ATMIN siRNA were exposed to 20 h of varying oxygen 
concentrations (21%, 2% and <0.1% O2) followed by 1 h of MMS treatment (0.1 - 0.5 mM as indicated) at the same 
oxygen tension. Cells were then reoxygenated and the media replaced. Colonies were allowed to form at 21% 
O2 over a period of 8 - 10 days. Mean surviving fractions are shown ± SD from three independent experiments. 
B, RKO cells were transfected with either Scr or ATMIN siRNA and expression of ATMIN and DYNLL1 mRNA was 
analyzed by qPCR at 48 h post transfection.
C, DYNLL1 mRNA expression was analyzed by qPCR in RKO cells exposed to 16 h of varying oxygen 
concentrations (21%, 2% and <0.1% O2). D, RKO cells were transfected with pMSCV - ATMIN vector or an empty 
vector control. 24 h later cells were transferred to hypoxic conditions (<0.1% O2) for 8 h. qPCR was then carried 
out for DYNLL1. E, DYNLL1 mRNA was analyzed by qPCR in RKO cells transfected with either Scr or p53 siRNA 
and exposed to 16 h of hypoxia (<0.1% O2). All qPCR bar graphs show mean mRNA expression ± SD from three 
independent experiments. F - G, Expression of DYNLL1 (Log10 conversion) in the breast (E) and lung (F) TCGA 
datasets is shown against hypoxia - inducible p53 signature (Log10 conversion). One - tailed p value is shown on 
each graph for each Pearson r (correlation coefficient).
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To date no validated hypoxia signatures, which are specific to the levels of hypoxia 
which induce replication stress i.e. <0.1% O2 exist. However, we recently identified a 
group of six genes, which are induced by p53 in response to hypoxia (<0.1% O2) and can 
predict p53 status in vivo in multiple cancer types [19]. Therefore, we used this group 
of genes to investigate a potential correlation between DYNLL1 expression and hypoxic 
p53 signaling in patient samples. Through analysis of the TCGA breast and lung cancer 
patient cohorts we found that DYNLL1 expression significantly and inversely correlated with 
the hypoxia - inducible p53 - dependent group of genes (Pearson r = -0.09197, p = 0.0013 
for breast and Pearson r = -0.2618, p < 0001 for lung cancers, respectively) (Figure 4E), 
suggesting that hypoxia- and p53 - dependent repression of the ATMIN target DYNLL1 
occurs in human cancers. Altogether our data shows that repression of ATMIN in hypoxia 
is likely to have multiple consequences, including contributing to the repression of DNA 
repair pathways and down regulation of the ATMIN target, DYNLL1.
Discussion
Despite having a role in ATM activation in response to replication stress, ATMIN does not 
play a role in hypoxia - induced ATM activation. Instead, we show for the first time that 
ATMIN is repressed in response to hypoxia and most significantly under severe hypoxia 
(<0.1% O2). Our data demonstrates that ATMIN repression is in part dependent on both p53 
and HIF - 1α. The involvement of both transcription factors suggests that ATMIN would be 
repressed in a broad range of hypoxic conditions and therefore in large areas of tumour. 
Repression of ATMIN in hypoxia is suggested to contribute to down regulation of BER 
and decreased expression of DYNLL1, as summarized in the proposed model (Figure 5). 
Importantly, we show that repression of DYNLL1 can be inversely correlated with p53 
signaling in human cancers suggesting that the consequences of ATMIN repression are 
likely to play a role in tumours in vivo.
The mechanism of repression of ATMIN protein in hypoxia remains unclear, although 
dependence on p53 and HIF - 1α in this process may suggest involvement of micro - RNAs 
(miRs). Both p53 and HIF - 1α are known to induce expression of multiple miRs, which 
are likely to inhibit protein translation [38, 39]. Analysis of the ATMIN mRNA sequence 
using available online resources (e.g. www.microrna.org) showed that multiple p53 or 
HIF - dependent miRs are predicted to bind to the ATMIN transcript, including miR - 373 
(a HIF - 1α target) and miR - 34 (a p53 target) [12, 40, 41]. In addition, a recent study, which 
screened for the miR - 124 targets involved in the DNA damage response found ATMIN 
to be regulated by miR - 124 [42]. Importantly, miR - 124 is a known direct target of p53 




It is noteworthy that the dependence on p53 and HIF - 1 for repression of ATMIN in hypoxia 
was less significant after longer exposure times to hypoxia (>16 h). This finding suggests 
that in chronic hypoxic conditions ATMIN might be repressed through an alternative 
mechanism. A recent study characterized the repression of the BER pathway in chronic 
hypoxia (72 h 0.2% O2) as a consequence of inhibited protein translation [5]. Together, these 
findings suggest that the repression of ATMIN occurs in hypoxia through mechanisms 
dependent on HIF - 1, p53 and eventual decrease in translation.
Finally, we show that ATMIN repression in hypoxia is linked with down regulation of DYNLL1 
expression. Numerous functions have been attributed to DYNLL1, including regulation of 
mitosis, spindle orientation, macropinocytosis, nuclear localization/translocation of some 
proteins e.g. 53BP1, PAK1 or ciliogenesis [44 - 47]. Our findings suggest that some or all of 
these processes will be altered in response to hypoxia through the decreased expression 
of DYNLL1. In support of this conclusions we have shown that 53BP1 does not form foci in 
response to hypoxia (<0.1% O2) and so there would be no requirement for this function 
of DYNNL1 [13]. Most importantly our data demonstrate that in the absence of functional 
p53 the hypoxia - mediated repression DYNNL1 described here is alleviated. The specific 
roles of DYNNL1 in hypoxia driven tumour progression therefore warrant further study.
Figure 5 ATMIN expression is repressed in response to hypoxia through mechanisms which include both 
HIF - 1α and p53.  
The involvement of both HIF - 1α and p53 in the repression of ATMIN suggests that this would occur in a 
significant fraction of the tumour, although p53 - mediated repression was more robust. The consequences 
of loss of ATMIN include increased sensitivity to DNA damaging agents requiring effective BER for repair and 
decreased expression of DYNLL1. Some of the potential consequences of loss of DYNNL1 in hypoxia are indicated 
and warrant further study. Loss of ATMIN contributes to the hypoxia - mediated repression of DNA repair and 
a decrease in DYNLL1 expression
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Supplementary data
Figure S1 ATMIN loss does not impair ATM activation in hypoxia
RKO cells were transfected with either Scr siRNA or ATMIN - specific siRNA. 24 h post transfection, cells were 
exposed for up to 8 h of hypoxia (<0.1% O2) followed by western blotting for the antibodies indicated.
Figure S2 ATMIN loss does not impair ATM activation in hypoxia
RKO cells were transfected with either Scr siRNA (-) or 2 different ATMIN - specific siRNAs (1 and 2). 24 h post 
transfection, cells were exposed to 3 h of hypoxia (<0.1% O2) followed by western blotting for the antibodies 
indicated.
Figure S3 ATMIN loss impairs Aphidicollin - dependent but not Hu - dependent ATM activation in RKO cells.
A - B, RKO cells were transfected with either Scr siRNA or ATMIN - specific siRNA. 24 h post transfection, cells 
were exposed to (A) 2 h of 2 mM hydroxyurea (Hu) or to (B) 16h of 1 μM aphidicolin (APH), followed by western 




Figure S4 ATM inhibition with KU - 55933 in hypoxia
RKO cells were treated with KU - 55933 in hypoxic conditions (<0.1% O2) for the times indicated followed by 
western blotting with the antibodies shown.
Figure S5 ATMIN loss does not alter apoptosis in hypoxia
A, RKO cells were transfected with either Scr or ATMIN siRNA and 48 h later exposed to hypoxia (<0.1% O2) for 8 
h. Protein lysates were analyzed by western blotting with the antibodies indicated. B, Cells from A were fixed 
and stained with DAPI. Apoptosis was assessed based on nuclear morphology. The bar graph shows mean ± 
SD apoptosis combined from 3 independent experiments.
Figure S6 ATMIN levels do not increase in response to Hu or APH.
RKO cells were exposed to DMSO, 1 mM Hu or 5 µg/ml APH for the indicated amount of time and western blot 
analysis was carried out for ATMIN and β - actin (loading control).
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Figure S7 ATMIN repression in hypoxia is regulated by p53 and HIF - 1α
A, HCT116 p53+/+ and p53-/- cells were exposed to hypoxia (<0.1% O2) for the times indicated and ATMIN 
protein levels were analyzed by western blotting. Blots for p53 and β - actin are shown as controls for p53 status 
and loading, respectively. B, RKO HIF - 1α+/+ and HIF - 1α-/- cells were exposed to hypoxia (<0.1% O2) for the times 
indicated and ATMIN protein levels were analyzed by western blotting. Blots for HIF - 1α and β - actin are shown 




Figure S8 ATMIN mRNA levels in hypoxia
A - D, MCF - 7 (A), U20S (B), HCT116 p53-/- (C) and RKO HIF - 1α-/- (D) cells were exposed to hypoxia (<0.1% O2) for 
the times indicated and mRNA levels of ATMIN were tested by qPCR. 18S was used as a reference gene.
Figure S9 The half - life of ATMIN is similar under hypoxic and normoxic conditions
RKO cells were treated with 25 μg/mL cycloheximide under normoxic (21% O2) or hypoxic (<0.1% O2) conditions 
for the times indicated. ATMIN expression was measured by western blotting and β - actin used as a loading 
control.
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Figure S10 ATMIN levels goes up with ATMIN cDNA transfection
RKO cells were transfected with ATMIN cDNA (+) or with empty vector (-) and exposed to hypoxia (0.1% O2) for 
8h followed by western blotting for the antibodies indicated. 2
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Inhibition of CDK4/CDK6 enhances 
radiosensitivity of HPV negative head and 
neck squamous cell carcinomas










Purpose: Human papillomavirus negative (HPV) head and neck squamous cell carcinomas 
(HNSCC) have a poor prognosis compared to HPV positive HNSCCs. Expression of p16 in HPV 
positive HNSCC is thought to mediate radiosensitivity via inhibition of cyclin - dependent 
kinase (CDK) 4/6. We used a clinically approved CDK4/CDK6 inhibitor, palbociclib, and 
assessed its effect on radiosensitivity in HNSCC.
Methods and Materials: The effect of palbociclib on radiosensitivity was determined in 
HPV negative and positive HNSCC cell lines using colony survival assays, immunofluorescent 
staining of repair proteins, homologous recombination (HR) assays, cell cycle and 
metaphase spread analyses.
Results: Only HPV negative HNSCC cells were radiosensitised by palbociclib, which also 
occurred at hypoxic levels associated with radioresistance. Palbociclib led to a decreased 
induction of BRCA1 and RAD51 after irradiation. HR was diminished and repair of 
radiation - induced DNA damage was delayed in the presence of palbociclib leading to 
increased chromosomal damage. Failure to repair radiation - induced damage led to cell 
death as a result of mitotic catastrophe.
Conclusions: Here, we highlight a therapeutic strategy to improve the radiosensitivity of 
HPV negative HNSCC, a patient group that has an unmet and urgent need for improved 
radiotherapy efficacy.
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Introduction
Head and neck squamous cell carcinomas (HNSCC) are the sixth most common type 
of cancer worldwide, and are associated with frequent recurrence [1]. Where possible, 
HNSCC are treated surgically, often combined with radiotherapy and/or platinum - based or 
anti - EGFR chemotherapy. A combination of radiotherapy and chemotherapy is commonly 
used as the primary treatment strategy due to the sensitive anatomical location of the 
tumours [2]. Treatment efficacy of both chemotherapy and radiotherapy is frequently 
reduced due to the presence of regions at low oxygen tensions in the tumours (hypoxia). 
Hypoxia has been shown to induce radioresistance and is an overall negative prognostic 
factor [3, 4]. Risk factors for HNSCC include, but are not limited to, prolonged alcohol and 
tobacco use or high - risk type human papilloma virus (HPV) infection [5]. A dichotomy has 
been observed in the treatment response between patients with HPV positive and HPV 
negative tumours. In general, patients with HPV negative HNSCC are less responsive to 
treatment, and have a poorer prognosis [6]. However, treatment for both HPV positive and 
HPV negative HNSCC remains the same, despite these significant differences in treatment 
response. Therefore, there is a critical and unmet need for improved therapy options for 
patients with HPV negative HNSCC.
In contrast to HPV negative HNSCC, HPV positive HNSCC arises from an oncogenic 
virus infection. High - risk types HPV (of which HPV16 and HPV18 are the most prevalent) 
integrate in the host genome, and induce the expression of the oncogenes E6 and E7 
that allow unlimited viral replication by facilitating unchecked cell division. E6 has been 
shown to bind to the tumour suppressor protein p53, and target it for ubiquitination and 
subsequent proteasomal degradation, thereby disabling a vital DNA damage response 
protein [7]. Similarly, E7 promotes proteasomal degradation of retinoblastoma protein (RB), 
an important cell cycle regulator [8]. The better prognosis observed in HPV positive patients 
compared to those that are HPV negative has, in part, been attributed to the increased 
radiosensitivity of HPV positive cancers. Indeed, it has been demonstrated in a number of 
studies that HPV positive cells are intrinsically more radiosensitive [9 - 12].
Both HPV encoded, E6 and E7 have been demonstrated to be key factors in mediating 
the relative radiosensitivity of HPV positive HNSCC cells (reviewed in [13]). Not only have 
E6 and E7 been shown to impair DNA damage signalling, but have also been linked to 
defective DNA damage repair [10, 14 - 16]. As a result of E7 - mediated RB degradation, the 
majority of HPV positive HNSCC overexpress p16 [17, 18]. Recently, expression of p16, a cyclin 
dependent kinase CDK4/CDK6 inhibitor and tumour suppressor, was found to contribute to 
the relative radiosensitivity of HPV positive HNSCC cells [14, 19]. In cooperation with cyclins, 




to S - phase is tightly controlled by CDK4 and CDK6, where, the formation of a complex of 
CDK4/CDK6 and cyclin D initiates the G1 to S transition by hyperphosphorylation of RB. As 
a consequence of this hyperphosphorylation, the repressive interaction between RB and 
the E2F transcription factor is lost, leading to the expression of E2F - regulated cell cycle 
progression genes such as cyclin A and E (reviewed in [20]).
Palbociclib, also known as Ibrance or PD - 0332991, is a CDK4/CDK6 inhibitor (IC50 of 
approximately 11 nM/16 nM) and has recently been shown to be effective in the 
treatment of breast cancer [21 - 23]. The PALOMA - 1 and PALOMA - 2 trials have compared 
the effectiveness of palbociclib in combination with the aromatase inhibitor, letrozole, in 
breast cancer patients [24]. In patients who received palbociclib, relatively mild side - effects 
(the most prevalent being neutropenia) were reported; leading to the conclusion that 
palbociclib is generally well tolerated [25].
In this study, we used a panel of HNSCC cell lines to demonstrate that clinically relevant 
concentrations of palbociclib can effectively radiosensitise HPV negative cells. Furthermore, 
we show that palbociclib - mediated radiosensitivity is dependent on the presence of 
hyperphosphorylated RB, which is lost in HPV positive cells. Importantly, we show that 
palbociclib is an effective radiosensitiser of cells exposed to hypoxia, which are associated 
with radiation resistance. Treatment with palbociclib led to the decreased expression of the 
essential homologous recombination proteins RAD51 and BRCA1. The increased cell death 
observed after treatment with palbociclib and radiation was attributed to impaired DNA 
repair and increased chromosomal aberrations, which led to mitotic catastrophe. Taken 
together, we provide mechanistic insight to suggest the combination of palbociclib and 
irradiation as an effective therapeutic strategy for the treatment of HPV negative HNSCC.
Materials and methods
Cell culture, transfections, and drug treatments
UT - SCC - 5, UT - SCC - 8, UT - SCC - 11, UT - SCC - 15, UT - SCC - 19A, UT - SCC - 24A, UT - SCC - 29, 
UT - SCC - 38, UT - SCC - 40, UT - SCC - 45, FaDu (Prof Grenman, University of Turku), UM - SCC - 47 
(Dr Carey, University of Pittsburgh), and 93 - VU - 147T (Dr Dorsman, VU University medical 
center) were cultured in DMEM (Sigma) supplemented with 4.5 g/L glucose, GlutaMax, 10% 
FBS, 100 U/mL penicillin/streptamycin, Non - essential amino acids (Gibco), HEPES (Gibco), 
and sodium pyruvate (Gibco). OE21 cells (Public Health England) were cultured in RPMI 
supplemented with 100 U/ml penicillin and streptomycin and 10% Fetal Calf Serum (FCS). 
HCT116, A549, and RKO (ATCC) were cultured in DMEM supplemented with penicillin, 
streptamycin, and 10% FCS. RPE1 cells (Prof Higgins, University of Oxford) were cultured 
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in DMEM/F - 12 medium supplemented with 10% FCS. U2OS DRGFP cells (Prof Humphrey, 
University of Oxford) were cultured in DMEM supplemented with 10% FCS and 5 mg/ml 
puromycin and 100 U/ml penicillin/streptomycin. pEGFP - E6 and pEGFP - E7 plasmids (Dr. 
Hibma, University of Otago) were used to transiently overexpress HPV - 16 E6 and E7 viral 
oncogenes. Overexpression was achieved using JetPrime (PolyPlus) reagent according to 
the manufacturer’s instructions. Drug treatments included palbociclib (Selleckchem, S1116) 
and abemaciclib (MedChemExpress HY - 16297).
Immunoblotting
Protein lysates were extracted with SDS lysis buffer consisting of 10 mM Tris - Cl, pH 7.5, 
0.1 mM EDTA, 0.1 mM EGTA, 0.5% SDS, 0.1 mM β - mercaptoethanol, protease/phosphatase 
inhibitors (Roche) followed by western blotting as described previously [38]. Western 
blots were imaged using the Odyssey infrared system (LI - COR). The following antibodies 
were used: RB (Cell Signaling, #9309), phospho - RB(S807/811) (Cell Signaling, #9308), β - actin 
(Santa Cruz Biotechnology, sc - 69879), RAD51 (Santa Cruz Biotechnology, sc - 6862), H3 
(Cell Signaling, #3638), phospho - H3 (Ser10) (Cell Signaling, #9701), HIF - 1α (BD 610959), p16 
(Abcam, ab108349), PARP (Cell Signaling #9532).
RT - qPCR
RNA was extracted using TRI reagent (Sigma - Aldrich) according to the manufacturer’s 
instructions. Reverse transcriptase reaction was carried out using the Verso cDNA synthesis 
kit (ThermoFisher). qPCR was carried out with SYBR green reagents (Applied Biosystems), 
and run on a 7500 Applied Biosystems thermal cycler. Primer sequences: 18S forward: 
5’-GCCCGAAGCGTTTACTTTGA - 3’; 18S reverse: 5’-TCCATTATTCCTAGCTGCGGTATC - 3’; 
RAD51  for ward:  5’-TGGA AGA AGA A AGC T T TGGC -  3’;  RAD51  reverse: 
5’-TCTTCACATCGTTGGCATTT - 3’; BRCA1 forward: 5’-GCGTCCCCTCACAAATAAAT - 3’; BRCA1 
reverse: 5’-CTTGACCATTCTGCTCCGTT - 3’. The ΔΔCt method was applied to analyse the 
results.
Cell cycle phase distribution and mitotic index assay
Cells were grown to approximately 80% confluence, and plated in a density of 4–5 x 105 
cells per 6 cm dish. After treatment, cells were trypsinised and fixed with ice - cold 70% 
ethanol. Cells were treated with RNAse A and incubated with 20 µg/ml propidium iodide 
at 37 °C for 15 min. Samples were run on a FACSCalibur and analysed using ModFit LT V3.2 
software. For the mitotic index, after the fixation the cell suspension was incubated with 
2% FCS in PBS for 15 min at room temperature, and stained for phospho - H3(S10) for 1 
hour at room temperature. After washing in PBS - Tween20 (0.1%), cells were incubated with 
AlexaFluor488 secondary antibody (Thermofisher A11070) for 1 hour at room temperature. 




cytometer as described. Phospho - H3 (Ser10) positive and containing 4n DNA were 
considered to be mitotic cells, as determined using FlowJo v10.0.7.
Immunofluorescence
2 - 5 x 104 cells were plated in 8 - well chamber slides (Nunc - Lab - Tek) and incubated overnight. 
Drug treatment and/or irradiation was carried out, and cells were subsequently washed and 
fixed in 4% formaldehyde. Cells were permeabilised in 1% Triton - X in PBS, blocked in 2% 
BSA in PBS - Tween (0.1%), and subsequently stained for 53BP1 (Novus NB100 - 305), RAD51 
(Santa Cruz Biotechnology sc - 8349), BRCA1 (Santa Cruz Biotechnology sc - 642), or α - tubulin 
(Santa Cruz Biotechnology sc - 5286). Secondary antibody: AlexaFluor488 (ThermoFisher 
A11070). Slides were mounted in ProLong Gold Antifade reagent with DAPI (ThermoFisher, 
P36961) and imaged on a ZEISS 780 confocal microscope.
Xenografts, and immunohistochemistry/immunofluorescence
HNSCC xenografts were grown as previously described [26]. OE21 cells (squamous 
oesophageal cancer cells) were grown and stained as previously described [27]. 
Xenograft tumour processing and sectioning was performed as previously described 
[26, 27]. Frozen HNSCC xenograft sections were fixed in ice - cold acetone for 10 minutes 
and pre - incubated with primary antibody diluent (BioRad). Sections were co - stained for 
phospho - RB(S807/811) (Cell Signaling, #9308), pimonidazole (Hypoxyprobe Inc, HP4 - 100kit) 
for hypoxia and vessels by 9F1 (Department of Pathology, Radboud University Medical 
Center Nijmegen). Following overnight cold incubation with primary antibody, Cy3 (Jackson 
ImmunoResearch, 711 - 167 - 003), or AlexaFluor647 (Molecular Probes, A21472) conjugated 
secondary antibodies were incubated for 30 minutes at 37°C. After washing with PBS, slides 
were sealed in fluoromount (Serva, 21634.01).
Metaphase spreads
Cells were incubated with 30 ng/mL KaryoMax colcemid (Gibco) for 2 hours at 37 °C. 
Cells were then harvested by trypsinisation, incubated in Optimal Hypotonic Solution 
(Genial Helix) for 20 min in 37 °C, and centrifuged for 10 min at 230 g. The cell pellet 
was resuspended and fixed in ice - cold fixative (3:1 methanol to glacial acetic acid) for a 
minimum of 30 min. The cell suspension was dropped on a microscopy slide and air - dried. 
Slides were then stained for two minutes with a Giemsa stain (Sigma - Aldrich), and washed 
with regular tap water. Images of metaphases were randomly acquired using a Lucia 
Metaphase Finder (Lucia Cytogenetics) with a 100x objective.
Homologous recombination assay
U2OS DRGFP cells were plated in a 6 - well plate at a concentration of 2– 4 x 105 cells per 
well and incubated overnight. Cells were treated with palbociclib and transfected with 
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5 µg I - SceI plasmid (Addgene plasmid #26477) using Lipofectamine 3000 reagent for 
24 hours and medium was refreshed. After another 24 hours, cells were harvested by 
trypsinisation and analysed by flow cytometry for GFP+ cells on a Gallios (Beckman Coulter) 
flow cytometer.
Colony survival assays
Cells were plated at a density of 250 - 12000 cells/well in a 6 - well plastic plate. Cells were 
treated with 0.5 µM palbociclib for 6 - 24 hours and irradiated. Medium was refreshed 24 
hours after IR and cells were left to form colonies for 8 - 14 days. Colonies were fixed and 
stained by crystal violet staining (50% methanol, 20% ethanol, 30% water, 5 mg/mL crystal 
violet).
Hypoxia and radiation treatment
Hypoxic treatments at <0.1% O2 were carried out in a Bactron chamber (Shel Lab) and at 
1 - 2% O2 in a Don Whitley M35 Hypoxystation. Radiation doses were delivered in a GSM 
D1 137 - Cesium gamma irradiator as previously described [28].
Statistical analysis
Statistical analysis was carried out using Graphpad Prism v7.02 software. For colony survival 
assays the plating efficiency per condition was determined by dividing the total number 
of counted colonies by the total number of plated cells. Surviving fractions (SF) were 
calculated by dividing the plating efficiency of treated cells by the plating efficiency of the 
control cells. Data was fitted according to the linear quadratic model using the formula 
SF = e−(αD + β(D*D)). Sensitiser enhancement ratio (SER) was calculated as SER37 = D(without 
sensitiser)/D(with sensitiser) for the same biological effect at SF = 37%. In single dose 
experiments, sensitiser enhancement ratio was calculated as SER (4 Gy) = SF(4 Gy without 
sensitiser)/SF(4 Gy with sensitiser). Similarly, the oxygen enhancement ratio (OER) at 
SF = 37% was determined by OER37 = D(hypoxic)/D(normoxic). Single variable comparisons 
between two groups was performed on the mean of three biological independent repeats 
using a two - tailed unpaired t - test with Welch’s correction (*p<0.05; **p<0.01). Comparison 
of multiple groups testing one variable (mitotic and apoptotic fraction, qPCRs, genome 
stability assay) was performed on the mean outcome of three independent biological 
repeats unless stated otherwise and a one - way ANOVA was. Comparison of multiple 
groups testing >1 variable (clonogenics, 53BP1/RAD51/BRCA1 foci, cell cycle phases) were 
analysed using a two - way ANOVA based on the mean of three independent biological 
repeats unless stated otherwise. For all multiple testing, Sidak’s or Tukey’s correction 
was applied and an adjusted p value was calculated accordingly: * p<0.033; ** p<0.0021; 
***p<0.0002; ****p<0.0001. Unless specified otherwise, error bars indicate the standard 





Palbociclib radiosensitises HPV negative HNSCC
In the HPV positive UM - SCC - 47, levels of phosphorylated RB (p - RB) were low and p16 high. 
Palbociclib had no effect on the levels of either p - RB(S807/811) or p16 in UM - SCC - 47, but 
significantly reduced the levels of p - RB(S807/811) in an HPV negative cell line (UT - SCC - 24A). 
In line with a previous report, palbociclib did not induce p16 expression in the HPV negative 
UT - SCC - 24A cell line (Figure 1A) [29]. Seven HPV negative and 3 HPV positive cells lines 
were treated with palbociclib for 6 hours and exposed to radiation (4 Gy) (Figure S1A - J). 
HPV positive cells were significantly more radiosensitive than HPV negative cells (surviving 
fraction (SF) after 4 Gy: 6.0% vs 23.0%, Figure S1K) [9]. Palbociclib alone also resulted in 
a significant difference in SF with an average SF of 56.6% and 92.8% for HPV negative 
and HPV positive cell lines respectively (Figure S1L). Consistent with previous reports, 
we demonstrated that p16 was overexpressed in HPV positive (UT - SCC - 45, UM - SCC - 47, 
93 - VU - 147T, UPCI:SCC090, and UPCI:SCC154), but not HPV negative (UT - SCC - 5, 8, 9, 11, 
15, 19A, 24A, 29, 38, UM - SCC - 6), and FaDu cell lines, with the exception of HPV negative 
UT - SCC - 40 cells (Figure S1M) [11]. Importantly, HPV negative cell lines were significantly 
more sensitive to the combination of palbociclib with radiation compared to the HPV 
positive (Figure 1B). A notable exception to this was HPV negative the UT - SCC - 40 cell line, 
which could not be radiosensitised by the addition of palbociclib, possibly due to high p16 
expression (Figure S1M). Next, UT - SCC - 24A cells were treated with palbociclib and 0 - 8 Gy IR 
and again, significant radiosensitisation was observed (Figure 1C). Furthermore, we tested 
two alternative schedules (Figure 1D and E). Palbociclib only radiosensitises when present 
both at the time of radiation and afterwards (Figure 1C and D), but not when palbociclib 
was removed before radiation treatment (Figure 1E). As the half - life of palbociclib in vivo is 
approximately 26 hours we adopted the schedule shown in Figure 1D i.e. palbociclib was 
added at the time of IR and left on the cells for the following 24 hours [30]. In addition, 
other HPV negative cancer cell lines (OE21/oesophageal, A549/lung, and RKO/colorectal) 
were found to be radiosensitised through the addition of palbociclib (Figure S2A - C). We 
hypothesized that HPV positive cells could not be radiosensitised by palbociclib due to low 
levels of p - RB as a result of E7 expression. Indeed, as expected, both transfection with E7 
and E6 increased the radiosensitivity of the HPV negative UT - SCC - 24A cells (Figure S2D/E) 
[9]. However, only the cells expressing E6 could be further radiosensitised by the addition 
of palbociclib, and there was no additional effect of palbociclib when E7 was expressed 
(Figure 1F - H).
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Figure 1 Palbociclib radiosensitises HPV negative HNSCC cell lines
A, p - RB(S807/811), RB, p16, and β - actin as determined by western blotting in HPV positive UM - SCC - 47 and 
HPV negative UT - SCC - 24A cells after 0.5 µM palbociclib (Palbo). B, Sensitiser enhancement ratios of seven 
HPV negative (UT - SCC - 5, UT - SCC - 8, UT - SCC - 11, UT - SCC - 24A, UT - SCC - 40, UM - SCC - 6, and FaDu) and three HPV 
positive (UT - SCC - 45, UM - SCC - 47, and 93 - VU - 147T) HNSCC cell lines treated with 0.5 µM palbo, incubated for 6 
hours, and exposed to 4 Gy. C - E, UT - SCC - 24A cells were exposed to three different schedules of 0.5 µM Palbo 
and IR. This included 6 h pre - incubation with Palbo followed by 0 - 8 Gy IR (C), 6 h pre - incubation with Palbo, 
removal of the drug followed by IR (D), or addition of the Palbo immediately followed by IR (E). F - H, UT - SCC - 24A 
were transiently transfected with EGFP - E7 (H) and EGFP - E6 (G) expression constructs, or mock transfected (F). 




Palbociclib - mediated radiosensitivity under hypoxic conditions
Thus, palbociclib has a radiosensitising effect when phosphorylated RB is present. Hypoxia 
leads to loss of RB phosphorylation, suggesting that hypoxic cells might be resistant to the 
radiosensitising effect of palbociclib [31]. Xenograft tumours of HPV negative UT - SCC - 8 
and UT - SCC - 5 were stained for p - RB(S807/811), pimonidazole to identify hypoxic regions, 
and 9F1 to visualize vessels (Figure 2A). Regions of hypoxia were evident in both tumours 
(green staining), at distance from vessels (blue). The majority of p - RB(S807/811) staining 
(red) was outside of the hypoxic regions confirming that hypoxia does indeed lead to 
loss of phosphorylated RB. This was also observed in OE21 tumours (Figure S3). However, 
as some p - RB(S807/811) staining was present in hypoxic regions we investigated the 
oxygen dependency of p - RB(S807/811) in vitro (Figure 2B). After 24 hours, p - RB(S807/811) 
had decreased by 10.9 - fold in cells exposed to O2 levels <0.1%, 2.2 - fold in cells exposed 
to 1% O2, and 1.1 - fold in cells exposed to 2% O2 (Figure S4A). Thus, palbociclib combined 
with radiation could be effective in cells exposed to 1 - 2% O2. To test this UT - SCC - 24A 
cells were exposed to hypoxia (1% O2) and then irradiated in the presence of palbociclib 
(Figure 2C). As expected, exposure to hypoxia (1% O2) led to increased radiation resistance 
demonstrated by an oxygen enhancement ratio of 1.34 (Figure 2C). However, addition 
of palbociclib radiosensitised hypoxic cells and led to a survival response comparable to 
normoxic (21% O2) cells (SER37 = 1.47). These data indicate that palbociclib can radiosensitise 
cells exposed to physiologically relevant levels of hypoxia. Although palbociclib is generally 
well tolerated, we investigated the response in non - cancer cells [25]. As expected, the 
level of p - RB(S807/811) was significantly reduced over time (Figure S4C), and RPE1 cells 
were radiosensitised by palbociclib (Figure 2D). Although the SER37 was lower for the 
RPE1 cells compared to UT - SCC - 24A, this was not significant (1.20 vs. 1.57 respectively, 
p = 0.082). These data support the conclusion that p - RB(S807/811) is the major determinant 
of radiosensitisation by palbociclib and could be used as a future biomarker.
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Figure 2 Expression of p - RB(S807/811) predicts response to palbociclib
A, Sections of UT - SCC - 5 and UT - SCC - 8 xenografts were stained for p - RB(S807/811) (red), hypoxic areas (green), 
and vessels (blue). Scale bars: 100 µm. B, UT - SCC - 24A cells were exposed to hypoxia (<0.1% - 2% O2) and the 
levels of p - RB(S807/811), RB, HIF - 1α, and β - actin determined by western blotting. C, UT - SCC - 24A cells were 
exposed to 2 hours of 1% or 21% O2, treated with 0.5 µM Palbo and immediately exposed to IR at 1% O2, and 
then incubated for an additional 24 hours in 1% O2. OER = oxygen enhancement ratio. D, RPE1 cells were treated 
with 0.5 µM Palbo, immediately exposed to IR, and incubated for 24 hours. Graph indicates surviving fraction 




Palbociclib mediated effects on the cell cycle are HPV dependent in HNSCC
As radiosensitivity varies throughout the cell cycle and inhibition of CDK4/6 is likely to 
affect cell cycle phase distribution we investigated this as a potential mechanism of 
palbociclib - mediated radiosensitivity [32 - 34]. HPV negative UT - SCC - 24A and HPV positive 
UM - SCC - 47 cells were exposed to palbociclib, radiation, or the combination, and the cell 
cycle was analysed. Palbociclib alone induced a significant G0/G1 arrest in UT - SCC - 24A 
cells, but not in the HPV positive UM - SCC - 47 cells (Figure 3A and B). Following IR, both 
cell lines accumulated in G2/M demonstrating a functional checkpoint, which was no 
longer apparent after 24 hours following radiation (Figure 3C and D). When the HPV 
negative UT - SCC - 24A cells were exposed to palbociclib plus IR the radiation - induced G2/M 
previously observed was abrogated and instead the cell cycle appeared unaffected (Figure 
3E). In contrast, the radiation - induced G2/M arrest observed in the HPV positive UM - SCC - 47 
was maintained in the presence of palbociclib (Figure 3F). These data demonstrate that 
palbociclib alters cell cycle distribution after IR in HPV negative, but not HPV positive cells. 
To fully characterise the effect on the cell cycle of palbociclib in combination with radiation 
we also investigated changes in the mitotic fraction using the marker p - H3(S10). Palbociclib 
treatment with or without IR resulted in a loss of p - RB(S807/811) in UT - SCC - 24A cells, which 
did not occur after IR alone. In response to palbociclib, p - H3(S10) levels decreased over time, 
indicating decreased numbers of mitotic cells. A single dose of 4 Gy depleted p - H3(S10) 
levels within 3 hours, but returned to normal after 24 hours. Combining palbociclib and 
IR resulted in a rapid depletion of p - H3(S10) levels, which did not recover over time (Figure 
3G). In order to quantify the effect of palbociclib and IR on the mitotic fraction, we carried 
out a flow cytometric analysis of p - H3(S10) levels. Consistent with the protein levels of 
p - H3(S10), palbociclib treatment reduced the mitotic fraction over time (Figure 3H). IR alone 
significantly reduced the mitotic fraction after 6 hours, but showed a subsequent recovery 
between 12 to 24 hours (Figure 3I). Following a combination of palbociclib and IR, the 
mitotic fraction was abolished after 6 hours, and did not recover after 24 hours (Figure 3J).
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Figure 3 Palbociclib affects cell cycle dynamics in HPV negative HNSCC
A - B, Cell cycle profile of UT - SCC - 24A (A) and UM - SCC - 47 (B) cell lines with 0.5 µM Palbo. C - D, Cell cycle profile of 
UT - SCC - 24A (C) and UM - SCC - 47 (D) cell lines after 4 Gy. E - F, Cell cycle profile of UT - SCC - 24A (E) and UM - SCC - 47 
(F) cell lines at indicated times after concurrent exposure to 4 Gy and 0.5 µM palbociclib. G, p - RB(S807/811), RB, 
p - H3(S10), H3, and β - actin as determined by western blotting of UT - SCC - 24A cells treated with 0.5 µM Palbo, 
4 Gy, or a combination. H - J, Mitotic indices as determined by a propidium iodide and p - H3(S10) staining of 




Palbociclib leads to persistent DNA damage after radiation
We hypothesized that palbociclib impaired DNA damage repair in HPV negative HNSCC, 
thereby leading to enhanced radiosensitivity. In both UT - SCC - 24A and UM - SCC - 47, a dose 
of 4 Gy led to a rapid increase in 53BP1 foci, which decreased over time (Figure 4A, B). 
Treatment with palbociclib in UT - SCC - 24A caused a significant retention of 53BP1 positive 
nuclei, suggesting delayed or impaired DSB repair (Figure 4A). In contrast, the resolution of 
53BP1 foci in HPV positive UM - SCC - 47 cells was not affected by palbociclib (Figure 4B). To 
further investigate the effect of combined palbociclib treatment and IR on DNA damage, 
we examined metaphase spreads from UT - SCC - 24A cells for chromosome aberrations 
(Figure 4C). We treated UT - SCC - 24A cells with palbociclib, 1 Gy, or the combination and 
blocked cells in metaphase. Analysis of chromosome aberrations showed that palbociclib 
alone does not increase the number of metaphases with chromosome aberrations. 
However, exposure to IR, and more significantly the combination of palbociclib and IR, 
induced a significant increase in chromosome aberrations (Figure 4D). Together, these 
data demonstrate that the combination of IR and palbociclib leads to the accumulation 
of DNA damage.
Palbociclib mediated deficiency in homologous recombination
The data so far suggest that palbociclib treatment results in a DNA repair defect. Both 
RAD51 and BRCA1 expression, key players in the HR pathway, are repressed by palbociclib, as 
well as abemaciclib, an alternative CDK4/CDK6 inhibitor (Figure 5A, S5). As RAD51 and BRCA1 
are both known E2F transcriptional targets [35, 36], unsurprisingly palbociclib reduced 
the expression of both RAD51 and BRCA1 approximately 3.5 - fold, also when combined 
with IR (Figure 5B, C). During normal HR, RAD51 and BRCA1 proteins redistribute to sites 
of DSBs after exposure to IR [37]. In response to IR, the fraction of cells positive for RAD51 
and BRCA1 foci increased over time, but this was reduced by palbociclib (Figure 5D, 
E). An HR reporter assay was used to further investigate the effect of palbociclib [38]. 
Transient transfection with an I - Sce restriction enzyme sequence containing plasmid 
resulted in an increased GFP positive population, indicating that the U2OS - DRGFP cells 
were homologous recombination proficient (Figure S5B). Treatment with both the I - Sce 
restriction plasmid and palbociclib resulted in a decreased GFP positive fraction (78% as 
compared to non - palbociclib treated cells) (Figure 5F). Taken together, this demonstrates 
that palbociclib treatment deregulates HR, leading to persistent DNA damage.
Combination of palbociclib and IR results in mitotic defects
We determined the number of apoptotic cells by nuclear morphology after treatment 
with palbociclib, IR, or a combination, and found no significant differences in the apoptotic 
fraction (Figure 6A, S6A). Moreover, none of the aforementioned treatments induced PARP 
cleavage (Figure S6B). Mitotic catastrophe, a process where damaged cells enter mitosis 
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prematurely or progress through mitosis with chromosomes unattached to the mitotic 
spindles, has been described as the key mechanism of death after IR [39]. We measured 
the fraction of mitotic cells that displayed defective mitoses, and thus were highly likely 
to die by mitotic catastrophe. A significant induction of aberrant mitoses was observed in 
the palbociclib and palbociclib/IR treated cells (Figure 6B - C).
Figure 4 Palbociclib exacerbates radiation induced DNA damage in HPV negative cells.
A - B, Quantification of cells positive for 53BP1 (>5 53BP1 foci in a single plane of view) in HPV negative 
UT - SCC - 24A (A) and HPV positive UM - SCC - 47 (B) cells (mean percentages of three biological replicates). 
Immunofluorescent representative images of untreated UT - SCC - 24A (A) or UM - SCC - 47 (B) cells or 24 hours 
after Palbo and 4 Gy treatment. Nuclei in blue, 53BP1 foci in green. Scale bars: 10 µm. C, Chromosome and 
chromatid aberrations in UT - SCC - 24A cells. Chromosome (I) or chromatid breaks (II), dicentric chromosomes (III), 
triradial (IV) and quadriradial exchanges (V) and fragments (VI) were scored. D, Quantification of metaphases 
containing chromosome/chromatid aberrations in UT - SCC - 24A cells 14 hours after exposure to 1 Gy (IR), 0.5 µM 




Figure 5 Palbociclib impairs DNA damage repair proteins RAD51 and BRCA1
A, BRCA1, RAD51, and β - actin in UT - SCC - 24A cells after 0.5 µM Palbo as determined by western blotting. B - C, 
Real - time PCR analysis of RAD51 (B) and BRCA1 (C) mRNA in UT - SCC - 24A cells treated with 4 Gy (IR) and/or 4 hours 
0.5 µM Palbo, normalized to 18S and relative to the untreated sample. D - E, Quantification of cells positive for 
RAD51 (D) and BRCA1 (E) (>5 foci) in HPV negative UT - SCC - 24A cells treated with 4 Gy IR and 0.5 µM Palbo (mean 
proportions of three biological replicates). F, U2OS cells were transiently transfected with an I - Sce expressing 
plasmid and exposed to a vehicle control or 0.5 µM for 24 hours, followed by 24 hours with fresh medium. HR 
efficiency relative to cells that were only transiently transfected with the vector.
Discussion
Here, we show that palbociclib significantly radiosensitised HPV negative, but not 
HPV positive HNSCC cells. We demonstrate that this is dependent on the presence of 
p - RB(S807/811). We found that palbociclib reduced the expression of BRCA1 and RAD51, 
which resulted in decreased protein recruitment after IR and reduced HR capacity. 
Consequently, there is a significant delay in DNA damage repair, and an increase in 
chromosome aberrations and mitotic catastrophe. Failure to repair radiation - induced DNA 
damage before entering mitosis is predicted to be the cause of the increased cell death 
observed in response to the combination of palbociclib and radiation.
To the best of our knowledge this is the first description of the palbociclib - mediated 
radiosensitisation that includes a mechanism for discriminating between responders 
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and non - responders [40 - 42]. Importantly, we demonstrate that palbociclib is an effective 
radiosensitiser in hypoxia, suggesting this approach could be used to target the most 
radiotherapy resistant tumour fraction.
 
Figure 6 Palbociclib/IR induces cell death via mitotic catastrophe
A, UT - SCC - 24A cells were exposed to 1 Gy IR, 0.5 µM Palbo, or a combination and incubated for 24 hours. 
Apoptotic fraction was determined by nuclear fractionation. Insert shows an example of an apoptotic cell 
indicated with an arrow. Scale bar: 10 µm. B, UT - SCC - 24A cells were exposed to 1 Gy IR, 0.5 µM Palbo, or a 
combination and incubated for 24 hours. Mitotic catastrophe was determined by abnormal mitotic morphology. 
A reduced dose of 1 Gy was used to ensure some mitotic cells survived for analysis. C, Fluorescent confocal 
microscopy images of 0.5 µM Palbo and 1 Gy treated UT - SCC - 24A cells, 24 hours after treatment. Shown are 
DAPI (blue) and α - tubulin (green). Scale bars: 10 µm.
However, palbociclib would not be efficacious in the near anoxic/bordering on necrotic 
areas of tumours. In addition, DNA repair processes such as HR are also repressed in these 
severely hypoxic conditions, limiting the effect of palbociclib [43 - 45]. However, at clinically 
relevant hypoxia levels of 1% O2 (8 mmHg) where significant reduction of the OER occurs, 
palbociclib is able to sensitise HNSCC cells to radiotherapy.
To rule out that the deficiency in HR, which commonly only takes place during late 
S - phase or G2 phase is a result of a change in cell cycle dynamics, we tested the effect of 
combined palbociclib and radiation treatment. Palbociclib has been previously shown to 
induce a G1 arrest through the reduction of RB phosphorylation, potentially explaining 
the decrease in HR [46]. However, while we observed a marked increase in cells in G1 
phase after palbociclib treatment, there was no change in cell cycle phase distribution 
after combination of palbociclib and IR. We speculate that the combination of palbociclib 
and radiation blocks cell populations in both G1 and G2 phases, and therefore present as 
a static population. As there was no observed decrease in S- of G2 - phase, we concluded 
that the palbociclib - induced deficiency in HR was not cell cycle dependent. The finding 




indicates that the effect of palbociclib is independent of its effect on cell cycle. For future 
in vivo experiments, it will be important to address the dependency on phosphorylated RB 
for palbociclib - mediated radiosentivity, as we have shown that the timing of palbociclib 
and irradiation treatment is critical.
Together, our data demonstrate that the combination of IR and palbociclib is extremely 
effective and leads to loss of cell viability and a failure to repair IR - induced DNA damage 
and subsequent mitotic catastrophe. Most importantly, we show that HPV status predicts 
the sensitivity to the combination of palbociclib and IR. The combination therapy described 
here could be relatively easily tested for the treatment of HPV negative HNSCC, which 
currently urgently needs novel therapeutic strategies to improve patient prognosis.
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Figure S1 Palbociclib radiosensitises HPV negative HNSCC cell lines
A - J, HPV negative cells (UT - SCC - 5 (A); UT - SCC - 8 (B); UT - SCC - 11 (C); UT - SCC - 24A (D); UT - SCC - 40 (E); UM - SCC - 6 
(F), FaDu (G) and HPV positive cells (UM - SCC - 47(H); UT - SCC - 45(I), 93 - VU - 147T (J)) were incubated with 0.5 
µM palbociclib (Palbo) for 6 hours and exposed to 4 Gy IR. 24 hours post irradiation, the culture medium was 
refreshed and the cells were allowed to form colonies over 8 - 14 days. K, 7 HPV negative cell lines (UT - SCC - 5, 
UT - SCC - 8, UT - SCC - 11, UT - SCC - 24A, UT - SCC - 40, UM - SCC - 6, FaDu) and 3 HPV positive cell lines (UM - SCC - 47, 
UT - SCC - 45, 93 - VU - 147T) were treated as described in A - J. The effect of IR alone was determined by colony 
forming assay. L, 7 HPV negative cell lines (UT - SCC - 5, UT - SCC - 8, UT - SCC - 11, UT - SCC - 24A, UT - SCC - 40, UM - SCC - 6, 
FaDu) and 3 HPV positive cell lines (UM - SCC - 47, UT - SCC - 45, 93 - VU - 147T) were treated as described in A - J. 
The effect of palbociblic alone was determined by colony forming assay. M, Levels of p16 and β - actin were 
determined by western blotting for a panel of HNSCC cell lines. UT: UT - SCC cell lines. UM: UM - SCC cell lines. 
93VU: 93 - VU - 147T. UPCI: UPCI:SCC cell lines. 
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Figure S2 Palbociclib radiosensitises lung, oesophageal, and colorectal cell lines.
A - C, Three cancer cell lines (OE21/oesophageal (A), A549/lung (B), RKO/colorectal (C)) were treated with 0.5 µM 
palbociclib and immediately exposed to 0 - 8 Gy. 24 hours post irradiation the culture medium was refreshed 
and the cells were allowed to form colonies for 8 - 14 days. Graphs show mean surviving fraction relative to 
unirradiated controls of two (B - C) or three (A) independent biological experiments. D, UT - SCC - 24A cells were 
transfected with 4 µg pEGFP - E7 or pEGFP - E6 plasmid or mock transfected and incubated for 24 hours. Shown 
are brightfield and fluorescent (green) images at 20x magnification. Scale bars: 100 µm. E, UT - SCC - 24A cells 
were transfected with 4 µg pEGFP - E7 or pEGFP - E6 plasmid or mock transfected and incubated for 24 hours. 




Figure S3 Inverse correlation of p - RB(S807/811) and hypoxia markers CAIX and pimonidazole in OE21 xenografts.
Immunohistochemistry images showing hypoxic regions (CAIX and PIMO), total RB and p - RB(S8 - 7/811) in OE21 
xenograft tumours. Nuclei were counterstained with haematoxylin. Scale bars: 100 µm.
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Figure S4. UT - SCC - 24A cells become radioresistant in hypoxia and palbociclib reduces RB phosphorylation 
in RPE1 cells.
A, UT - SCC - 24A cells were exposed to 2%, 1%, or <0.1% O2 for the indicated times and levels of p - RB(S807/811) 
and β - actin were determined by western blotting. Western blot bands were quantified using ImageJ software. 
p-(RB807/811) protein abundance was corrected for β - actin and is displayed relative to an untreated sample. 2% 
O2 and 1% O2 represent data from n=2 biological repeats, <0.1% O2 represents data from n=3 biological repeats. 
B, RPE1 cells were treated with 0.5 µM Palbo for the indicated amounts of time. Levels of p - RB(S807/811), RB, 




Figure S5 Abemaciclib affects proliferation and HR markers and U2OS DRGFP cells are a valid model for mea-
suring HR
A, UT - SCC - 24A cells were exposed to 4 Gy, 0.5 µM abemaciclib (Abema), or a combination and incubated for the 
indicated amount of time. Levels of p - RB(S807/811), RB, Rad51, p - S10 - H3, H3, and β - actin were determined by 
western blotting. B, Representative flow cytometry plots of U2OS DRGFP cells that were transfected with 5 µg 
I - Sce expression constructs (I - Sce+) or mock transfected (I - Sce-). A minimum of 50,000 cells was analysed. Single 
cells were selected (gating not shown) and based on I - Sce- transfected cells, a GFP+ gate was determined.
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Figure S6 Palbociclib does not induce apoptosis in UT - SCC - 24A cells.
A, UT - SCC - 24A cells were exposed to 4 Gy (IR), 0.5 µM Palbo, or a combination and incubated for the indicated 
amount of time. Levels of p - RB(S807/811), RB, PARP, cleaved (cl) PARP, and β - actin were determined. B, 
UT - SCC - 24A cells were exposed to 1 Gy (IR), 0.5 µM Palbo, or a combination and incubated for 3 hours. Apoptotic 
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Radiotherapy is an important treatment modality of head and neck squamous cell 
carcinomas (HNSCC). Multiple links have been described between the metabolic activity 
of tumours and their clinical outcome. Here we test the hypothesis that metabolic 
features determine radiosensitivity, explaining the relationship between metabolism and 
clinical outcome. Radiosensitivity of 14 human HNSCC cell lines was determined using 
colony forming assays and the expression profile of approximately 200 metabolic and 
cancer - related genes was generated using targeted RNA sequencing by single molecule 
molecular inversion probes. Results: Correlation between radiosensitivity data and 
expression profiles yielded 18 genes associated with radiosensitivity or radioresistance, of 
which ATP citrate lyase (ACLY) was of particular interest. Pharmacological inhibition of ACLY 
caused an impairment of DNA damage repair, specifically homologous recombination, and 
lead to radiosensitisation in HNSCC cell lines. Examination of a The Cancer Genome Atlas 
(TCGA) cohort of HNSCC patients revealed that high expression of ACLY was predictive 
for radiotherapy failure, as it was only associated with poor overall survival in patients 
who received radiotherapy (hazard ratio of 2.00, 95% CI: 1.12–3.55; p = 0.0184). These 
data were further validated in an independent cohort of HNSCC patients treated with 
chemoradiation. Furthermore, patients with poor locoregional control after radiotherapy 
have significantly higher nuclear ACLY protein levels. Together, we here show that ACLY 
affects DNA damage repair, and is a predictive factor for radiotherapy outcome in HNSCC.
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Introduction
Head and neck squamous cell carcinomas (HNSCC) are malignancies of the epithelium 
lining the nasal and oral cavity as well as the pharynx, and annually affects 650,000 people 
worldwide [1]. Together with surgery and (concurrent) chemotherapy, radiotherapy (RT) is 
an essential part of standard treatment for patients with HNSCC. Although RT is generally 
highly effective, tumours recur in a substantial number of patients with advanced stage 
disease [2]. In HNSCC originating in the oropharynx, the odds of treatment success are 
significantly affected by the human papillomavirus (HPV) status of the tumour. HPV 
positive tumours constitute approximately 5%–60% of HNSCC cases, depending on the 
specific anatomical location [3]. HPV positive oropharynx tumours have been shown to 
be significantly more radiosensitive, and this is reflected in the patient population where 
HPV positive patients have a strikingly better prognosis, locoregional control, and five 
year survival [4 - 8]. The mechanisms leading to radioresistance especially in HPV negative 
patients have been extensively studied and have been attributed to DNA damage repair, 
cell cycle arrest, activation of oncogenes, microenvironmental changes, as well as changes 
in tumour metabolism [9].
Malignant cells/tissues have been shown to have a significantly different metabolism 
than non - malignant tissues and this is considered to be one of the hallmarks of cancers 
[10]. In addition, HNSCCs undergo extensive metabolic reprogramming upon malignant 
transformation, including others changes in oxidative phosphorylation, the tricarboxylic acid 
cycle, fatty acid metabolism, and increase of glycolysis [11 - 13]. These reports indicate that, 
overall, in cancer cells the utilization of glucose and glutamine as a primary energy source 
is enhanced, matching the leading theory that cancer cells switch to aerobic glycolysis to 
generate sufficient macronutrients to allow for cellular growth and proliferation [11].
Interestingly, metabolic reprogramming has previously been linked to changes in 
radiosensitivity, and has been shown to contribute to the development of radioresistant 
tumour cells. Increased aerobic glycolysis has been demonstrated to lead to elevated levels 
of lactate, pyruvate, and acetate, as well as changes in the redox state of cells. Overall, these 
changes affect the antioxidizing capacity of cells, enabling them to effectively scavenge 
DNA - damaging reactive oxygen species produced by ionising radiation [14].
In this study, we investigate the association between radiosensitivity and the metabolic 
gene profile in HNSCC. Hereto, we use a panel of HNSCC cell lines to identify clinically 
relevant metabolic transcripts that could confer radioresistance, irrespective of HPV status. 
We show that expression of ATP citrate lyase (ACLY), the enzyme converting citrate to 




ACLY led to impaired homologous recombination and increased radiosensitivity, which 
is in line with a recently described role for ACLY in the DNA damage repair pathway [15]. 
Furthermore, we show in two independent patient cohorts that patients who receive RT 
have a poorer prognosis in the case of high ACLY expression, and that nuclear ACLY may 
represent a novel target for radiosensitisation in HNSCC.
Materials and methods
Cell lines, reagents, and irradiation
UT - SCC - 5, UT - SCC - 8, UT - SCC - 9, UT - SCC - 11, UT - SCC - 15, UT - SCC - 19A, UT - SCC - 24A, 
UT - SCC - 29, UT - SCC - 38, UT - SCC - 40, UT - SCC - 45, FaDu (Kindly provided by Prof Grenman, 
University of Turku), UM - SCC - 6, UM - SCC - 47 (Kindly provided by Dr Carey, University 
of Pittsburgh), 93 - VU - 147T (Kindly provided by Dr Dorsman, Amsterdam University 
Medical Center), and UPCI:SCC - 154 (DSMZ) were cultured in DMEM medium (Gibco) 
supplemented with 4.5 g/L glucose, GlutaMAX, 10% FBS, 100 u/mL penicillin/streptomycin, 
non - essential amino acids (Gibco), HEPES (Gibco), and sodium pyruvate (Gibco). U2OS 
DRGFP cells (provided by Prof Tim Humphrey, University of Oxford) were cultured in 
DMEM supplemented with 10% FCS and 5 mg/mL puromycin and 100 U/mL penicillin/
streptomycin. Cells were treated with 5 µM BMS303141 (Sigma - Aldrich, St. Louis, MO, USA) 
in DMSO or 10 µM C75 (Merck) in DMSO for 6 h prior to irradiation. Single dose irradiation 
was delivered using a 320 kV XRAD irradiator (RPS Services Limited, Surrey, UK)) at a dose 
rate of 3.1 Gy/min. An overview of cell line characteristics and tissue origin can be found 
in Table S1.
Homologous recombination assay
U2OS DRGFP cells were plated in a 6 cm dish at a concentration of 2.5 x 105 cells per well and 
left to attach overnight. Cells were treated with an ACLY inhibitor (BMS303141, Selleckchem, 
Munich, Germany) or Rad51 inhibitor (B02, Calbiochem) for 6 h and then transfected with 
10 µg pCBASceI plasmid (Addgene #26477) using Lipofectamine 3000 reagent for 24 h. 
Medium was refreshed after 24 h and cells were harvested by trypsinisation 48 h after 
transfection. The fraction GFP positive cells was determined by flow cytometry using a 
FACS Canto II (BD Biosciences, Franklin Lakes, NJ, USA).
Single molecule Molecular Inversion Probe sequencing
RNA was isolated from 14 cell lines using TRIzol reagent (ThermoFisher Scientific, Waltham, 
MA, USA) and reverse transcribed with Superscript II (ThermoFisher Scientific) using random 
hexamer primers, according to the manufacturer’s instructions. Targeted RNA sequencing 
using smMIPs has been described in detail before [16, 17]. SmMIPs were designed against 
81
ACLY Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas
target regions of interest (UCSC human genome assembly hg19 and splice - variant specific 
FASTA sequences) based on the MIPgen algorithm as described by Boyle et al., including a 
random octanucleotide unique molecule identifier [18]. SmMIPs were pooled at 100 µM/
smMIP (1078 smMIPs, ~200 transcripts) and phosphorylated using T4 Polynucleotide Kinase 
(New England Biolabs, Ipswich, MA, USA) in T4 DNA ligase buffer (NEB) for 45 min at 37 °C, 
followed by 20 min inactivation at 65 °C. Phosphorylated smMIPs were hybridized to 50 
ng of cDNA, followed by enzymatic gap - fill by primer extension and ligation in a reaction 
including Ampligase buffer (Epicentre, Madison, WI, USA), dNTPs, Hemo KlenTaq enzyme 
(New England Biolabs, NEB, Ipswich, MA, USA) and DNA ligase (Ampligase, Epicentre), 
incubated for 10 min at 95 °C followed by 18 h at 60 °C. Non - circularized smMIPs and 
remaining RNA and cDNA were removed by exonuclease treatment with 10 U Exonuclease 
I and 50 U of Exonuclease III (both NEB) for 45 min at 37 °C, followed by heat inactivation 
(95 °C, 2 min). The circularized smMIP library was subjected to standard PCR with 2x 
iProof High - Fidelity DNA Polymerase master Mix (Bio - Rad, Hercules, CA) with a primer set 
containing a unique barcoded reverse primer for each sample. The pool was then purified 
using AMPureXP beads (Beckman Coulter Genomics, High Wycombe, UK) according to 
manufacturers’ instructions. smMIP - PCR libraries were sequenced on the Illumina Nextseq 
platform (Illumina, San Diego, CA, USA) at the Radboudumc sequencing facility. Reads 
were mapped against reference transcripts (UCSC human genome assembly hg19 and 
variant - specific FASTA sequences) using the SeqNext module of JSI SequencePilot version 
4.2.2 build 502 (JSI Medical Systems, Ettenheim, Germany). The unique molecule identifier 
was used to reduce all identical PCR amplification products to one consensus read (unique 
read). Unique read counts for each smMIP were normalized to the total unique read count 
within a sample and multiplied by 106 (Fragments per Million, FPM). Individual transcript 
levels were expressed as mean FPM of all smMIPs targeting that transcript.
Colony forming assays
Cells were plated at a density of 150–19,200 cells/well in a 6 - well polystyrene culture plate 
(Corning). Cells were incubated overnight, treated with BMS303141, C75, or a DMSO control 
for 6 h and irradiated while still in single - cell phase. Medium was refreshed 24 h after IR and 
cells were left to form colonies for 8–14 days. Colonies were fixed and stained by crystal 
violet staining (50% methanol, 20% ethanol, 30% water, 5 mg/mL crystal violet).
Radiosensitivity analysis and linear quadratic fitting
Statistical analysis was carried out using Prism v8.01 (GraphPad). For colony survival 
assays the plating efficiency per condition was determined by dividing the total number 
of counted colonies by the total number of plated cells. Surviving fractions (SF) were 
calculated by dividing the plating efficiency of treated cells by the plating efficiency of 




formula SF = e−(αD + β(D*D)). The dose permitting a 37% clonogenic survival (D37) was used as 
a measure for cellular radiosensitivity and was calculated from the α and β generated by 
Prism LQ fitting. Sensitiser enhancement ratio (SER) was calculated as SER37 = D (without 
sensitiser)/D (with sensitiser) for the same biological effect at SF = 37%.
siRNA interference and real time quantitative PCR (RT - qPCR)
siRNA mediated depletion was performed using the Lipofectamine RNAiMAX system 
(Invitrogen) according to the manufacturer’s instruction. Cells were transfected for 72 h with 
scrambled siRNA (SIC002 MISSION esiRNAm Sigma - Aldrich) or ACLY targeting pooled siRNA 
(EHU08192 1MISSION esiRNA, Sigma - Aldrich). RNA isolation and RT - qPCR was performed as 
previously described [5]. HPRT forward: 5’-TATTGTAATGACCAGTCAACAG - 3‘; HPRT reverse: 
5’-AAGCTTGCTGGTGAAAAGGA - 3’; ACLY forward: 5’-TGCTCGATTATGCACTGGAAGT - 3’; ACLY 
reverse: 5’-ATGAACCCCATACTCCTTCCCAG - 3’.
Immunofluorescence
5 × 104 cells were plated in 8 - well chamber slides (Nunc - Lab - Tek) and incubated overnight. 
Treatment with BMS303141/C75 was carried out and cells were irradiated with 2 Gy. Cells 
were fixed in 4% formaldehyde, permeabilized in 1% Triton - X in PBS and blocked in 
2% bovine serum albumin in PBS - Tween (0.1%). Cells were subsequently stained with 
1:1000 DAPI (Cell Biolabs) and 1:250 53BP1 (Novus NB100 - 305) primary antibody and 1:500 
secondary Fab Cy3 antibody (Jackson ImmunoResearch, Ely, UK). Slides were mounted in 
fluoromount (Serva Electrophoresis GmbH, Heidelberg, Germany) and imaged on a Leica 
microscope.
TCGA data extraction and selection criteria
Xena browser (https://xenabrowser.net/) was utilized to extract data from the HNSC TCGA 
dataset [19]. From this dataset, radiotherapy status, sample type, time to event (death), 
event status, recurrence free survival, TNM status, and RNA sequencing expression data 
of genes of interest were extracted. Samples that were non - primary tumour (e.g., normal 
tissue or metastatic tissue) were excluded, as well as samples from patients with MX or 
M1 status of where radiotherapy status was unknown. Data was censored after 5 years 
follow - up. A total of 445 samples were selected for analysis, of which 288 patients received 
radiotherapy.
TCGA data analysis
Patient and gene expression data was analysed using SPSS v25.0.0.1 (IBM, Armonk, NY, 
USA). Optimal cut - off points for survival analysis were determined using the Cut - off Finder 
webtool (http://molpath.charite.de/cutoff/index.jsp). The optimal cut - off point for overall 
survival was determined as the highest or lowest hazard ratio that was significant (outside 
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the 95% confidence interval) [20]. Based on the optimized cut - off values for expression 
of the gene of interest, overall survival and recurrence free survival were evaluated using 
Kaplan–Meier analyses, and tested for statistical significance using the log - rank test. Hazard 
ratios were calculated between high and low expression groups using a Cox regression 
model.
Validation dataset
As a validation cohort, we used clinical data and gene expression profiles of the Pramana 
HNSCC patient cohort [21]. This cohort contained data of 91 HNSCC patients who were 
all treated with cisplatin and radiotherapy. An extensive description of the patient cohort 
can be found in the original publication.
Immunohistochemistry
Of a previously described cohort of HNSCC patients, 19 paraffin embedded biopsies were 
selected based on locoregional control; 9 biopsies of patients that had a poor locoregional 
outcome, and 10 biopsies of patients with favourable locoregional control (Table S3) 
[22]. Sections of 5 µM thickness were cut, deparaffinated and rehydrated. Sections were 
incubated in citrate buffer (Dako) at 96 °C for 30 min, cooled, and blocked using 5% normal 
donkey serum in primary antibody diluent (Bio - rad) at room temperature for 30 min. 
Total ACLY was stained using an ACLY antibody (HPA022434, Sigma - Aldrich) 1:25 at 4 °C 
overnight, followed by a 0.3% H2O2 peroxidase block and secondary antibody incubation 
with 1:200 F (ab) donkey anti rabbit Biotin (Jackson Immuno Research). Sections were 
then incubated in Vextastain avidin - biotin - complex reagent (Vector), rinsed with water, 
and incubated with diaminobenzidine (Vector). Afterwards, they were dehydrated and 
mounted in HistoChoice mounting medium. Images were acquired on a Leica DM 6000 
microscope at 20 x magnification. Scoring of nuclear or cytoplasmic staining of total ACLY 
was performed blindly by two independent researchers after a technician had randomised 
the images.
Statistics
For in vitro assays, single variable comparisons between two groups were performed on 
the mean of three biological independent repeats using a two - tailed unpaired t - test with 
Welch’s correction. For experiments involving multiple variables, an ANOVA was performed, 
followed by Sidak’s correction for multiple testing. Testing of categorical variables was 
done using a Pearson’s Chi - squared test. Unless specified otherwise, error bars indicate the 
standard error of the mean of three biological replicates. Statistical significance is indicated 





Multiple metabolic genes associate with radioresistance and –sensitivity
To investigate the link between radiosensitivity and the metabolic gene profile, we first 
characterized the radiosensitivity of a panel of HNSCC cell lines. This panel of 14 different 
HNSCC cell lines showed that there is a high variability in radiosensitivity between the lines 
(Figure 1A,B). Using a targeted sequencing approach by means of single molecule molecular 
inversion probes (smMIPs) for high - risk HPV types (HPV16, HPV18, HPV33, and HPV52) we 
validated the previously established HPV status in the cell lines (Supplementary Figure 
S1A). Using linear quadratic model fitting, the α and β, of each cell line were determined, 
which are the main parameters of intrinsic cellular radiosensitivity. Subsequently, the 
radiation dose permitting 37% survival (D37) was interpolated from the linear quadratic 
model (Supplementary Figure S1B). As expected, the D37 was significantly lower for HPV 
positive HNSCC cell lines compared to HPV negative HNSCC cell lines (p = 0.013) (Figure 
S1C), indicating that the HPV positive cells were more sensitive to irradiation, confirming 
previous reports [4, 8]. We then performed smMIP sequencing for approximately 200 
metabolic and cancer - related targets [16, 23] to investigate whether gene transcripts could 
be identified that correlate with radiosensitivity or radioresistance. When we compared the 
four most radioresistant and radiosensitive cell lines (UT - SCC - 5, UT - SCC - 15, UT - SCC - 19A, 
UT - SCC - 11 vs. UT - SCC - 40, 93 - VU - 147T, UM - SCC - 47 and UT - SCC - 45), we found that in 
the former expression levels of the tricarboxylic acid cycle, glutamine metabolism, and 
lipogenesis pathways were up regulated (Supplementary Figure S1D). Using a Spearman’s 
rank test to test for significant correlation between the D37 and gene transcripts, 18 targets 
were detected that significantly correlated with either radioresistance or radiosensitivity 
(Table 1). Of these transcripts, 16 correlated positively with radioresistance, and two with 
radiosensitivity.
Inhibition of ACLY affects DNA damage repair and radiosensitises HNSCC cells
As the ATP citrate lyase (ACLY) enzyme has recently been implicated to play a role 
in the DNA damage repair pathway [15] and it is one of our top hits to correlate with 
radiosensitivity, we hypothesized that ACLY may be relevant for further study. There 
was no significant difference in ACLY expression levels between HPV positive and HPV 
negative HNSCC cells, suggesting that HPV status is not a confounding factor (p = 0.09) 
(Supplementary Figure S2). To investigate whether ACLY indeed affects DNA damage repair 
and subsequent radiosensitisation of HNSCC cell lines, we depleted ACLY expression via 
siRNA in the most radioresistant cell line, UT - SCC - 15. siRNA mediated depletion of ACLY 
was confirmed 72 h after transfection (Figure S3A) and radiosensitised UT - SCC - 15 cells to 
irradiation (Figure S3B). To move towards a more clinically realistic setting, we opted to 
further validate this using pharmacological inhibition of ACLY using BMS303141. UM - SCC - 6 
85
ACLY Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas
and UT - SCC - 5 cells were treated with 5 µM BMS303141 for 6 h before irradiation, and 
thereafter colony survival was assessed as measure for radiosensitisation. DNA damage 
repair was assessed by staining for 53BP1, an important repair factor which is rapidly 
recruited to sites of double - strand breaks [24]. BMS303141 treatment had a significant 
radiosensitising effect on both UT - SCC - 5 and UM - SCC - 6 cells (sensitiser enhancement 
ratio at 37% survival (SER37) = 1.29; p < 0.001 and p = 0.0068 respectively) (Figure 2A,B).
Figure 1 Characterization of 14 HNSCC cell lines. 
A, Schematic representation of the approach to determine radioresistance or -sensitivity associated metabolic 
transcripts. B, 10 HPV negative (UT - SCC - 5, 8, 11, 15, 19A, 24A, 29, 38, 40, and UM - SCC - 6) and four HPV positive 
(UT - SCC - 45, UM - SCC - 47, 93 - VU - 147T, and UPCI: SCC154) cell lines were exposed to 0, 2, 4, 6, or 8 Gy. Survival 




ACLY inhibition followed by 2 Gy ionizing radiation (IR) resulted in a significant defect 
in DNA damage repair, as shown by an increased number of residual 53BP1 foci 24 h 
post - IR (UT - SCC - 5, p = 0.0088; UM - SCC - 6, p = 0.0029) (Figure 2C,D, Supplementary 
Figure S3C,D). We then determined whether the defect in DNA damage repair could 
be a consequence of defective homologous recombination using a GFP based reporter 
system [25]. Pre - incubation with BMS303141 or B02, a RAD51 inhibitor used as positive 
control of homologous recombination inhibition, resulted in a significant decrease of the 
GFP positive fraction (p = 0.0036), indicating that ACLY inhibition repressed homologous 
recombination (Figure 2E,F). These data demonstrate that ACLY significantly influences 
DNA damage repair, which is in line with a previous report that explored the effect of 
ACLY - mediated histone acetylation on homologous recombination [15]. To investigate 
whether other functions of ACLY distinct from homologous recombination repair can 
be involved, we inhibited fatty acid synthetase (FAS), responsible for the production of 
palmitate from acetyl - CoA and malonyl - CoA, with C75. Contrary to BMS303141, treatment 
with C75 did not lead to an increase of residual 53BP1 foci in UM - SCC - 6 and UT - SCC - 5 cells 
(UM - SCC - 6, p = 0.933; UT - SCC - 5, p = 0.195), nor did it cause radiosensitisation (p = 0.184) 
(Supplementary Figure S3E–G), indicating that the radiosensitising effect of ACLY inhibition 
is independent of fatty acid synthesis.
High ACLY levels are associated with poor prognosis in HNSCC patients receiving 
radiotherapy
Next, we assessed whether ACLY expression levels were associated with HNSCC patients’ 
responses to RT, using an experimental and validation cohort. For the experimental cohort, 
we extracted gene expression data of 445 patients from the HNSCC TCGA dataset (Table 
S2). To objectively stratify patients in two groups (low ACLY expression and high ACLY 
expression), we used Cut - off Finder [20] to determine the optimal cut - off point in patients 
who did or did not receive RT. The optimal cut - off point was determined to be at 81.3% of 
the population, and was used in all subsequent analyses. Patients that were treated with 
RT and had high ACLY expression, had a significantly worse overall survival than patients 
with low ACLY expression (hazard ratio (HR) = 2.00; 95% confidence interval (CI) 1.12–3.55; 
p = 0.0184) (Figure 3A). In contrast, ACLY expression did not correlate with the overall 
prognosis of patients that did not receive RT (HR = 0.893; 95% CI 0.504 - 1.58; p =0.697) 
(Figure 3B). Together, these results are in line with our preclinical data suggesting that 
patients with high ACLY expressing tumours have a superior DNA damage repair capacity, 
leading to radioresistance. Of note, ACLY expression did not affect the recurrence free 
survival, both in patients who did and who did not receive RT (RT+ HR = 1.293; 95% CI 
0.684–2.45; p = 0.389; RT− HR = 0.804; 95% CI 0.320–2.02; p = 0.660) (Supplementary Figure 
S4A,B). Overall, no major differences were observed regarding TNM status in patients with 
high ACLY expression versus patients with low ACLY expression (Table 2).
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Table 1 Genes significantly correlating with D37 values of 14 HNSCC cell lines. Spearman’s rho correlation was 
used to determine the strength of association. Shown are transcripts and their encoded proteins that are 
associated with radioresistance or -sensitivity.
Gene 
Name








ACACA Acetyl - CoA carboxylase alpha 0.596 0.025 Resistance
ACLY ATP citrate lyase 0.670 0.009 Resistance
ALDOA Aldolase, fructose - bisphosphate A −0.538 0.047 Sensitivity
BRAF B - Raf 0.657 0.011 Resistance
EGF Epidermal growth factor 0.573 0.032 Resistance
GCLC Glutamate cysteine ligase 0.534 0.049 Resistance
GLDC Glycine dehydrogenase 0.650 0.012 Resistance
GLUL Glutamine synthetase 0.666 0.009 Resistance
GOT1 Glutamate oxaloacetate transaminase 0.684 0.007 Resistance
E2, E6, E7 
(HPV)
E2, E6, E7 (all transcripts) -0.547 0.043 Sensitivity
IDH3A Isocitrate dehydrogenase 3, mitochondrial, 
alpha
0.578 0.030 Resistance
KDR Vascular endothelial growth factor receptor 2 0.602 0.023 Resistance
L2HGDH L - 2 - hydroxyglutarate dehydrogenase 0.604 0.022 Resistance
MYC V - myc avian myelocytomatosis viral oncogene 
homolog
0.692 0.006 Resistance
PFKM Phosphofructokinase 1 0.640 0.014 Resistance
RPIA Ribose 5 - phosphate isomerase A 0.710 0.004 Resistance
SDHD Succinate dehydrogenase complex, subunit D 0.604 0.022 Resistance
To validate that patients who received RT have a poorer prognosis when expressing high 
levels of ACLY, we tested an alternate HNSCC patient cohort [21]. In this validation cohort 91 
patients were included, all treated with a combination of cisplatin and RT (Supplementary 
Table S3). Like the TCGA HNSCC cohort, follow - up time was censored at five years. The 
same cut - off point as for the TCGA cohort was applied (e.g., 81.3%) and survival analysis 
was performed using Kaplan - Meier analyses. For this cohort, only locoregional control data 
was available. Again, patients who had a high ACLY expression had a significantly worse 
locoregional control than patients with low ACLY expression, confirming the results of the 
HNSCC TCGA cohort (HR = 4.17; 95% CI 1.35–12.86; p = 0.0130) (Figure 3C). Taken together, this 
strongly suggests that HNSCC patients who receive RT have an overall worse prognosis when 




Figure 2 Inhibition of ACLY exacerbates radiation induced DNA damage in HNSCC cells and impairs homol-
ogous recombination
A - B, UM - SCC - 6 (A) and UT - SCC - 5 (B) cells were treated with 5 µM BMS303141 for 6 h and irradiated with 2, 
4, or 6 Gy. Survival was determined by colony formation assay. C - D, Quantification of cells positive for 53BP1 
foci (>5 53BP1 foci/nucleus in a single plane of view) in UM - SCC - 6 (C) and UT - SCC - 5 (D) cells. Shown are mean 
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percentages of three biological replicates. Immunofluorescent representative images of examples of UM - SCC - 6 
or UT - SCC - 5 cells, 24 h post irradiation, with or without 5 µM BMS303141 pre - treatment. Nuclei in blue, 53BP1 
foci in red. E, Homologous recombination assay. U2OS cells have been stably transfected with a construct 
containing a GFP gene containing a I - SceI restriction site (SceGFP) as well as a stop codon at the same site. 
Upon transfection with an I - SceI encoded plasmid, a double strand break is induced at the I - SceI site. Repair 
of this break via homologous recombination occurs through utilization of the internal GFP (iGFP) fragment 
downstream of the SceGFP. Successful homologous recombination results in the restoration of a functional 
GFP gene. F, U2OS DRGFP cells were treated for 6 h with 5 µM BMS303141 or 5 µM BO2 (RAD51 inhibitor), and 
transfected with pCBASceI plasmid. 48 h post transfection, cells were harvested and the GFP positive fraction 
was determined using flow cytometry. Representative images from flow cytometry experiments are shown 
on the right, with DMSO Sce- as a negative control, and 5 µM B02 Sce+ as a positive control. In the graph, data 
are shown from two biological replicates..
Figure 3 High ACLY expression predicts poor response in RT treated HNSCC patients.
A - B, Kaplan–Meier analysis of HNSCC patients that have high or low ACLY expression based on the optimal 
cut - off point. Shown are plots for overall survival of HNSCC patients that received radiotherapy (A) and patients 
that did not (B). C, Kaplan–Meier analysis of HNSCC patients that have high or low ACLY expression based 





Nuclear ACLY localisation is associated with locoregional control in HNSCC patients
To further investigate the clinical impact of ACLY levels in more detail, we tested the levels of 
total ACLY protein in biopsies of HNSCC patients. 19 biopsies of HNSCC patients of a previously 
described cohort [22] were selected for analysis, based on the locoregional control; nine 
patients with poor locoregional control (locoregional event within 177 ± 36 days), and ten 
patients with good locoregional control (all minimal recurrence free survival of three years) 
(Supplementary Table S4). We hypothesized that patients with a poor locoregional control 
had higher levels of ACLY than patients with a good locoregional control. Overall, ACLY 
expression seemed ubiquitously expressed in all patient samples, yet demonstrated a marked 
pattern in terms of cellular localization (Figure 4A). Strikingly, patients with poor locoregional 
control had significantly higher levels of ACLY in the nucleus (p = 0.037). In patients with good 
locoregional control, ACLY was almost unequivocally expressed in the cytoplasm, but not 
the nucleus (Figure 4B). This indicates that not only ACLY expression, but also its localization 
could play a critical role in determining treatment response in HNSCC patients.
Table 2 Clinical characteristics of The Cancer Genome Atlas HNSCC cohort. Statistical significance between low versus 
high ACLY expression and RT+ and RT- patients was tested using a Chi - square test. * p < 0.05, ** p < 0.01; *** p < 0.001.
Variable Low ACLY High ACLY RT- RT+
N % N % p - Value N % N % p - Value
Gender Female 98 27.1 18 21.7 0.313 55 35.0 61 21.2 0.001 *
Male 264 72.9 65 78.3 102 65.0 227 78.8
Clinical T 
status
T1 + T2 136 37.6 18 21.7 0.141 84 53.5 70 24.3 <0.001 **
T3 + T4 215 59.4 63 75.9 69 44.0 209 72.6
Tx or 
missing
11 3.0 2 2.4 4 2.5 9 3.1
Clinical N 
status
N0 168 46.4 36 43.4 0.975 98 62.4 106 36.8 <0.001 **
N1 - 3 178 49.2 45 54.2 54 34.4 169 58.7
Nx or
missing
16 4.4 2 2.4 5 3.2 13 4.5
Clinical M 
status
M0 343 94.8 80 96.4 0.667 152 96.8 271 94.1 <0.001 **
Mx or 
missing
19 5.2 3 3.6 5 3.2 17 5.9
Clinical 
stage
Stage I + II 82 22.7 14 16.9 0.677 66 42.0 30 10.4 <0.001 **
Stage III + IV 271 74.8 67 80.7 87 55.4 251 87.2
Missing 9 2.5 2 2.4 4 2.5 7 2.4
Received 
radiotherapy
Yes 238 65.7 50 60.2 0.344 124 79.0 238 82.6 0.344
No 124 34.3 33 39.8 33 21.0 50 17.4
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Figure 4 Nuclear ACLY staining is associated with poor outcome in HNSCC patients. 
A, Immunohistochemistry images showing total ACLY in HNSCC patient biopsy sections. The left pane 
corresponds to a representative section of a patient with poor locoregional control; the right pane to a patient 
with good locoregional control. Images are at 20× (top) or 60× (bottom) magnification. B, Chi - squared test of 
patients with low vs. high regional control and nuclear or cytoplasmic staining. 
Discussion
In this study, we have shown that a targeted RNA sequencing approach allowed to 
identify gene transcripts that are associated with radioresistance in HNSCC cell lines. One 
of the top hits, ACLY, correlated with radioresistance, and inhibition of ACLY resulted in 
impaired homologous recombination, leading to decreased DNA damage repair and 
radiosensitisation. Furthermore, we demonstrated that high ACLY expression in patient 




survival, and that nuclear ACLY is mainly found in HNSCC patients with poor outcome. It has 
previously been described that ACLY is overexpressed in malignant tissues as compared 
to normal tissues, which could provide for an optimal therapeutic window, yet the cause 
of high ACLY expression in HNSCC patients has not been investigated [26]. Experiments 
performed in visceral adipose tissue suggest that ACLY levels could be elevated as a 
result of an hypoxic environment, and that ACLY could be a possible target gene of the 
hypoxia - inducible factor 1α [27]. In that case, ACLY could correlate with the occurrence 
of hypoxic tumours, and the observed poor treatment response could be also partially 
attributed to the lack of oxygen required for effective irradiation.
ACLY catalyzes the production of acetyl - CoA and oxaloacetate from citrate and CoA, 
and thereby plays a crucial role in fatty acid synthesis and acetylation reactions [28]. A 
number of mechanisms could be proposed for the DNA damage repair deficiency that 
was observed after ACLY inhibition. Inhibition of general fatty acid synthesis would deprive 
cells of the macronutrients required for cell proliferation, as well as fatty acids required 
to repair radiation - associated peroxidised lipids. Inhibition of FAS or FASN expression 
has been previously shown to sensitise prostate cancer and non - small cell lung cancer 
cells to irradiation [29, 30]. However, FAS inhibition did not result in an increase in DNA 
damage or radiosensitisation in HNSCC cell lines. Interestingly, we now show that direct 
inhibition of ACLY results in impaired DNA repair within hours, specifically homologous 
recombination. Previously it has been demonstrated that nuclear ACLY promotes the cell’s 
choice for homologous recombination through elevated levels of acetylated histones at 
the site of double strand breaks [15]. A shift in DNA damage repair to the virtually error - free 
homologous recombination pathway, rather than the more error - prone non - homologous 
end - joining, is likely to result in an improved DNA damage repair efficacy and thereby 
contributes to radioresistance.
Additionally, we show that high ACLY expression is a prognostic factor for worse overall 
survival in a cohort of HNSCC patients. In line with its apparent role in DNA damage 
repair, high ACLY expression predicted worse outcome only in patients that received RT, 
but not in patients that did not, thus indicating that ACLY is a predictive biomarker for 
RT success, of which there is a critical need in HNSCC. In a validation cohort where all 
patients have been treated with chemoradiation (platinum - based chemotherapy and 
RT), better locoregional control was observed in patients who had low ACLY expression 
levels. This further strengthens the notion that ACLY mediates radioresistance, and thus 
high levels of ACLY result in poor treatment success. Furthermore, while ACLY protein 
seemed ubiquitously expressed, ACLY localization was strikingly different between patients 
with good versus poor locoregional control. Localization in the nucleus was significantly 
associated with poor locoregional control, in line with data from an earlier report that 
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demonstrates that, while acetyl - CoA is able to diffuse through nuclear pores, the activity 
between nuclear and cytoplasmic acetyl - CoA pools differs [31]. Overall, this supports the 
hypothesis that nuclear - located ACLY facilitates the production of nuclear acetyl - CoA, 
which in turn affects the histone acetylation status of the chromatin, and thereby deters 
the cell’s choice for homologous recombination as the preferred pathway for DNA damage 
repair [15].
Conclusions
As radiotherapy is an important treatment option in HNSCC, it is critical to elucidate 
the mechanisms that contribute to the development of radioresistance and to devise 
strategies for targeting this. It is becoming clear that metabolic reprogramming contributes 
to radioresistance, and affects treatment outcome. Here, we show that nuclear - located 
ACLY, an enzyme that catalyses the production of acetyl - CoA and oxaloacetate from citrate 
and CoA, correlates with radioresistance in HNSCC cell lines as well as different patient 
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Table S1 Cell line characteristics







UT - SCC - 5 58 Male T1N1M0 Tongue Primary Negative
UT - SCC - 8 42 Male T2N0M0 Supraglottic larynx Primary Negative
UT - SCC - 11 58 Male T1N0M0 Larynx Primary Negative
UT - SCC - 15 51 Male T1N0M0 Tongue Recurrence Negative
UT - SCC - 19A 44 Male T4N0M0 Glottic larynx Primary Negative
UT - SCC - 24A 41 Male T2N0M0 Tongue Primary Negative
UT - SCC - 29 82 Male T2N0M0 Glottic larynx Primary Negative
UT - SCC - 38 66 Male T2N0M0 Glottic larynx Primary Negative
UT - SCC - 40 65 Male T3N0M0 Tongue Primary Negative
UT - SCC - 45 76 Male T3N1M0 Floor of mouth Primary Positive (HPV33)
UM - SCC - 6 37 Male T2N0M0 Oropharynx Primary Negative
UM - SCC - 47 53 Male T3N1M0 Oral cavity Primary Positive (HPV16)
93 - VU - 147T 58 Male T4N2 Floor of mouth Primary Positive (HPV16)
UPCI:SCC154 54 Male T4N2 Tongue Primary Positive (HPV16)



































Clinical stage Stage I + II















ACLY Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas
Table S3 Clinical characteristics of the patients selected from the HNSCC cohort previously described by van der 
Heijden et al. Categorical values were tested using a Chi - squared test. Differences in age were tested by means 
of an independent t - test with Welch’s correction. Stars indicate statistically significant (p < 0.05) differences
Variable Low ACLY (N = 75) High ACLY
(N = 16)
p - value



































Table S4 Clinical characteristics of the patients selected from the HNSCC cohort previously described by 
Liskamp et al. A selection of 10 patient with high locoregional control and 9 patients with poor locoregional 
control was made. Categorical values were tested using a Chi - squared test. Differences in age were tested by 
means of an independent t - test with Welch’s correction. n.a.: not available. * p < 0.05. 
Variable Good (n = 10) Poor (n = 9) p - value









































































Figure S1 Characterisation of HPV status, radiosensitivity and metabolic pathway expression of 14 HNSCC 
cell lines. 
A, Expression of high - risk HPV genes E2, E6, and E7 was tested and pooled. 14 HNSCC cell lines were tested for 
HPV16, HPV18, HPV33, and HPV52. Shown are fragments per million mapped fragments (FPM) for all high - risk 
HPV types for all cell lines. B, Radiosensitivity data of 14 HNSCC cell lines was fitted using the linear quadratic 
model. The dose permitting 37% survival was interpolated from this model using the generated α and β values. 
Shown are the α and β for each cell line, and the corresponding D37. C, D37 data were interpolated from survival 
curves in 1B using linear quadratic model fitting. D37 data are shown for 10 HPV negative and 4 HPV positive cell 
lines respectively. Statistical test: two - sided t - test with Welch’s correction. D, Overview of metabolic pathway 
expression in four radioresistant vs. four radiosensitive HNSCC cell lines. Shown are genes that were enriched (red) 
or depleted (green) in radioresistant vs radiosensitive cells by at least a 1.5 - fold change in either direction.
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Figure S2 ACLY expression does not differ between HPV positive and -negative cell lines
Gene expression of ACLY was measured in 14 HNSCC cell lines using smMIPs. Comparison of ACLY expression 
between HPV positive and HPV negative cell lines was done using an unpaired, two - sided t - test with Welch’s 




Figure S3 ACLY, but not FAS, inhibition leads residual DNA damage and radiosensitisation. 
A, Depletion of ACLY expression in UT - SCC - 15 cells was performed using 0.5 or 2.5µg pooled siRNA for 72 hours, 
followed by confirmation by RT - qPCR. Error bars indicate standard deviation of three technical replicates. B, 
ACLY was depleted in UT - SCC - 15 cells using pooled ACLY siRNA for 72 hours. Subsequently, cells were plated for 
a colony forming assay and irradiated with the indicated 2, 4, 6, or 8 Gy. Error bars indicate standard deviation of 
three technical replicates. C - D, UM - SCC - 6 (C) and UT - SCC - 5 (D) cells were treated with 5 µM BMS303141 or DMSO 
control for 6 hours and irradiated with 2 Gy. 24 hours post - irradiation, quantification of 53BP1 foci was performed. 
Shown are percentages of cells containing a number of 53BP1 foci per nucleus. Bins indicate the following: 0: 0 - 4 
foci; 5: 5 - 9 foci etc. E - F, UM - SCC - 6 (E) or UT - SCC - 5 (F) cells were treated with 10 µM 10 C75 or DMSO control for 6 
hours and were irradiated with 2 Gy. Quantification of cells positive for 53BP1 foci in UM - SCC - 6 (E) and UT - SCC - 5 
(F) cells. Shown are mean percentages of three biological replicates and indicates cells that are positive for 53BP1 
(>5 53BP1 foci per nucleus) in a single plane of view. G, UT - SCC - 5 cells were treated with 10 µM C75 or DMSO 
control for 6 hours and irradiated with 2, 4, or 6 Gy. Survival was determined by colony formation assay. Shown 
are mean values of two biological repeats with three technical replicates each.
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Figure S4 ACLY is not associated with recurrence free survival outcome. 
A - B, Kaplan - Meier analysis of a TCGA cohort of HNSCC patients that have high or low ACLY expression based 
on the optimal cut - off point for overall survival. Shown are plots for recurrence free survival of HNSCC patients 




AKT inhibition as a strategy for targeting 
hypoxic HPV positive HNSCC









Background: Human papillomavirus (HPV) infection in head and neck squamous cell 
carcinomas (HNSCC) is commonly associated with better response to (chemo-)radiotherapy 
and overall prognosis. However, hypoxia is one of the most well - known factors negatively 
affecting treatment outcome in both HPV positive and -negative HNSCC patients. Despite 
HPV positive patients having a relatively good prognosis, hypoxic HPV positive tumours are 
associated with poor treatment outcome and prognosis, and are reported not to respond 
to hypoxia modification, demonstrating an unmet need for HPV positive HNSCC patients 
with hypoxic tumours. Previously, it has been shown that under hypoxic conditions, the 
pro - survival PI3K/AKT pathway is up regulated, and can be exploited to target hypoxic 
HNSCC cells. In this study, we aim to investigate whether AKT inhibition affects the response 
to radiotherapy under hypoxia, and determine whether this could be a viable treatment 
strategy for HNSCC patients with hypoxic HPV positive tumours.
Methods: Thirteen HNSCC cell lines (9 HPV negative and 4 HPV positive) were characterized 
in this study. AKT protein abundance after hypoxia was assessed by western blot. Survival 
in response to hypoxic incubation, AKT inhibition and/or irradiation was assessed using 
CCK8 assays or colony forming assays.
Results: AKT was activated in response to hypoxia in both HPV negative and -positive 
cell lines, which could be abrogated by the AKT inhibitor MK2206. HPV positive cell lines 
were highly sensitive to AKT inhibition in normoxic conditions. In both HPV positive and 
negative cell lines, AKT inhibition was significantly more efficacious in hypoxia than in 
normoxia. Moreover, hypoxia significantly reduced the effectiveness of irradiation in all 
HNSCC lines irrespective of HPV status, yet could be reversed by AKT inhibition specifically 
in HPV positive cells.
Conclusions: These data suggest that HNSCC tumours are dependent on AKT to survive 
hypoxia, and that AKT inhibition is specifically effective in radioresistant hypoxic HPV 
positive cells. Targeting AKT may thus be a potential way to overcome hypoxia induced 
radioresistance, particularly in HPV positive HNSCC tumours.
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Introduction
Strong evidence exists that human papillomavirus (HPV) infection in head and neck 
squamous cell carcinomas (HNSCC), and subsequent overexpression of p16 (also known 
as p16INKa), is associated with favourable outcome [1]. Strikingly, HPV positive patients 
have, in response to radiotherapy, a better prognosis, locoregional control, and survival 
[1 - 6]. In line with this, patient derived HPV positive HNSCC cell lines or xenografts are 
significantly more radiosensitive than HPV negative cell lines, which is likely due to a 
defect in homologous recombination repair [7 - 12]. This potentially contributes to the 
observed improved radiotherapy response. Current efforts exist to discriminate between 
these patients, and focus on de - escalation of radiation schemes, or replacement of 
systemic/targeted therapies for HPV positive patients. Unfortunately, recent efforts to 
replace cisplatin with cetuximab for HPV positive patients in a cisplatin/radiotherapy 
combination yielded unsatisfactory results [13, 14]. Other trials are currently attempting 
to achieve similar tumour control in HPV positive patients by de - escalation and/or volume 
reduction of radiation dose, thereby reducing the short- and long - term side effects of 
radiotherapy [15, 16]. The first outcomes of these trials are expected between 2021 and 
2023. Despite the relatively favourable outcome of HPV positive HNSCC patients, still a 
substantial subset suffers from poor treatment outcome due to treatment resistance. One 
of the most well - known factors that negatively affects the efficacy of radiotherapy is the 
occurrence of tumour hypoxia, i.e. low oxygen concentrations. The oxygen concentration 
can range from mild hypoxia (≤ 2% O2) to severe hypoxia (≤ 0.1% O2) and results from the 
tumour’s demand for oxygen exceeding the supply [17]. The occurrence of hypoxia in a 
tumour contributes to poor response to radiotherapy, and serves as a prognostic factor for 
poor outcome [18 - 20]. Briefly, severe hypoxia desensitizes tumour cells for radiotherapy by 
limiting the free oxygen radicals produced by ionizing radiation, which in turn leads to less 
DNA damage. Moreover, both severe and mild hypoxia activate survival pathways and the 
DNA damage response, contributing to cellular resistance to radio- and chemotherapy [19].
In HNSCC, hypoxia modification by nimorazole has been shown to be an effective strategy 
for counteracting the negative effects of hypoxia, thereby leading to improved outcome 
in HPV negative patients. However, HPV positive tumours lack a response when treated 
with hypoxia - modifying regimes [21]. At first, this was attributed to the possibility that 
radioresistance would not play a role in HPV positive tumours. However, recent work 
showed that hypoxic HPV positive HNSCC cells become radioresistant as well and thereby 
lose the radiosensitive ‘advantage’ in hypoxia [22]. Moreover, hypoxia provides HPV positive 
cells a means for treatment escape, as these cells form a dormant pool that is responsible 
for tumour repopulation after chemoradiation [23]. At the population level as well, there 




as high expression of hypoxia - inducible factor 1α (a common marker for hypoxia) in HPV 
positive HNSCC patients was associated with an unfavourable prognosis [24]. Together, 
this highlights the need for new targeting strategies for hypoxic HPV positive HNSCC.
One of the pathways that has been previously described to contribute to cellular survival in 
response to hypoxia is the AKT pathway [25]. In addition, the PIK - 3/AKT pathway is involved 
in repression of apoptosis, DNA repair, and cell growth and thereby provides an important 
survival signal for cells undergoing stress such as hypoxia and irradiation [26]. One of the 
mechanisms for AKT activation (by phosphorylation of S473 and T308 residues) is due to 
hypoxia - specific p53 - dependent up-regulation of INPP5D and PHLDA3 [25]. Importantly, 
inhibition of phosphorylated AKT strongly sensitized HNSCC cells to hypoxia, indicating 
that these cells are addicted to the AKT pathway [27]. As hypoxic tumour cells are especially 
radio- and chemoresistant, the use of AKT inhibition poses a therapeutic target for these 
resistant cells.
In this study we demonstrate that AKT inhibition sensitizes HPV positive and -negative 
HNSCC cells to hypoxia. Specifically, we show that HPV positive cells are highly sensitive 
to AKT inhibition, and radiosensitises cells both in normoxia and hypoxia.
Materials and methods
Cell culture, reagents, irradiation, and hypoxic incubation
UT - SCC - 5, UT - SCC - 8, UT - SCC - 11, UT - SCC - 19A, UT - SCC - 24A, UT - SCC - 29, UT - SCC - 38, 
UT - SCC - 40, UT - SCC - 45 (Kindly provided by Prof Grenman, University of Turku), UM - SCC - 6, 
UM - SCC - 47 (Kindly provided by Dr Carey, University of Pittsburgh), 93 - VU - 147T (Kindly 
provided by Dr Dorsman, Amsterdam University Medical Center), UPCI:SCC - 154 (DSMZ) 
were cultured in DMEM medium (Gibco) supplemented with 4.5 g/L glucose, GlutaMAX, 
10% FBS, 100 u/mL penicillin/streptomycin, non - essential amino acids (Gibco), HEPES 
(Gibco), and sodium pyruvate (Gibco). Previously, we confirmed that UT - SCC - 45 cells were 
positive for HPV33, UM - SCC - 47, 93 - VU - 147T and UPCI:SCC154 were positive for HPV16, 
and the rest were HPV negative [28]. Cells were incubated with MK2206 (Selleckchem) 
or a DMSO control for 48 hours and/or incubated in a 0.1% O2 atmosphere using a H35 
Don Whitley hypoxystation for 6 to 48 hours. Single dose irradiation was delivered using 
a 320 kV XRAD irradiator (RPS Services Limited) at a dose rate of 3.1 Gy/min. Irradiation in 
a hypoxic atmosphere was conducted by means of tailor - made sealed perspex boxes 
(Oxford Institute for Radiation Oncology, Oxford, UK).
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Colony forming assay
Cells were plated at a density of 150 - 4000 cells/well in a 6 - well polystyrene culture plate 
(Corning). After overnight incubation and attachment, cells were treated as described 
above. Medium was refreshed 24 hours after IR and cells were left to form colonies for 
8 - 14 days. Colonies were fixed and stained by crystal violet staining (50% methanol, 20% 
ethanol, 30% water, 5 mg/ml crystal violet).
CCK8 viability assay
10,000 cells/well were plated in a flat - bottom 86 wells plate (Corning) and incubated 
overnight. Viability in response to 48 hours incubation with MK2206 was determined Cell 
Counting Kit 8 (CCK8) (Sigma - Aldrich) assay according to the manufacturer’s instructions. 
Inhibitory concentration for 50% survival (IC50) was determined using GraphPad Prism 8.01.
Immunoblotting
Immunoblotting was performed as previously described [29], with the exception that 
membranes were imaged on a Bio - Rad chemidoc using chemiluminescence. Antibodies: 
AKT (Cell Signaling), S473 phospho - AKT (Cell Signaling), β - actin (Cell Signaling).
Statistics
Single variable comparisons between two groups were performed on the mean of two 
or three biological independent repeats using a two - tailed unpaired t - test with Welch’s 
correction. Unless specified otherwise, error bars indicate the standard error of the mean 
of three biological replicates. Statistical significance is indicated as follows: * p < 0.05, ** p 
< 0.01; *** p < 0.001. For clonogenic assays, plating efficiency (PE) and surviving fraction 
(SF) was determined as follows: PE = number of colonies counted/number of cells plated. 
SF = PEtreatment / PEcontrol. Sensitizer enhancement ratios (SER) were calculated as follows: 
SER = (SFhypoxia, MK2206 / SFhypoxic, DMSO) / (SFnormoxia, MK2206 / SFnormoxia, DMSO). Similarly, the 
oxygen enhancement ratio (OER) was determined as follows: OER = (SFhypoxia, 2 Gy / SFhypoxia) 
/ (SFnormoxia, 2 Gy / SFnormoxia).
Results
HPV positive cells up-regulate AKT in response to hypoxia and are more 
sensitive to AKT inhibition
Previously, we demonstrated that AKT is phosphorylated in response to hypoxia in HPV 
negative HNSCC [27]. To investigate whether this also occurs in HPV positive cell lines, 
we exposed the HPV positive HNSCC cell line UM - SCC - 47 to short (6 hours) and long 




line UM - SCC - 6. Both cell lines showed a rapid induction of AKT phosphorylation after 6 
hours, which was sustained even after 72 hours, (Figure 1). This activation of AKT could 
be effectively abrogated by the use of the allosteric AKT inhibitor, MK - 2206 (Figure 1). 
We then investigated the difference in sensitivity for the AKT inhibitor to determine 
whether HPV positive and -negative HNSCC cell lines respond differently. Using a Cell 
Counting Kit - 8 viability assay, we determined the relative sensitivity to MK2206 for eight 
cell lines, of which their HPV status had been previously determined [28]. Four HPV 
negative (UT - SCC - 5, UT - SCC - 11, UT - SCC - 38 and UM - SCC - 6) and four HPV positive cell lines 
(UT - SCC - 45, UPCI:SCC154, 93 - VU - 147T, and UM - SCC - 47, indicated with an *) were treated 
with incremental doses of MK2206 for 48 hours, and were subsequently tested for their 
viability. Strikingly, HPV positive cells were significantly more sensitive to AKT inhibition, 
with an average IC50 of 11.60 ± 4.77 µM for HPV positive cells as compared to 19.73 ± 
4.44 µM for HPV negative cells (p = 0.0471) (Figure 2A - I). This indicates that in normoxic 
conditions, HPV positive HNSCC cells are almost twice as sensitive to AKT inhibition than 
HPV negative cells.
Figure 1 AKT is phosphorylated in HPV positive and negative cells in response to hypoxia. 
Two HNSCC cell lines (UM - SCC - 6, HPV negative; UM - SCC - 47, HPV16 positive) were exposed to indicated times 
of hypoxia (0.1% O2) and concurrently treated with 2 µM MK2206. Levels of AKT, phosphorylated S473 AKT, and 
β - actin were determined by western blotting.
AKT inhibition sensitises HNSCC cells to hypoxia
Next, we investigated the sensitizing effect of AKT inhibition to hypoxia in both HPV 
negative and -positive cells. In brief, cells were concurrently exposed to MK2206 as well 
as 0.1% O2 for 48 hours, and clonogenic survival was assessed by colony forming assays 
(Figure 3A). As one of the HPV positive cell lines was unable to form colonies, we conducted 
the experiment on the remaining three HPV positive cell lines. In line with our results 
using the viability assays (figure 2), we observed that HPV positive cells were significantly 
(p = 0.001) more sensitive to AKT inhibition in normoxic (21% O2) conditions (figure 3A - B). In 
contrast, there was no difference in survival in response to hypoxia only (p = 0.392) (figure 
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3C). We observed that both in HPV negative and -positive cells AKT inhibition was more 
cytotoxic in hypoxic conditions than in normoxic condition, as expressed by a sensitiser 
enhancement ratio >1. The sensitiser enhancement ratio for HNSCC cells was 1.57 and 1.52 
for HPV positive and -negative cells respectively, which was not statistical significantly 
different (p = 0.890) (Figure 3D). This indicates that both HPV positive and -negative cells 
rely on AKT activation under hypoxic conditions for cellular survival.
Hypoxia - induced radioresistance in HPV positive cells can be reversed by AKT 
inhibition
We next investigated whether hypoxic radioresistant HNSCC cells can be sensitized to 
irradiation by AKT inhibition. In brief, 2 HPV negative (UT - SCC - 5 and UT - SCC - 11) and 2 
HPV positive (UT - SCC - 45 and 93 - VU - 147T) tumour lines were exposed to six hours 0.1% 
O2 with concurrent AKT inhibition and subsequently irradiated under continuing hypoxic 
conditions (Figure 4A). As expected, both HPV positive and HPV negative cells became 
more resistant to irradiation in hypoxic conditions, with an oxygen enhancement ratio 
of 1.41 and 1.76 for HPV negative and -positive cells respectively (Figure 4B). We then 
investigated the sensitizing effect of MK2206 on irradiated cells, both in normoxia and 
hypoxia. In HPV negative cells, MK2206 was equally effective in sensitizing cells to irradiation 
in both normoxia or hypoxia, as the sensitizer enhancement ratio was approximately 0.90. 
However, hypoxic irradiated HPV positive cells were significantly (p = 0.012) more sensitized 
by MK2206 than normoxic cells (Figure 4C), with a sensitizer enhancement ratio of 1.34. 
This demonstrated that AKT inhibition is effective in sensitizing hypoxic HPV positive cells 
that are otherwise radioresistant.
Discussion
In this study, we show that AKT inhibition sensitizes both HPV positive as well as HPV 
negative HNSCC cells to hypoxia. Furthermore, HPV positive cell lines are more sensitive 
to AKT inhibition in normoxic conditions, and specifically hypoxic HPV positive cells can 
be sensitized to irradiation by AKT inhibition.
These results are particularly interesting regarding the recent work that has been done 
in HPV positive HNSCC to attempt to de - escalate radiotherapy dose or replace systemic 
platinum - based therapies with cetuximab, which unfortunately did not yield satisfactory 
results [13, 14]. This indicates that, while HPV positive HNSCC cancers are more radiosensitive 
relative to HPV negative and patients overall have a better prognosis, it is important 
to differentiate treatment. In order to successfully achieve this, optimized treatment 




avoid overtreatment of patients that lead to unnecessary side - effects. Some reports have 
demonstrated that some HPV positive HNSCC cells can acquire radioresistance or become 
dormant, and thereby provide a pool of hard - to - target cells that could be responsible for 
tumour repopulation as well as migration and metastasis. One of the inducers of both 
dormancy and radioresistance in HPV positive HNSCC cells is tumour hypoxia [22, 23]. We 
confirmed that HPV positive HNSCC indeed become radioresistant, as well as up - regulate 
the AKT survival pathway in response to hypoxia. These two mechanisms provide a means 
of resistance, and are in line with previous research that demonstrate that hypoxic HPV 
positive HNSCC have a poor prognosis [24].
Figure 2 HPV positive cells are more sensitive to AKT inhibition than HPV negative HNSCC cells. 
A - H, UT - SCC - 5 (A), UT - SCC - 11(B), UT - SCC - 38 (C), UM - SCC - 6 (D), 93 - VU - 147T (E), UT - SCC - 45 (F), UPCI:SCC154 (G), 
and UM - SCC - 47 (H) cells were exposed to incremental concentrations of MK2206 for 48 hours, before viability 
was assessed a CCK8 assay. Normalized survival was plotted and IC50 curves were fitted. Shown are mean 
values of three biological replicated ± standard deviation. I, IC50 values of HPV positive and HPV negative cell 
lines were compared by an unpaired t - test with Welch’s correction. Dots indicate mean values of individual 
cell lines. Asterisks indicate HPV positive status.
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Figure 3 AKT inhibition sensitized HNSCC cells to hypoxia, regardless of HPV status. 
A, UT - SCC - 5, UT - SCC - 8, UT - SCC - 11, UT - SCC - 19A, UT - SCC - 24A, UT - SCC - 29, UT - SCC - 38, UT - SCC - 40, UM - SCC - 6, 
UM - SCC - 47, 93 - VU - 147T, and UT - SCC - 45 cells were exposed to 2 µM MK2206 (MK+), 0.1% O2, or a combination 
for 48 hours. Survival was assessed by colony forming assay. Shown are means of 2 independent biological 
experiments ± standard deviation. Asterisks indicate HPV positive status. B, Summarized survival after 48 hours 
2 µM MK2206 treatment in 9 HPV negative cell lines and 3 HPV positive cell lines. Survival was compared by 
an unpaired t - test with Welch’s correction. Dots indicate mean values of individual cell lines. C, Summarized 
survival after 48 hours 0.1% O2 treatment in 9 HPV negative cell lines and 3 HPV positive cell lines. Survival was 
compared by an unpaired t - test with Welch’s correction. Dots indicate mean values of individual cell lines. D, 
Sensitizer enhancement ratio for 9 HPV negative and 3 HPV positive cell lines. Sensitizer enhancement ratio 
above 1 demonstrates superior efficacy of MK2206 in hypoxic environments than in normoxic environments. 
Sensitizer enhancement ratio was compared by an unpaired t - test with Welch’s correction. Dots indicate mean 




Figure 4 AKT inhibition sensitized HPV positive HNSCC cells to irradiation in hypoxia. 
A, HPV negative (UT - SCC - 5, UT - SCC - 11) and HPV positive (UT - SCC - 45, 93 - VU - 147T) HNSCC lines were exposed 
to 2 µM MK2206 (MK+) and/or 0.1% O2 for six hours, and then irradiated with 2 Gy in the same atmosphere. 
Survival was assessed by colony forming assay. Shown are means of 2 independent biological experiments ± 
standard deviation. Asterisks indicate HPV positive status. B, Oxygen enhancement ratio of two HPV positive and 
two HPV negative cell lines. Ratios were compared by an unpaired t - test with Welch’s correction. Dots indicate 
mean values of individual cell lines. C, Sensitizer enhancement ratio for 2 HPV negative and 2 HPV positive cell 
lines. Sensitizer enhancement ratio above 1 demonstrates superior radiosensitising effect of MK2206 in hypoxic 
environments than in normoxic environments. Sensitizer enhancement ratio was compared by an unpaired 
t - test with Welch’s correction. Dots indicate mean values of individual cell lines.
We demonstrate that HPV positive HNSCC cells are more sensitive to AKT inhibition 
than HPV negative cells, even in normoxic conditions. A previous study reported that 
HPV positive cell lines possessed higher expression of PIK3CA, an upstream activator of 
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AKT [30]. This could indicate that HPV positive HNSCC cells are more dependent on the 
AKT pathway for survival, and are in turn more sensitive to its inhibition. In line with this, 
another study demonstrated an association between HPV infection and elevated levels of 
phosphorylated AKT in HNSCC [31]. In addition, overexpression of HPV oncogene E6 leads 
to degradation of p53, as well as activation of AKT and mTORC1 in cervical cancer models, 
thereby promoting protein synthesis [32]. This is one of the possible mechanisms by which 
HPV positive HNSCC cells become dependent on AKT signalling, and are therefore more 
sensitive to its inhibition.
In addition to HPV positive cells being more sensitive to AKT inhibition, they were also 
radiosensitised by it, both in normoxia and hypoxia. Multiple studies have demonstrated 
that AKT inhibition can radiosensitise cells that lack p53 signaling [25, 33].
Interestingly, the majority of HPV negative HNSCC have acquired p53 mutations, whereas 
in HPV positive HNSCC, p53 is actively degraded by the proteasome. At first glance, 
the p53 pathway could then not be an explanation for the observed differences in the 
radiosensitising effect of MK2206. However, oncogenic mutations in p53 have been shown 
to not always lead to a complete loss of p53 signaling [26]. This could indicate that HPV 
negative HNSCC that have acquired p53 mutations are therefore not radiosensitized by 
AKT inhibition. The exact mechanisms contributing to the radiosensitising effects of AKT 
inhibition and the role of p53 in HNSCC remain to be more closely investigated.
From a clinical perspective, it will be interesting to see the response of hypoxic HPV positive 
HNSCC to dose de - escalating strategies, seeing as in vitro these particular subsets are more 
radioresistant. So far, this study as well as others have shown that hypoxia desensitizes not 
only HPV negative but also HPV positive HNSCC to irradiation and could therefore pose a 
risk in terms of de - escalation. This is emphasized by the observation that the occurrence 
of hypoxia in HPV positive and -negative HNSCC tumours is comparable, and that patients 
with HPV positive tumours do not respond to nimorazole [21, 34].
However, implementing AKT inhibition as a clinical strategy for treating HPV positive 
HNSCC could prove challenging at this point. Currently, the main focus for HPV positive 
HNSCC tumours is to de - escalate treatment, as opposed to adding an additional systemic 
therapy. Therefore, it is important to determine whether any of the current treatment 
modalities can be safely reduced or replaced by AKT inhibition. In terms of toxicity of the 
AKT inhibitor, MK2206 has been tested in phase II trials and has been demonstrated to have 
limited or mild side - effects [35]. In conclusion, we believe that AKT inhibition could be a 
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Introduction: Human cancer cell lines are one of the most frequently used models to 
study cancer biology and mechanisms of chemo- and radioresistance. To study head and 
neck squamous cell carcinomas (HNSCC) in vitro, a large variety of HNSCC cell lines have 
been developed. In this study, we aimed to characterise in detail a panel of 22 HNSCC cell 
lines, thereby providing a tool for future research into tumour - specific treatment options 
in HNSCC.
Methods: Both HPV positive and HPV negative tumour cell lines were collected from 
both commercial and collaborative sources. Short tandem repeat (STR) profiling was used 
to confirm the identity of the cell lines. Targeted sequencing was performed to detect 
mutations for 23 tumour suppressor- and oncogenes. HPV status, p16 status, radiosensitivity 
data and hypoxia data is summarised from all cell lines.
Results: We detected HPV transcripts in 5 cell lines, all of which overexpressed p16. One 
HPV negative cell line overexpressed p16. We detected mutations in KIT (SCCNij185), 
PIK3CA (SCCNij185) and CDKN2A (UT - SCC - 5 and UT - SCC - 38). TP53 mutations were the most 
frequent, occurring in 16/22 cell lines. HPV infection and TP53 mutations were almost 
mutually exclusive, with the exception of 93 - VU - 147T. The cell lines exhibited a wide range 
of sensitivities towards hypoxia and irradiation.
Conclusions: Here, we provide an in - depth description of a large set of frequently used 
HNSCC cell lines, with widely diverse characteristics as found in HNSCC patients.
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Introduction
Head and neck squamous cell carcinomas (HNSCC) are a malignant disease occurring 
in the mucosal regions of the oral cavity, hypopharynx, oropharynx, larynx and other 
sites in the upper respiratory tract. It is a heterogeneous group of malignancies that, 
depending on disease type and location, has a relatively poor prognosis. 5 year survival 
rates in oropharyngeal cancer are approximately 65% [1]. Current treatment of HNSCC 
includes surgery, platinum - based chemotherapy, radiotherapy, EGFR targeting therapies 
(cetuximab) or a combination of these treatment modalities. As of 2016, the FDA has 
approved the use of PD1 immune checkpoint inhibitors for HNSCC patients with recurrent 
disease that are refractory to platinum - based therapies [2]. The most well - described 
risk factors for HNSCC include smoking, alcohol consumption, and high - risk human 
papillomavirus (HPV) infection. Particularly in oropharyngeal cancer, the prevalence of 
HPV infection is relatively high with up to 81.4% of the patients infected with the virus 
[3, 4]. Several studies have shown that patients with HPV positive tumours, and -more 
specifically- subsequent p16 overexpression, have an improved prognosis. In these patients, 
there is superior locoregional control in response to radiotherapy, and overall- and even 
disease free survival [1, 5 - 7]. In order to identify mechanisms that influence sensitivity 
or resistance to treatment, molecular and cellular characterisation of HPV positive and 
HPV negative cells has been widely employed. In vitro as well as in vivo characterization 
of these mechanisms heavily depends on the use of HNSCC cell lines, and many have 
been distributed over the world to study the disease. A little over 300 HNSCC cell lines 
of various tumour origins and patient characteristics such as age, sex, and ethnicity have 
been established [8]. A significant drawback of the widely available HNSCC cell lines and 
their distribution across the globe is that cross - contamination and mislabelling have led to 
contradictions in literature and incorrect conclusions drawn from experiments performed 
with the wrong cell lines [9]. Here, we provide genetic analysis of a set of HNSCC cell lines 
that are widely used, using short tandem repeat profiling. Additionally, we established a 
database - like compendium about multiple genetic, molecular, and cellular characteristics. 
These include cell morphology, mutation status of 23 tumour suppressor and oncogenes, 
HPV status, p16 status, and hypoxia- and radiosensitivity. Together, this makes a useful tool 
for other researchers who wish to study different subsets of HNSCC cells.
Materials & methods
Cell culture
UT - SCC - 5, UT - SCC - 8, UT - SCC - 9, UT - SCC - 11, UT - SCC - 15, UT - SCC - 19A, UT - SCC - 24A, 




Prof Grenman, University of Turku. UM - SCC - 6 and UM - SCC - 47 were kindly provided by 
Dr Carey, University of Pittsburgh). FaDu cells were kindly provided by Michael Baumann 
(German Cancer Research Center, Heidelberg). 93 - VU - 147T was kindly provided by Dr 
Dorsman, Amsterdam. University Medical Center). UPCI:SCC090 and UPCI:SCC154 were 
purchased at DSMZ. All cell lines were cultured in DMEM medium (Gibco) supplemented 
with 4.5 g/L glucose, GlutaMAX, 10% FBS, 100 u/mL penicillin/streptomycin, non - essential 
amino acids (Gibco), HEPES (Gibco), and sodium pyruvate (Gibco). The SCCNij lines were 
derived from patient biopsies obtained between 1996 and 2006 at the Radboud university 
medical center and passaged as xenograft models in BALB/c nu/nu mice [10, 11]. Cell line 
characteristics are described in Table 1.
Microscopy
All cells (except SCCNij) were grown to approximately 70% confluency. Phase - contrast 
images were taken using a Zeiss AXIO microscope and Zeiss AxioCam ICc5 camera (Zeiss, 
Oberkochen, Germany) at 100x magnification. Software used was Zen 2012 (Blue edition).
Genomic DNA extraction
HNSCC cell lines (aside from SCCNij) were cultured to approximately 70% confluency 
and then harvested by cell scraping. Genomic DNA extraction was performed by using 
a genomic DNA extraction kit (Norgen Biotek, Thorold, Canada). Cells were lysed using 
a digestion buffer, followed by an RNAse A treatment (10 kU per sample). Proteinase 
K treatment was performed for approximately 1 hour at 55 °C. Samples were washed 
with 100% ethanol and transferred to a binding column and centrifuged at >5000 g 
for 3 minutes. Lysates bound to the column were then repeatedly washed with 100% 
ethanol and subsequently eluted into a nucleic acid free tube. gDNA was quantified by 
spectrophotometric analysis. For SCCNij tumours, ex vivo frozen chunks were thawed and 
homogenized using sonification. Genomic DNA was then isolated in a similar manner as 
described above.
Mutation analysis
Mutation analysis of a panel of cancer related oncogenes and tumour suppressor genes 
was performed by single molecule Molecular Inversion Probe (smMIP) sequencing. 
Sequencing was performed on 100 ng genomic DNA at the department of Pathology, 
Radboud university medical center, according to a previously described protocol [12]. 
Targeted genes are described in Table 2.
STR profiling
Short tandem repeat (STR) profiling was performed by Eurofins genomics (Ebersberg, 
Germany) on gDNA extracted from the HNSCC cell lines. STR analysis was performed 
121
Genotyping and characterization of 22 HNSCC cell lines
for 16 markers, including CSF1PO, D2S1338, D3S1358, D5S818, D7S820, D8S1179, D13S317, 
D16S539, D18S51, D19S433, D21S11, FGA, TH01, TPOX, vWA and Amelogenin. Where possible, 
STR profiles were compared to previously published consensus profiles, as well as the 
Cellosaurus database of existing STR profiles. STR analyses were not performed for the 
SSCNij lines, as these are grown in mice, which would result in mixed STR profiles.
Results
HNSCC cell line panel characteristics and genotyping
We collected 22 HNSCC cell lines frequently used in in vitro and in vivo studies (Table 1). 
For SCCNij cell lines, patient characteristics were largely anonymized, aside from tumour 
stage, lesion type, and tumour location. From the remaining 18 cell lines, 100% were 
derived from male HNSCC patients. Patients were on average 57 (± 13.6) years old at time 
of the biopsy. Out of 22 cell lines, 18 (81.8%) cell lines were derived from primary tumours, 
whereas 3 (13.6%) were derived from recurrences, and 1 cell line (4.5%) from a metastasis. 
The cell lines had various anatomical origins, with 9 cell lines (40.9%) originating from the 
oral cavity (tongue, floor of mouth), 11 cell lines (50%) from the larynx (supraglottic and 
glottic larynx), 1 cell line from the oropharynx (4.5%), and 1 cell line from the hypopharynx 
(4.5%). In this panel, 10 cell lines (45.5%) were derived from T1 - T2 stage tumours, 11 cell lines 
from a T3 - T4 stage tumour (50%), and of one cell line (4.5%) T stage was not available. 13 
cell lines (59.1%) were from patients with N0 disease, 8 cell lines (36.4%) from patients with 
N1 - 2 stage disease, and of one cell line (4.5%) N stage was not available. Lastly, 18 cell lines 
(81.8%) were derived from M0 stage disease, whereas M stage information was lacking from 
all other cell lines (18.2%). The STR profiles of the UT - SCC - 19A, UT - SCC - 24A, UT - SCC - 45, 
UM - SCC - 6, UM - SCC - 47, 93 - VU - 147T and UPCI:SCC090 cell lines were identical to previously 
reported profiles [9, 13 - 16]. The remaining profiles were found to be unique as compared 
to another and to the Cellosaurus database (Table 2). Commonly, the amelogenin locus on 
the X and Y chromosomes is used for gender identification. However, loss of detectable 
Y chromosome occurs frequently in older male donors and cell lines. Therefore, an X 
genotype in cell lines does not confirm that the cell line and donor are female [17, 18].
HNSCC cell line morphology
In addition to genetic characterization, information about cellular morphology is important 
to establish the authenticity of a cell line. For example, prolonged passaging and exposure 
to different culture media could potentially lead to changes in morphology, polarity, 
epithelial - mesenchymal transition and therefore cellular behaviour [19, 20]. In order to 
document the morphology of our HNSCC cell line panel, we imaged each cell line at 100x 




of these cell lines is of particular interest, as the colony forming assay is currently the golden 
standard for radiosensitivity experiments [21]. UT - SCC - 5, UT - SCC - 8, UT - SCC - 9, UT - SCC - 11, 
UT - SCC - 19A, UT - SCC - 29, UT - SCC - 38, UT - SCC - 40 and FaDu demonstrate excellent colony 
forming abilities and produce tightly packed, round colonies. UT - SCC - 15, UT - SCC - 45 and 
UM - SCC - 6 cells form colonies, yet are relatively less tightly packed, and show a little more 
diffuse pattern. Lastly, UM - SCC - 47, 93 - VU - 147T, UPCI:SCC090 and UPCI:SCC - 154 are able 
to form colonies, yet either form very spread out, irregularly shaped colonies (UM - SCC - 47 
, UPCI:SCC154 and 93 - VU - 147T), or very dense, small colonies (UPCI:SCC090).
Table 1 HNSCC cell line patient characteristics







UT - SCC - 5 58 Male T1N1M0 Tongue Primary [22]
UT - SCC - 8 42 Male T2N0M0 Supraglottic larynx Primary [22]
UT - SCC - 9 81 Male T2N0M0 Glottic larynx Primary [22]
UT - SCC - 11 58 Male T1N0M0 Glottic larynx Recurrence [23]
UT - SCC - 15 51 Male T1N0M0 Tongue Recurrence [24]
UT - SCC - 19A 44 Male T4N0M0 Glottic larynx Primary [25]
UT - SCC - 24A 41 Male T2N0M0 Tongue Primary [22]
UT - SCC - 29 82 Male T2N0M0 Glottic larynx Primary [22, 25]
UT - SCC - 38 66 Male T2N0M0 Glottic larynx Primary [24]
UT - SCC - 40 65 Male T3N0M0 Tongue Primary [24]
UT - SCC - 45 76 Male T3N1M0 Floor of mouth Primary [24]
UM - SCC - 6 37 Male T2N0M0 Oropharynx Primary [26]
UM - SCC - 47 53 Male T3N1M0 Tongue Primary [27]
93 - VU - 147T 58 Male T4N2 Floor of mouth Primary [28]
UPCI:SCC090 46 Male T2N0 Base of tongue Recurrence [29]
UPCI:SCC154 54 Male T4N2 Tongue Primary [29]
FaDu 56 Male NA Hypopharynx Metastasis [30, 31]
SCCNij153 Unknown Unknown T3N2M0 Supraglottic larynx Primary [10]
SCCNij167 Unknown Unknown T4N2M0 Supraglottic larynx Primary [10]
SCCNij172 Unknown Unknown T4N0M0 Supraglottic larynx Primary [10]
SCCNij185 Unknown Unknown T4N1M0 Supraglottic larynx Primary [10]
SCCNij202 Unknown Unknown T4N0M0 Supraglottic larynx Primary [10]
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Table 2 STR profile of HNSCC cell lines
Cell line STR profile markers
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338
UT - SCC - 5 13, 14 30, 30 10, 10 10, 10 16, 16 7, 9.3 9, 12 11, 11 17, 22
UT - SCC - 8 13, 14 30, 31.2 10, 10 10, 11 15, 15 9.3, 9.3 8, 14 12, 12 19, 25
UT - SCC - 9 12, 13 29, 31.2 8, 12 10, 11 15, 15 7, 9.3 12, 12 11, 12 25, 25
UT - SCC - 11 12, 12 28, 28 9, 11 10, 10 17, 17 6, 9 9, 11 9, 11 19, 20
UT - SCC - 15 13, 13 28, 28 8, 9 12, 15 15, 15 6, 8 11, 11 11, 12 19, 19
UT - SCC - 19A 10, 14 30, 32.2 12, 12 12, 12 15, 15 6, 6 11, 12, 13 12, 13 19, 19
UT - SCC - 24A 13, 15 29, 30 11, 11 13, 13 16, 16 9.3, 9.3 12, 14 11, 11 20, 20
UT - SCC - 29 10, 13 31, 31 8, 1 12, 12 16, 18 9.3, 9.2 11, 11 11, 11 17, 20
UT - SCC - 38 13, 13 32.2, 32.2 8, 10 9, 12 16, 16 9.3, 9.3 9, 12 12, 14 20, 20
UT - SCC - 40 12, 14 29, 31.2 8, 10 11, 13 17, 17 7, 9 11, 12 12, 12 17, 25
UT - SCC - 45 13, 18 31.2, 31.2 11, 12 10, 12 15, 15 7, 9.3 11, 14 9, 13 19, 19
UM - SCC - 6 11, 14 28, 35.1 10, 11 10, 10 15, 15 6, 9.3 13, 13 9, 12 19, 20
UM - SCC - 47 15, 15 29, 30 11, 11 11, 13 15, 15 7, 9.3 8, 9, 11 8, 13 25, 25
93 - VU - 147T 13, 15 31, 31 10, 11 11, 12 15, 17 7, 9 12, 12 9, 11 20, 24
UPCI:SCC090 12, 12 29, 31 9, 10 11, 12 14, 14 7, 7 11, 11 12, 13 22, 22
UPCI:SCC154 12,12 28,29 9,10 10,12 16,16 7,7 9,12 13,13 25,25




Table 2 STR profile of HNSCC cell lines (continued)
Cell line STR profile markers
D19S433 vWA TPOX D18S51 AMEL* D5S818 FGA Comparison 
to consensus
Reference
UT - SCC - 5 15, 15 15, 16 8, 12 18, 18 X, Y 10, 10 22, 23 NA
UT - SCC - 8 13, 13 14, 16 8, 8 13, 13 X 10, 11 21, 21 NA
UT - SCC - 9 15, 15 14, 16 8, 8 18, 20 X, Y 13, 14 20, 20 NA
UT - SCC - 11 13, 14 16, 17 9, 11 15, 17 X, Y 13, 13 22, 23 NA
UT - SCC - 15 15, 15.2 17, 18 8, 9 12, 14 X 12, 13 25, 25 NA
UT - SCC - 19A 13.2, 18.2 14, 19 8, 10 16, 16 X 12, 12 24, 24 Identical [16]
UT - SCC - 24A 12, 14.2 16, 18 11, 11 18, 18 X 10, 10 19, 22 Identical [16]
UT - SCC - 29 14, 14 17, 18 8, 8 15, 15 X, Y 11, 11 21, 21 NA
UT - SCC - 38 13, 15 18, 20 11, 11 15, 22 X, Y 11, 11 22, 22 NA
UT - SCC - 40 12, 12 17, 19 8, 12 13, 13 X, Y 13, 13 22, 22 NA
UT - SCC - 45 14, 15 18, 20 11, 11 15, 15 X 11, 12 21, 23 Identical [14]
UM - SCC - 6 11, 14 15, 16 11, 11 11, 19 X, Y 12, 12 23, 23 Identical [9, 13]
UM - SCC - 47 14, 15 18, 18 10, 11 18, 18 X, Y 11, 12 23, 25 Identical [9, 13 - 15]
93 - VU - 147T 14, 15 18, 18 9, 11 16, 16 X 11, 12 22, 22 Identical [14, 15]
UPCI:SCC090 13, 13 17, 17 8, 8 14, 18 X, Y 11, 12 20, 20 Identical [14, 15]
UPCI:SCC154 15.2, 16 17, 17 8, 9 15, 15 X,Y 11, 12 20, 24 Identical [14]
FaDu 14, 16 15, 17, 
18
11, 11 16, 16 ND 12, 12 21, 23 Identical [9, 32]
NA: not available. *Due to frequent loss of Y chromosomes in cell lines, amelogenin (AMEL) is not used for 
comparison to consensus. ND: Not detected
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Figure 1 HNSCC cell line morphology. 




Mutations in HNSCC cell lines
Cancer arises by accumulation of genetic mutations, both activating mutations in 
oncogenes, as well as inactivating mutations in tumour suppressor genes. Information 
about both activating and inactivating mutations becomes more important in the age 
of personalized medicine, as specific mutations are known to affect treatment response. 
For example, the presence of inactivating BRCA mutations in breast cancer predicts the 
sensitivity to PARP inhibitors [33, 34]. Therefore, we characterized the presence of mutations 
in well - known oncogenes and tumour suppressor genes using smMIP sequencing of 23 
oncogenes and tumour suppressor genes. This method was previously established to test 
for clinical mutations in patient - derived samples and covers 41 hotspot regions required 
for cancer diagnoses and/or predictive diagnostics (Table 3) [12].
Table 3 Panel of sequenced mutation hotspots across 23 genes
Gene Exon Targeted codons
AKT1 03 E17
BRAF 15 D594 - K601
CDKN2A 01a, 01b, 02, 03 >95% of all coding sequences and splicing sequences
CTNNB1 03 D32 - S45
EGFR 12, 18 - 21 S492, E709, exon 19, exon 20, L858 - L861
ERBB2 (HER2) 20 Y772 - Y781
GNA11 04, 05 R183, Q209
GNAQ 04, 05 R183, Q209
GNAS 08, 09 R201, Q227
H3F3A 02 K28, G35
H3F3B 02 K37
HRAS 02, 03 G12, G13, H27, A59, Q61
IDH1 04 R132
IDH2 04 R140, R172
JAK2 14 V617
KIT 08, 09, 11, 13, 14, 17 Exon 8, 9, 11, K642 - N655, exon 14, D816 - Y823
KRAS 02, 03, 04 G12, G13, A59, Q61, K117, A146
MPL 10 W515
MYD88 05 L265
NRAS 02, 03, 04 G12, G13, A59, Q61, K117, A146
PDGFRA 12, 14, 18 Exon 12, 14, V824 - D842
PIK3CA 10, 21 E542 - Q546, M1043 - G1049
TP53 01 - 11 >95% of all coding sequences and splicing sequences
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In our HNSCC cell line panel we detected a number of mutations, mostly in the TP53 gene. 
In four cell lines a mutation was detected in addition to the TP53 mutation (Table 4). The 
CDK2NA gene was mutated in both UT - SCC - 5 and UT - SCC - 38. In UT - SCC - 5, a deletion 
in the CDK2NA gene resulted in a frameshift and premature stop codon (c.331_352del, 
p.Gly111Leufs*28), whereas in UT - SCC - 38, a splice mutation was detected (c.151 - 1G>T). 
Furthermore, in SCCNij185 we found a mutation in KIT (c.2122C>A, p.His708Asn). Lastly, a 
mutation in PIK3CA (c.1633G>A, p.Glu545Lys) was found in SCCNij185.
As mentioned, mutations were most frequently observed in the TP53 gene, with 16 of 
the 22 cell lines (72.3%) harbouring either a missense- or nonsense mutation, splice 
mutation, or deletion. TP53 is one of the best described tumour suppressor genes, and 
acts as a transcription factor linked to DNA damage response signalling, G1 - S arrest, and 
apoptosis [35]. The TP53 gene encodes the p53 protein, and is highly conserved throughout 
evolution and species. It is located on human chromosome 17p13.1, and consists of 11 
exons. Exon 1 is non - coding, whereas exons 2 to 11 are translated into the p53 protein. 
Multiple isoforms of p53 have been reported, which are achieved via alternative splicing in 
exon 9. The p53 protein consists of several functional domains, starting at the N - terminus 
with a transactivation domain, followed by a proline - rich domain, a DNA binding domain 
(DBD), nuclear localization sequence, oligomerization domain, and finally another nuclear 
localization sequence. Importantly, most of the described pathogenic mutations in TP53 
are located in the DNA binding domain, which usually inactivates p53’s ability to interact 
with DNA and therefore abrogate its transcriptional activity [36]. Strikingly, all of the TP53 
mutations that were detected were localised in the DNA and/or rendered a significant part 
of the DBD dysfunctional through frameshifts, premature stop codons, or inappropriate 
intron retention (Figure 2).
The mutations in the TP53 gene, or lack thereof, were found to be identical to the original 
reports for UT - SCC - 5 [37], UT - SCC - 8 [37], UT - SCC - 9 [37], UT - SCC - 11 [24], UT - SCC - 15 [38], 
UT - SCC - 19A [24], UT - SCC - 24A [39], UT - SCC - 29 [24], UT - SCC - 45 [14], FaDu [24] UM - SCC - 6 
[40], UM - SCC - 47 [40], 94 - VU - 147T [41], UPCI:SCC090 [29, 42] and UPCI:SCC154 [29]. To the 
best of our knowledge, the TP53 mutation status of UT - SCC - 38 has not yet previously been 
tested, so no comparison was possible. We found a discrepancy between the original 
report and our data on the mutation status of UT - SCC - 40. UT - SCC - 40 was previously 
reported to have a TP53 mutation (c.637C>T p.Arg213*), yet we did not detect any [24]. 
Interestingly, a later report showed a lack of p53 protein in UT - SCC - 40 [43]. This could 
potentially indicate the presence of wildtype p53, as it is under normal circumstances 
actively degraded by MDM2, and mutated p53 is more often detectable as a (truncated) 
protein [44]. However, we cannot exclude the possibility that our UT - SCC - 40 cell line is not 




this using STR analysis, as the lab where the cell line originated has not published any STR 
profile for this cell line. Furthermore, this is the first time the TP53 mutation status of the 
SCCNij cell lines has been determined, and can therefore not be compared to any other 
reports.
Table 4 Mutations detected in HNSCC cell lines
Cell line TP53 mutation Additional mutations
UT - SCC - 5 c.452_453delinsAT; p.Pro151His CDKN2A c.331_352del; p.Gly111Leufs*28
UT - SCC - 8 c.763A>T; p.Ile255Phe
UT - SCC - 9 Δ exon 2 - 9
UT - SCC - 11 c.560_589del; p.Gly187_Arg196del
UT - SCC - 15 c.560 - 1G>T
UT - SCC - 19A c.853G>A; p.Glu285Lys
UT - SCC - 24A c.673 - 2A>T
UT - SCC - 29 c.673 - 2A>T
UT - SCC - 38 c.310C>T; p.Gln104* CDKN2A c.151 - 1G>T
UT - SCC - 40 c.375+5G>A
UT - SCC - 45
FaDu c.673 - 1G>A
UM - SCC - 6
UM - SCC - 47








SCCNij185 c.457_469del; p.Pro153Serfs*13 KIT c.2122C>A, p.His708Asn
PIK3CA c.1633G>A, p.Glu545Lys
SCCNij202 c.783 - 1G>T
c.673: coding DNA sequence change at position 673; p.: amino acid change; G>A: guanine to adenine 
substitution; Pro151His; amino acid 151 change from proline to histidine; -1G>T: substitution in splice site; del: 
deletion; ins: insertion; fs: frameshift; *:stop codon.
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HPV and p16 status
HPV status and p16 status have shown to be important factors that determine how 
well tumours and patients respond to treatment. Characterisation and documentation 
of these factors is therefore important. While HPV status and p16 status are commonly 
used interchangeably in literature, they have different effects on treatment outcome. We 
previously have reported the p16 and HPV status and summarise them here (Figure 3). 
Previously, we have demonstrated that UT - SCC - 45 is infected with HPV33, and UPCI:SCC090, 
UPCI:SCC154, 93 - VU - 147T, and UM - SCC - 47 are infected with HPV16, whereas we did not 
detect any HPV in other HNSCC cell lines [10, 45]. In all the HPV positive cell lines (UT - SCC - 45, 
UM - SCC - 47, UPCI:SCC090, UPCI:SCC154, 93 - VU - 147T) p16 was overexpressed, but also in 
the HPV negative UT - SCC - 40 cell line [46]. Interestingly, previous reports have shown that 
HPV positive HNSCC do not always have overexpressed p16 [47]. This, and our own findings 
stress the difference between HPV and p16 status.
Figure 2 TP53 mutations in HNSCC cell lines. 
Shown is the TP53 wildtype (WT) transcript including exon locations and functional domains. For every detected 
TP53 mutation, the consequence for the TP53 transcript is shown for each cell line. TAD: transactivation domain; 





Figure 3 HNSCC cell line panel mutation, HPV, and p16 status. 
Shown are 22 cell lines and their mutation status of 23 tumour suppressor- and oncogenes. In addition, HPV 
and p16 status are shown.
Radiosensitivity and hypoxia sensitivity
A significant number of HNSCC cell lines in our panel has been used for in vitro and in vivo 
studies regarding mechanisms that confer radioresistance or radiosensitivity to cells. For 
a number of these cell lines, we have collected and summarised the available data on 
their relative radiosensitivity (Table 5). We reported both the original surviving fractions in 
response to 2, 5, 6, and 8 Gy, as well as the derivative D37 (dose required for 37% survival) 
as calculated using the linear quadratic model: SF = e−(αD + β(D*D)). As hypoxia (low tissue 
oxygen concentrations, usually below 2% O2), and especially severe hypoxia (<0.1% O2) is 
one of the best described variables to negatively affects radiosensitivity, we also included 
cellular sensitivity to low oxygen tensions. In addition, we summarise the hypoxic fractions 
that have been reported to occur in in vivo xenografts of individual cell lines, as measured 
using the hypoxia - marker pimonidazole (Table 5).
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In this study, we have characterised a panel consisting of 22 unique HNSCC cell lines. We 
extensively tested for genetic identity as well as mutations in a set of tumour suppressor- 
and oncogenes. In addition, we documented cellular morphology, HPV infection- and p16 
status. Lastly, we report cellular sensitivity to irradiation as well as hypoxia. Taken together, 
we provide a comprehensive database that may be used by other researchers to select 
the appropriate culture model for HNSCC.
Several other investigators have attempted to summarise and characterise the available 
HNSCC cell line models that are in circulation between universities and research institutes 
[9, 13, 14, 24]. However, several of the cell lines we have studied have not yet been 
previously characterised and documented. We compared the STR profiles of each cell 
line and compared them to previously published profiles where possible. All previously 
characterised cell lines matched with the STR profiles we described here. Furthermore, for 
the first time we publish the STR profiles of UT - SCC - 5, -8, -9, -11, -15, -29, -38, and -45, which 
were all unique profiles not matching any currently known cell lines.
The cell line panel described here spans both HPV negative and HPV positive subtypes, 
and includes radio- and hypoxia sensitivity, as well as the degree of hypoxia observed in 
xenograft studies. Taken together, this provides valuable information regarding the tumour 
microenvironment and intrinsic sensitivity to irradiation, both explicitly important factors 
that determine success of radiotherapy.
Regarding patient characteristics, our HNSCC cell line panel was relatively diverse in terms 
of TNM stage and anatomical location. Previous studies have shown HNSCC, and especially 
HPV positive HNSCC, is more prevalent in males than females [49]. In our HNSCC cell line 
panel all cell lines had been derived from male patients, which is a factor that has to be 
taken into account when selecting for a diverse HNSCC cell line panel.
The mutation profile of the cells in this study was established using targeted sequencing. 
We found mutations in PIK3CA, KIT, CDKN2A, but mostly in TP53 (72.3% of all cell lines). This 
is unsurprising given that in HPV negative HNSCC, 86% of the tumours have been reported 
to bear TP53 mutations [50]. Interestingly, HPV status and TP53 mutations were almost 
mutually exclusive, except in the 93 - VU - 147T cell line. This is also reflected in the HNSCC 
patient population, where HPV positive tumours almost never harbour TP53 mutations [50, 
51]. Of all the TP53 mutations we detected, in all 16 cell lines they lead to either abolished 
or defective TP53 transcripts at the level of the DNA binding domain. This has previously 
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been reported to be the hotspot of TP53 mutations in HNSCC and we confirm this in our 
cell line panel [52].
Additionally, we collected data regarding HPV and p16 status. These are often used 
interchangeably, yet may orchestrate different responses in terms of radiosensitivity [46]. 
All HPV positive cell lines overexpressed p16, which is a canonical feedback mechanism 
attributed to the effects of E7 in the cell. As a result of E7 expression, RB is primed for 
proteasomal degradation, which in turn liberates the E2F transcription factor. One of the 
transcription targets of E2F is CDK2NA, which encodes the p16 protein, completing the 
feedback loop [53]. We found that UT - SCC - 40 is a HPV negative cell line that overexpressed 
p16, which is not caused by any CDKN2A activating mutations. It remains unclear why 
UT - SCC - 40 overexpresses p16, yet it does belong to one of the most radiosensitive cell 
lines in our panel, alongside with the HPV positive cell lines. This further strengthens the 
notion that mainly p16, and not HPV status, is a main determinant of radiosensitivity.
The radiosensitivity data we collected confirms that HPV positive HNSCC cell lines are 
more radiosensitive than HPV negative cell lines, and is in agreement with previous 
publications[45, 46, 54 - 56]. To the best of our knowledge no other reports exist that 
describe the sensitivity of these HNSCC cell lines to hypoxia.
Taken together, we have established a comprehensive and informative HNSCC cell line 
database. We believe that these cell lines are suitable models to study HNSCC disease in 
vitro and in vivo and may provide a valuable tool for investigators wishing to study the 
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Chapter 7
Head and neck cancer: towards differential treatment for HPV positive and 
-negative patients
Over the course of the previous decade, it has become apparent that the HPV status of 
HNSCC patients greatly affects their response to chemoradiation, and significantly affects 
treatment outcome, prognosis, and survival [1 - 7]. Independent of differences in patient 
population (age, sex, smoking and alcohol history, tissue origin, genetic background), 
HPV status has been shown to be a highly prognostic factor for a favourable outcome. 
Currently, there is no differentiation in treatment for HPV positive versus HPV negative 
cancers, leading to the most likely scenario that some HPV negative patients may be 
undertreated, whereas HPV positive patients may be overtreated. Therefore, it is important 
to work towards differential treatment, and develop personalised treatment options for 
these subtypes. In this thesis, we aimed to discern the mechanisms that contribute to both 
radioresistance and -sensitivity in both HPV positive and -negative HNSCC by examining 
DNA damage repair pathways, metabolic gene expression, and response to hypoxia. 
As a result, we identified a number of differential approaches for specific targeting of 
HPV positive and negative HNSCC. In this chapter, these findings are put into a broader 
perspective, and suggestions for further research are discussed.
Hypoxia: bad news, regardless of HPV status
In nearly all solid tumours, occurrence of hypoxia is associated with therapy resistance and 
poor prognosis [8 - 12]. As a result of both moderate and severe, acute and chronic hypoxia, 
concomitant resistance mechanisms against chemotherapeutics and radiotherapy develop 
[13]. The occurrence of hypoxia in HNSCC has been extensively studied, as well as strategies 
to countermand hypoxia - induced radioresistance and chemoresistance.
At present, the only clinically implemented hypoxia modifier is nimorazole, which is 
currently used in Denmark only , while an Europe wide trial (NIMRAD) is ongoing and 
results are expected at the end of 2020 [14]. Nimorazole therapy has demonstrated 
improved loco - regional control and failure - free survival, and is currently used concurrently 
with radiotherapy. Interestingly, hypoxia modification by nimorazole was only successful in 
p16 negative (often framed as HPV negative) HNSCC [15]. Initially, this was attributed to HPV 
positive tumours either being “too sensitive” for irradiation to be further radiosensitised, 
or that these tumours must be less hypoxic and therefore not targetable by nimorazole. 
However, several studies have shown that the hypoxic fraction in HPV/p16 positive HNSCC 
does not significantly differ from HPV/p16 negative HNSCC [12, 16, 17]. Furthermore, other 
reports have demonstrated that hypoxic HPV positive cells are in fact radioresistant [18, 
19]. From our work in Chapter 3, we can confirm that HPV positive cells, when in a hypoxic 
environment (<0.1% O2 in this instance), are desensitised to irradiation to the same degree 
as HPV negative HNSCC cells. This is in line with a previously published report, which 
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showed HPV positive cell lines developed radioresistance under severe hypoxia [19]. 
Additional effects of hypoxia on HPV positive cells specifically include the reduction of 
HPV E6 and E7 expression, and dissociation of E6 and E6AP, which in turn leads to the 
(partial) recovery of p53 and retinoblastoma (RB) protein function under hypoxia [20, 21]. In 
response to this, tumour cells become dormant and radioresistant, yet can be re - activated 
during spells of normoxia. This provides for a highly resistant pool of HPV positive cells that, 
after reoxygenation, offer a possibility for repopulation of the tumour [20]. Thus, multiple 
reports have demonstrated that hypoxic HPV positive HNSCC cells and tumours respond 
poorly to radiotherapy and are associated with poor prognosis, and should therefore be 
targeted differently.
Aside from these HPV specific effects, hypoxia activates multiple survival pathways in 
HNSCC, such as the PIK3CA/AKT/mTOR pathway [22 - 24], HIF - 1α signalling, and the DNA 
damage response (DDR) [25 - 27]. In case of the former, previous work has demonstrated 
that in response to hypoxia, AKT is activated through p53 - dependent signalling, and that 
HNSCC cells become dependent on this survival signalling[22]. In turn, this proves to be an 
attractive mechanism to target hypoxic HNSCC cells. In earlier studies, we showed that HPV 
negative HNSCC cell lines and xenografts could be effectively sensitised to irradiation by 
AKT inhibition using small molecule inhibitor MK2206 [24]. In Chapter 5, we show that also 
HPV positive HNSCC cells not only become more resistant to irradiation under hypoxia, but 
that they activate the AKT signalling pathway as well. Interestingly, HPV positive HNSCC cells 
could be sensitised to hypoxia, and their hypoxia - induced radioresistance remedied using 
the AKT inhibitor MK2206. Thus, this provides a potential therapeutic opportunity to target 
a so called “wolf in sheep’s clothes”, as it allows for effective targeting of a resistant subset 
of HPV positive HNSCC. So far, the question remains by which mechanism HPV positive 
HNSCC cells become more susceptible to AKT targeting. A possible explanation that we 
could offer is that the amount of activating mutations in PIK3CA is higher in HPV positive 
HNSCC tumours than HPV negative tumours [28 - 30] Our data from Chapter 6, where we 
performed a mutation analysis for PIK3CA however, did not show any differences in PIK3CA 
mutations in our HNSCC cell line panel. Therefore, in our cell models, the differences in AKT 
inhibition sensitivity could not be explained by any mutations in PIK3CA.
Implications for DNA damage repair: suitable for targeting?
Both radiotherapy and certain classes of chemotherapeutics aim to damage the DNA of 
cancer cells to such an extent that a cell is unable to proliferate and survive, commonly 
orchestrated through apoptosis and mitotic catastrophe [31]. Whilst the DNA damage 
repair pathways of cancer cells are commonly, at least partially defective, a cancer cell 
relies on the remaining DNA damage repair pathways to repair any DNA defects that 




combining DNA damage repair inhibitors with chemotherapy or radiotherapy could be 
particularly interesting.
Within the field of HNSCC, there are a number of potential candidate proteins within 
every DNA damage repair pathway that are currently under investigation, either as a 
target for monotherapy, or in combination with cetuximab, platinum - based therapies or 
radiotherapy. The DNA damage repair pathways include non - homologous end joining 
(NHEJ) and homologous recombination (HR) for double strand breaks (DSBs), and mismatch 
repair (MMR), base excision repair (BER) and nucleotide excision repair (NER) for single 
strand breaks. Effector proteins that are currently targeted using small molecule inhibitors 
are DNA - PK (NHEJ), RAD51 (HR), ATM (DSB sensor), ATR (single strand break (SSB) sensor) 
among others [32 - 37]. In most studies, an attempt is made to select specific cell/patient 
populations that will respond the most (e.g. demonstrate the highest radiosensitisation) 
to a particular inhibitor. In the context of a deficient DNA damage repair pathway, a cancer 
cell becomes dependent on other repair pathways to adequately respond to DNA damage. 
By targeting that secondary pathway using an aforementioned DNA damage inhibitor, 
synthetic lethality is generated. A well - known example of this is synthetic lethality achieved 
by PARP inhibition in BRCA mutated breast cancer [38]. In this particular example, the HR 
pathway is defective as a result of a BRCA loss of function mutation. PARP is responsible for 
DNA damage repair signalling (specifically BER) in the context of single strand breaks, that 
result in DSBs if not repaired. In turn, these DSBs lead to replication - associated lesions and 
cell death if not repaired by HR, explaining high sensitivity of BRCA mutated cells to PARP 
inhibition [39]. PARP inhibitors (olaparib among others) have been shown to be effective 
in breast cancer and ovarian cancer patients who have BRCA mutations, and therefore 
show synthetic lethality [40, 41].
In the context of HNSCC there is an important distinction between the DNA damage repair 
pathways that are used in response to irradiation. Multiple studies have demonstrated that 
as a result of E6 and E7 overexpression, HPV positive HNSCC cells have acquired a defect 
in HR among others [42 - 44]. This effect was attributed to multiple mechanisms, discussed 
in Chapter 1. Briefly, as a result of p16 and TRIP12 overexpression, a reduced recruitment 
of RAD51 was observed, leading to a defect in HR [45]. In addition, up - regulation of 
XRCC1, DNA polymerase β, and PARP1 specifically in HPV positive HNSCC demonstrated 
favouritism towards BER and NHEJ [44]. This demonstrates that differences in DNA damage 
repair pathways between HPV positive and -negative HNSCC dictate the effectiveness 
and radiosensitising capacity of a DNA damage repair inhibitor. To put our own finding 
into perspective: we showed that a combination of palbociclib, a cyclin dependent 
kinase (CDK) 4/6 inhibitor, and irradiation not only led to more unresolved DNA damage 
and chromosomal instability, but that this was dependent on the loss of RAD51 and 
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BRCA1 as well [46]. As a consequence, we observed a deficiency in HR. We observed 
this radiosensitising effect only in HPV negative HNSCC cell lines, which was attributable 
to the fact that palbociclib mimics the function of p16. This result confirms that the 
differences between DNA damage repair pathways in HPV positive and negative HNSCC 
result in a different response to DNA damage repair inhibiting compounds. Importantly, 
our studies in Chapter 3 and Chapter 6 highlight the discrepancy between HPV status 
and p16 status, and the subsequent consequences of this. Indeed, all of the cell lines that 
were positive for HPV infection overexpressed p16 on the protein level, yet one cell line 
(UT - SCC - 40) overexpressed p16 but was not HPV positive. This particular HPV negative 
cell line was insensitive to palbociclib, and was not radiosensitised by it, demonstrating 
the necessity of active p16 and loss of RB for the radiosensitising effect of palbociclib. To 
date, one phase II clinical trial for HPV negative HNSCC patients is testing the effect of 
neoadjuvant palbociclib monotherapy followed by cisplatin and radiotherapy/cetuximab 
(NCT03389477), and is expected to be completed in 2026.
In Chapter 4 we discovered that overexpression of the metabolic gene ATP citrate lyase 
(ACLY) was associated with radioresistance and poor outcome in patients that had received 
irradiation. We described a role for ACLY in the promotion of HR and demonstrated that 
inhibition of ACLY specifically inhibited this type of DNA damage repair. This was in 
agreement with a previous study that demonstrated that nuclear ACLY promoted HR by 
acetylation of histones near DSBs, thereby facilitating BRCA1 recruitment [47]. Interestingly, 
we did not observe any link between ACLY expression and HPV status in vitro. Because all 
cell lines that received pharmacological ACLY inhibition were HPV negative, we can at 
least conclude that in HPV negative cell lines this led to radiosensitisation likely due to 
the observed deficiency in HR. We tested the hypothesis that inhibition of downstream 
fatty acid synthesis could be responsible for the radiosensitising effect of ACLY inhibition. 
While previous reports have shown that inhibition of fatty acid synthetase (FAS) could 
result in radiosensitisation of lung and prostate cancer cell lines [48, 49], we did not 
observe radiosensitisation of HNSCC cell lines in response to a FAS inhibitor. Therefore, 
we concluded that the radiosensitisation caused by ACLY inhibition was independent of its 
effects on the fatty acid synthesis pathways, and indeed is mediated via the HR pathway.
The observations of Chapter 3 and Chapter 4 together attest to the notion that targeting 
HR may be a viable strategy for HPV negative HNSCC, but not HPV positive HNSCC. However, 
the defect in HR in HPV positive HNSCC may provide a window for an alternate treatment 
with DNA damage inhibitors, namely PARP inhibitors. Specifically, because of their defect 
in HR and their up - regulation of NHEJ and BER genes, this type of HNSCC may prove to 
be a suitable target for PARP inhibition. However, the first in vitro experiments combining 




[44, 50]. Two studies examined the cellular sensitivity to PARP inhibition without any DNA 
damaging agents and found enhanced sensitivity to PARP inhibition by veliparib both in 
vitro and in vivo [51], as well as enhanced sensitivity to olaparib in HPV positive cells [52]. 
Another two research groups assessed the effect of PARP inhibition on the radiosensitivity 
of HPV positive HNSCC. Paradoxically, one study showed a radiosensitising effect of PARP 
inhibitors in HPV positive HNSCC [50], whereas one study observed only a radiosensitising 
effect in HPV negative HNSCC cells [44]. Unfortunately, the study that demonstrated the 
radiosensitising effect of olaparib did not report any tests in HPV negative cell lines. As 
of now, it remains unclear whether PARP inhibition could be a viable option to further 
radiosensitive HPV positive cells.
So far, we have focused on the differences between HPV positive and negative HNSCC 
in terms of DNA damage repair and subsequent targets for radiosensitisation. In contrast 
to this, there are some striking similarities between these two types of cancer that could 
potentially be exploited for therapeutic strategies. In general, both HPV positive and 
-negative HNSCC cells lack a functional G1/S checkpoint as a result of deficient or impaired 
p53 signalling. We confirmed this in Chapter 3, where we demonstrated that, in response 
to irradiation, HPV positive and -negative cells accumulate in the G2, but not G1 phase. 
In HPV negative cells, over 70 % of tumours harbour a p53 mutation [30]. In contrast, 
HPV positivity in HNSCC and p53 mutations are almost completely mutually exclusive [30, 
53]. The expression of the HPV oncogene E6 leads to proteasomal degradation of p53, 
resulting in a defective G1 checkpoint. As a consequence, both HPV positive and negative 
HNSCC cells are almost completely dependent on a functional G2/M checkpoint to repair 
any damaged DNA. G2 checkpoint inhibition might therefore be an interesting target to 
sensitise cells to irradiation and prevent DNA damage repair. For example, Wee1, a nuclear 
kinase involved in the inhibition of CDK1 and G2/M progression, has been shown to be 
overexpressed in HPV positive HNSCC, making these cells dependent on it. In both HPV 
positive and -negative cells, Wee1 inhibition showed some promising preliminary results, 
as it triggered apoptosis in HPV positive cells as well as radiosensitised them, and remedied 
cisplatin resistance in p53 mutated HPV negative HNSCC [54 - 56]. The first trial combining 
Wee1 inhibitors with docetaxel and cisplatin demonstrated that the combination was 
safe and tolerable, and Phase II trials are currently underway [57]. Thus, G2 checkpoint 
inhibition via Wee1 inhibitors might prove to be an attractive target for both HPV positive 
and -negative HNSCC.
Apart from genotoxic agents that induce physical DNA damage, the DDR is also activated 
by severe levels of hypoxia. In response to these low oxygen tensions (<0.1% O2), several 
components of the DDR are inhibited under hypoxic stress, such as targets of the BER, 
MMR, and HR pathways. In contrast, other DDR genes and proteins are up - regulated, 
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such as p53 and ATM [25]. The up - regulation of ATM occurs in the context of replication 
stress, and is currently believed to play a role in preventing progression in S phase in 
hypoxic conditions. Therefore, ATM may play a role in maintaining genomic stability in the 
context of hypoxia by regulating replication [58]. Because ATM is an important signalling 
protein in the DDR, and responsible for the induction of a proper G2/M checkpoint 
by activating BRCA2 and p53, it could be a potentially interesting therapeutic target. 
Indeed, ATM inhibitors have been shown to drastically enhance radiosensitivity in in 
vitro models, and to have limited toxicity in in vivo [34, 37]. ATM activation in response to 
hypoxia (among others) was described as being dependent on a co - factor, ATM interactor 
(ATMIN) [59 - 61]. To determine whether ATMIN could be a potentially interesting target, we 
examined the ATM activating properties of ATMIN in hypoxic conditions, and performed 
ATMIN knockdown experiments to determine any effects on radiosensitivity (Chapter 2). 
Unfortunately, previous results from a different group that showed ATMIN - dependent ATM 
activation could not be replicated [62]. Furthermore, we did not observe any effects on 
radiosensitivity in response to ATMIN knockdown. In fact, we consistently demonstrated 
that ATMIN protein abundance decreased over time in hypoxia, and showed that this 
was p53 and HIF - 1α dependent. In short, we contradict that ATMIN is required for ATM 
activation in hypoxia, and expect that it will not be a suitable target for radiosensitisation.
Metabolism
Altered metabolism has long been recognised as one of the key characteristics of 
malignancies, and is considered to be one of the hallmarks of cancer [63]. Like many 
other solid cancers, HNSCC display a change towards glycolytic metabolism, even under 
normoxic conditions, called the Warburg effect [64]. This indicates that prior to, during, 
and/or after oncogenesis, HNSCC cells undergo extensive metabolic reprogramming. 
Overexpression of the EGFR receptor for example, has been shown to be a driver of 
metabolic changes in HNSCC, via the PIK3CA/AKT/mTOR pathway [65]. In addition to 
changes in glucose metabolism, alterations in glutathione metabolism, lipid metabolism, 
TCA cycle, oxidative phosphorylation, and amino acid metabolism have been described 
in HNSCC [66]. This indicates that the metabolic reprogramming occurs on an extensive 
scale, and could require a personalised approach to target HNSCC disease with different 
metabolic backgrounds. There is increasing evidence that metabolic changes in HNSCC 
may affect treatment outcome by conferring chemo- or radioresistance, and could affect 
patient prognosis [67]. Current efforts to target metabolic pathways include, but are not 
limited to, glucose metabolism inhibitors (GLUT - 1 , HK2, LDHA), lipid metabolism inhibitors 
and amino acid metabolism (ASCT2), with so far mixed results [68].
New evidence suggests there may be important differences between the metabolism 




metabolism and oxidative phosphorylation were elevated in HPV negative HNSCC in 
comparison to HPV positive HNSCC in an in vitro setting [66]. A meta - analysis comparing 
18FDG - PET results from HPV positive and HPV negative patients showed there was a strong 
trend towards HPV negative patients having a higher uptake, and thus suggests having a 
higher metabolic rate [66]. Other effects of HPV infection in HNSCC on metabolism include 
E6 mediated ROS production and elevated mitochondrial respiration [69, 70] In Chapter 4, 
we show that the four most radioresistant cells (4 HPV negative cell lines) have up - regulated 
genes in the glycolysis, TCA, glutamate and lipid metabolism pathways compared to the 
four most radiosensitivity cell lines (3 HPV positive, 1 HPV negative). While this comparison 
does not directly translate to differences between HPV positive and HPV negative HNSCC, 
we believe it demonstrates that differences in metabolism may play an important role in 
the cell’s ability to adequately respond to irradiation or stressors like hypoxia.
Perspectives
In this thesis, we described mechanisms that mediate the radiosensitivity of HPV positive 
HNSCC, and tried to exploit these in HPV negative HNSCC. In this approach, we have taken 
into account the different origins of HNSCC tumours and mutation status, and mostly 
performed in vitro testing of a large and diverse HNSCC cell line panel. We recognise 
that one of the limitations of using an in vitro HNSCC panel is the lack of a realistic 3D 
tumour microenvironment (TME). Most importantly, any effects the immune system 
could have on the tumour’s response to irradiation or other stresses, has not been taken 
into account. Several studies have shown that the immune composition of the tumour 
microenvironment differs greatly between HPV positive and –negative HNSCC [71, 72]. 
Unsurprisingly, the TME of HPV positive HNSCC contains a significant higher amount of 
immune cells that have been activated in response to the presence of HPV [73, 74]. In 
turn, HPV negative HNSCC have been described as being “colder”. Recently, it has become 
more apparent that the immune composition of the TME has a significant impact on the 
response to irradiation and vice versa [75, 76]. The effects of irradiation on the immune 
response greatly depends on the microenvironmental context, such as type of immune 
infiltrate (naieve/cytotoxic T - cells, regulatory T-cells, dendritic cells, tumour associated 
macrophages etc.), presence of other stromal cells, cytokines, as well as the irradiation 
dose and fractionation [77]. Depending on the context, local irradiation can induce both an 
immunosuppressive as well as an immunostimulatory environment, and in some cases lead 
to a systemic effect [78]. Interestingly, a recent publication demonstrated that palbociclib, 
which we found to be a strong radiosensitiser in HPV negative HNSCC, provoked an 
anti - tumour response that was mediated by the production of IFNγ, increased antigen 
presentation, and enhanced T - cell killing [79]. This provides with a window of opportunity 
to further examine palbociclib as an agent to both radiosensitise tumour cells as well as 
enhance the anti - tumour immune response in an in vivo and clinical setting.
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One of the main questions that remains is whether we are currently ready to start 
differential treatment for HPV positive and HPV negative HNSCC patients. The first 
clinical trials (NCT01898494, NCT01687413, NCT03323463, NCT03215719) that de - escalate 
treatment for HPV positive HNSCC patients have started and the earliest endpoints are 
expected to be reached in 2021 - 2023. Some trials have failed to yield satisfactory results, 
like the De - ESCALaTE HPV trials that aimed to replace radiotherapy + cisplatin therapy by 
radiotherapy + cetuximab treatment [80, 81]. Two other trials are attempting to achieve 
similar tumour control in HPV positive patients by de - escalation and/or volume reduction 
of radiation dose, thereby reducing the short- and long - term side effects of radiotherapy 
[82, 83]. However, there are some issues that need to be resolved in order to succesfully 
differentiate treatment/achieve succesful de - escalation:
Firstly, the matter of HPV positive versus p16 positive HNSCC must be acknowledged and 
addressed consistently. We have confirmed there is a discrepancy between HPV and p16 
status, as well as response to in vitro treatment, and this is also reflected in the patient 
population. Any investigation or trial therefore should have mechanistical motivation 
whether to target HPV positive of p16 positive HNSCC.
Secondly, we believe that addressing hypoxia not only in HPV negative, but also in HPV 
positive HNSCC will contribute to treatment success. Especially in the context of treatment 
de - escalation, hypoxic cancer cells will most likely be undertreated and provide a means 
for tumour repopulation. Several excellent hypoxic gene signatures exist that reflect the 
hypoxic state of HNSCC tumours, and they may be used to select severely hypoxic HPV 
positive tumours to be excluded from de - escalation.
Lastly, differences in genetic background, tumour microenvironment, DNA repair capacity, 
metabolism, and immune composition play an essential role in therapy response. The 
future of HNSCC treatment not only lies within de - escalation only, but continuous 
development of personalised treatment for HNSCC subtypes. In this regard mechanistical 
insights are invaluable, as they will pave the way for new synthetically lethal treatments, 
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Treatment for head and neck squamous cell carcinomas (HNSCC) can consist of several 
modalities: surgical resection, radiotherapy, chemotherapy and/or targeted therapy against 
the epidermal growth factor receptor using monoclonal antibodies (cetuximab). Within 
HNSCC, two major subtypes are distinguishable: human papillomavirus (HPV) positive and 
-negative tumours. Overall, HPV negative tumours are more radio- and chemoresistant, 
and patients have a relatively poor prognosis, a higher chance of recurrences, and shorter 
overall survival. In contrast, HPV positive tumours and cells are relatively radiosensitive. This 
is reflected in the treatment outcomes of patients afflicted with HPV positive tumours, as 
they have an overall superior outcome and survival rates. Despite these differences, there 
is no differential treatment for these HNSCC subtypes. In this thesis, we examined the 
molecular mechanisms that determine the radiosensitivity of HPV positive and -negative 
cells, and identified pathways in each subtype that could be suitable for targeting. A 
complicating factor for treatment in both subtypes is the occurrence of hypoxia, or low 
oxygen tension. Severe hypoxia (<0.1% O2) causes radioresistance due to lack of oxygen 
molecules to ‘fix’ the DNA damage. In addition, low oxygen tensions affect cellular 
mechanisms related to DNA damage repair and activate the DNA damage response, as 
well as survival mechanisms like the AKT pathway. Therefore, hypoxia is an important 
variable to take into consideration for any treatment of solid tumours.
One of the most important factors mediating double strand break (DSB) repair in response 
to irradiation is ATM. ATM is recruited to DSBs and is in turn responsible for phosphorylating 
and activating downstream effector proteins such as CHK2 and p53, making it a master 
regulator of the DNA damage response and maintaining the G1/S checkpoint. Aside 
from DSBs, ATM can be activated by a number of cellular stresses, like replication stress 
or hypoxia. Recently, the ATM interactor (ATMIN) was identified as a critical factor for 
replication stress - induced activation of ATM, suggesting an essential role for ATMIN in 
ATM regulation during hypoxia. In addition, ATMIN is involved in base - excision repair. We 
hypothesized that if ATMIN was responsible for activation of ATM in hypoxia, inhibiting it 
could alter the DNA damage response and radiosensitise hypoxic cells. We investigated 
the role of ATMIN in the activation of ATM, and found that ATMIN was dispensable for 
hypoxia - induced ATM activation (Chapter 2). In contrast to ATM, inhibition of ATMIN did 
not affect cell survival or radiosensitivity in hypoxia. Moreover, we show that in hypoxic 
conditions ATMIN expression is repressed, and subsequently ATMIN protein abundance is 
reduced. We show repression of ATMIN in hypoxia is mediated by both p53 and HIF - 1α in 
an oxygen dependent manner. The biological consequence of ATMIN repression in hypoxia 
is decreased expression of the target gene, DYNLL1. An expression signature associated with 
p53 activity was negatively correlated with DYNLL1 expression in patient samples further 
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supporting the p53 dependent repression of DYNLL1. Taken together, we conclude that 
ATMIN was not a suitable target for radiosensitisation of the chosen cell models.
Although ATMIN was not a suitable target for radiosensitisation, the DNA damage response 
remained a pathway of interest. In HNSCC, HPV positivity is linked to overexpression of p16, 
a protein that inhibits cyclin dependent kinases (CDK) 4 and 6. p16 was linked to a defect in 
the homologous recombination (HR) DNA damage repair pathway, and is at least partially 
responsible for the enhanced radiosensitivity of HPV positive cells.
Therefore, we hypothesized that mimicking p16 overexpression using a CDK4/6 inhibitor, 
palbociclib, could enhance radiosensitivity in HPV negative HNSCC cells (Chapter 3). We 
confirmed in a large set of cell lines that palbociclib radiosensitises p16 negative, but not 
-positive cells. The combination of irradiation and palbociclib led to a substantial increase 
of unrepaired double strand breaks (DSBs), chromosomal aberrations, and mitotic defects. 
In addition, palbociclib treatment resulted in loss of BRCA1 and RAD51 expression and 
a subsequent defect in HR. Importantly, the radiosensitising effect of palbociclib was 
unaffected by the presence of hypoxia, strengthening its suitability as a radiosensitizer 
for HPV negative HNSCC.
Because multiple links have been described between the metabolic activity of tumours 
and their clinical outcome, we hypothesized that metabolic gene expression could 
mediate radioresistance or -sensitivity in HNSCC cells (Chapter 4). To further increase our 
understanding of mechanisms contributing to radioresistance or -sensitivity in HNSCC, 
we employed targeted RNA sequencing on a panel of fourteen HNSCC cell lines for 
approximately 200 metabolism - related genes. The expression of these genes was correlated 
with the D37, a measure for radiosensitivity. Eighteen genes significantly correlated with either 
radioresistance or – sensitivity. One of the main hits, ATP citrate lyase (ACLY), was associated 
with radioresistance. Pharmacological inhibition of ACLY using BMS303141 caused impairment 
of DNA damage repair and led to increased residual DSBs after irradiation, as well as a defect 
in HR. Examination of a TCGA (The Cancer Genome Atlas) cohort of HNSCC patients revealed 
that high expression of ACLY was predictive for radiotherapy failure, as it was associated 
with poor overall survival in patients who received radiotherapy, but not in patients who 
did not receive radiotherapy. We then confirmed this finding in an independent validation 
cohort of the Netherlands Cancer Institute containing patients that had been treated with 
chemoradiation. In this cohort, high ACLY expression also associated with poor outcome, 
confirming the observations from the TCGA cohort. Closer examination of ACLY protein 
levels and localization showed specifically that patients with poor locoregional control had 
higher levels of nuclear localized ACLY protein. Together, we showed that ACLY affects DNA 




After investigating mechanisms that cause radioresistance in HPV negative HNSCC 
(Chapter 3) or mediate radioresistance in general (Chapter 4), we next investigated targets 
for radiosensitisation of HPV positive cells. Previous studies suggested that hypoxia not 
only induced radioresistance in HPV positive HNSCC cells, yet also causes them to become 
dormant. As a result, this creates a pool of radioresistant cells that are hard to target, and 
become active once reoxygenated, providing a means for tumour repopulation. Previous 
work in our lab showed hypoxic HPV negative cells activate the AKT survival pathway, 
which can be targeted using the AKT inhibitor MK2206. We hypothesized that hypoxic 
HPV positive cells would activate this survival pathway as well, and that it could be used to 
target HPV positive HNSCC (Chapter 5). First of all, we confirmed that HPV positive HNSCC 
cells become radioresistant in hypoxic conditions and that in response to hypoxia, the AKT 
pathway is activated. Strikingly, both in normoxic and hypoxic conditions, HPV positive 
HNSCC were highly sensitive to AKT inhibition. AKT inhibition sensitized HPV positive cells 
to both hypoxia and irradiation. These data suggest that HNSCC tumours are dependent on 
AKT to survive hypoxia, yet that AKT inhibition is most potent in radioresistant hypoxic HPV 
positive cells. Targeting AKT may thus be a potential way to overcome hypoxia induced 
radioresistance, particularly in HPV positive HNSCC tumours.
Most of the investigations we performed in this thesis were done using in vitro models of 
HNSCC. While in vitro models will always have their limitations, the wide array of HNSCC cell 
lines used have proven very useful to detect mechanisms of radioresistance for both HPV 
positive and -negative HNSCC. In Chapter 6 we performed a comprehensive characterization 
of the HNSCC cell lines used throughout this thesis, providing a tool for future research 
into HNSCC subtypes. We summarized the origins of the cell lines, ranging from patient 
characteristics to the anatomical origins of the cell lines, as well as cellular morphology. Where 
possible, short tandem repeat profiling was performed to confirm the genetic identity of 
the cell lines. In addition, genotyping of a set of 23 tumour suppressor and -oncogenes was 
performed. A significant portion of the HNSCC cell lines carry a pathogenic TP53 mutation, 
as well as mutations in CDKN2A (encoding p16), KIT, and PIK3CA. In addition to this, we 
summarize both HPV and p16 status and demonstrate an existing discrepancy between the 
two. Consistent with previous reports HPV infection and TP53 mutations are almost mutually 
exclusive. In addition to these characteristics, radiosensitivity and hypoxia sensitivity data 
are summarized. Here, we provide an in - depth description of a large set of frequently used 
HNSCC cell lines, with widely diverse characteristics as found in HNSCC patients.
To conclude, in this thesis several mechanisms have been described that provide HNSCC 
cells with a mechanism to overcome to overcome hypoxia and irradiation. We show that 
some of these mechanisms can be exploited to radiosensitise cells, and suggest differential 




De behandeling van hoofd- en halskankers omvat meerdere strategieën, zoals 
radiotherapie, chemotherapie, het chirurgisch verwijderen van een tumor, doelgerichte 
therapie tegen de epidermale groeifactor receptor, of een combinatie hiervan. In het 
algemeen wordt er onderscheid gemaakt tussen twee typen hoofd - halskanker: humaan 
papillomavirus (HPV) positieve tumoren, en HPV negatieve tumoren. HPV negatieve 
tumoren zijn doorgaans minder gevoelig voor zowel chemo- als radiotherapie, wat leidt 
tot een slechtere prognose voor patiënten met dit type tumoren. Naast dat zij een hogere 
kans op recidieven hebben, is ook hun totale levensverwachting slechter. In schril contrast 
hiermee staan de HPV positieve tumoren: deze zijn relatief gevoelig voor radiotherapie en 
reageren beter op de behandeling. De patiënten met dit type tumoren hebben ook een 
lagere kans op recidieven en een hogere levensverwachting. Ondanks deze verschillen 
worden patiënten met één van deze twee type tumoren hetzelfde behandeld. In dit 
proefschrift heb ik de moleculaire mechanismen onderzocht die bepalen hoe gevoelig 
cellen zijn voor radiotherapie, en heb ik getracht voor beide typen tumor een zwakke plek 
te vinden die als aangrijpingspunt voor nieuwe therapieën kan dienen. Een complicerende 
factor is dat hypoxie, een laag zuurstofgehalte in het (tumor)weefsel, in beide typen tumor 
voorkomt. Een hoge mate van hypoxie (<0.1% O2) heeft namelijk negatieve gevolgen 
voor de effectiviteit van bestraling. Daarnaast kan hypoxie ervoor zorgen dat cellen al 
enkele processen activeren zoals signaalroutes voor DNA schade reparatie of cel overleving 
via AKT signalen. Mede hierdoor is het belangrijk om ook hypoxie mee te nemen als 
belangrijke variabele voor het al dan niet slagen van een behandeling.
Eén van de belangrijkste factoren voor de reparatie van dubbelstrengs DNA breuken als gevolg 
van bestraling is ATM. ATM verplaatst zich in de cel naar de precieze locatie van deze breuken, 
en fosforyleert en activeert een reeks aan effectoreiwitten zoals CHK2 en p53. Hiermee speelt 
het ATM eiwit een centrale rol in de start van de DNA schade respons, en het starten en 
in stand houden van het G1/S checkpoint. Naast DNA schade kunnen ook andere cellulaire 
stressfactoren ATM activeren, zoals hypoxie en replicatiestress. Voor deze processen is een 
cofactor nodig: ATM interactor (ATMIN). Recentelijk is aangetoond dat ATMIN een cruciale rol 
speelt in de activatie van ATM in hypoxie. Aan de hand hiervan stelden wij de hypothese op dat 
wanneer wij de functie van ATMIN konden blokkeren, we hypoxische cellen gevoeliger konden 
maken voor bestraling. Eerst wilden we aantonen wat de rol was van ATMIN in het activeren 
van een ATM response in hypoxie: deze bleek verwaarloosbaar te zijn (Hoofdstuk 2). In 
tegenstelling tot ATM, leidde remming van ATMIN niet tot een toename van radiogevoeligheid 
in hypoxie. Daarnaast toonden we aan dat het ATMIN eiwit zelf juist onderdrukt wordt door 
hypoxie en dat dit afhankelijk is van HIF - 1α en p53. Al met al concludeerden we dat ATMIN geen 




De DNA schade respons bleef, ondanks het negatieve resultaat van ATMIN, een proces waarop 
wij graag onze aandacht wilde richten. In hoofd - halskanker leidt een infectie met HPV vrijwel 
altijd tot overexpressie van het p16 eiwit. Dit eiwit staat erom bekent cycline - afhankelijke 
kinases (CDK) 4 en 6 te remmen en heeft hiermee invloed op de celcyclus. Daarnaast is 
aangetoond dat p16 overexpressie leidt tot een defect in de homologe recombinatie, een 
proces dat dubbelstrengs DNA breuken herstelt. Hierdoor bestaat het vermoeden dat p16 
overexpressie leidt tot een verminderde capaciteit om DNA breuken te herstellen en dit de 
radiogevoeligheid van HPV positieve kankercellen kan verklaren.
Op basis hiervan stelden wij een hypothese op dat door het nabootsen van p16 overexpressie 
met behulp van een CDK4 en -6 remmer, palbociclib, we HPV negatieve cellen gevoeliger 
konden maken voor bestraling (Hoofdstuk 3). We testten een groot panel HPV positieve 
en -negatieve cellijnen en toonden aan dat palbociclib inderdaad alleen HPV negatieve 
cellen gevoeliger maakte voor bestraling. De combinatie van palbociclib en bestraling leidde 
tot een forse toename van ongerepareerde dubbelstrengs DNA breuken, chromosomale 
afwijkingen, en mitotische defecten. Bovendien leidde behandeling met palbociclib tot 
onderdrukking van de BRCA1 en RAD51 genen, welke resulteerde in verminderde effectiviteit 
van homologe recombinatie. Daarnaast bleek de combinatie van palbociclib en bestraling 
ook effectief in hypoxische omstandigheden. Dit benadrukt dat deze combinatie geschikt 
zou kunnen zijn voor de behandeling van HPV negatieve hoofd - halskankers.
Er bestaat een veelvoud aan bewijs dat ook de metabole activiteit van tumoren invloed 
kan hebben op klinische aspecten en de prognose. Wij vermoedden dat metabole 
genexpressie daarnaast ook gerelateerd zou kunnen zijn aan de cellulaire gevoeligheid 
voor bestraling (Hoofdstuk 4). We gebruikten gerichte RNA sequencing om in veertien 
cellijnen vast te stellen wat de genexpressie was van ongeveer 200 metabole genen. Dit 
correleerden we aan de D37, wat een maat is voor hoe gevoelig cellen zijn voor bestraling. 
Achttien genen correleerden met (on)gevoeligheid voor bestraling, waarvan ACLY éen 
van de belangrijkste hits was. Farmacologische remming van ACLY door BMS303141 
zorgde voor onderdrukking van reparatie van dubbelstrengs DNA breuken, welke toe te 
wijden was aan wederom verminderde effectiviteit van homologe recombinatie. In een 
grote online dataset van hoofd - halskanker patiënten toonden we aan dat overexpressie 
van ACLY predictief was voor het succes van radiotherapie met betrekking tot de totale 
levensverwachting. Deze bevinding hebben we daarna bevestigd in een onafhankelijk 
cohort van het Nederlands Kanker Instituut waarin hoofd - halskanker patiënten werden 
behandeld met chemotherapie en radiotherapie. Op cellulair niveau konden we aantonen 
dat patiënten met een slechte locoregionale controle meer nucleair ACLY eiwit bevatten. 
Samengevat bevestigden we dat ACLY invloed heeft op DNA schade reparatie en dat het 
predictief kan zijn voor het succes van radiotherapie als behandeling in hoofd - halskanker.
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Hierna verlegden wij de focus naar HPV positieve cellen. Eerder onderzoek toonde namelijk 
aan dat hypoxie in HPV positieve cellen leidde tot ongevoeligheid voor bestraling. Dit creëert 
een cluster van sluimerende kankercellen die lastig te bereiken zijn met conventionele 
therapie. Op het moment dat normoxie weer intreedt, worden deze cellen weer actief 
en kunnen ze voor tumorgroei zorgen. Eerder werk van ons lab bewees dat deze cellen 
overlevingsprocessen in de vorm van de AKT signaalroute aanzetten wanneer er hypoxie 
optreedt, welke onderdrukt kan worden met de AKT - remmer MK2206. We veronderstelden 
dat HPV positieve cellen dit proces ook toepasten, en dat AKT remming hiervoor een geschikte 
behandeling zou kunnen zijn (Hoofdstuk 5). We bevestigden dat HPV positieve cellijnen 
ongevoeliger voor bestraling werden en AKT activeerden in hypoxische omstandigheden. 
Opvallend genoeg bleken HPV positieve cellen gevoelig voor AKT remming in zowel 
normoxische als hypoxische omstandigheden, en maakte AKT remming ze bovendien 
gevoeliger voor bestraling. Dit suggereert dat AKT remming een interessante en geschikte 
manier zou kunnen zijn om hypoxie - geïnduceerde radioresistentie te overwinnen.
De meeste onderzoeken en experimenten in dit proefschrift zijn uitgevoerd op in vitro 
modellen van hoofd - halskankers. Hoewel in vitro modellen altijd hun tekortkomingen 
zullen blijven houden, hebben we aangetoond dat we met behulp van tientallen cellijnen 
mechanismes van radiogevoeligheid kunnen ontdekken. In Hoofdstuk 6 hebben we een 
uitgebreide karakterisatie van onze cellijnen gedaan, welke als naslagwerk kan dienen voor 
vervolgonderzoek naar verschillende hoofd - halskanker types. We hebben de afkomst van 
de cellijnen samengevat, alsook patiënten achtergrond, anatomische locatie, en cellulaire 
morfologie. Indien mogelijk is ook de genetische identiteit van de cellijnen bevestigd 
met behulp van short - tandem repeat profiling. Daarnaast is er een profiel opgesteld 
van 23 tumor suppressor- en oncogenen. Een groot deel van de cellijnen bevatte een 
pathogene TP53, CDKN2A (coderend voor p16), KIT, of PIK3CA mutatie. We hebben ook 
bevestigd of de cellijnen p16 tot overexpressie brachten en of ze geïnfecteerd waren met 
HPV. Als laatste is ook data van de gevoeligheid voor bestraling en hypoxie toegevoegd. 
Kort samengevat toonden we aan dat de meeste HPV positieve cellijnen ook p16 tot 
overexpressie brachten, maar dat p16 overexpressie niet altijd gepaard ging met HPV 
infectie. In overeenstemming met eerder gepubliceerd onderzoek toonden we aan dat 
TP53 mutaties vrijwel niet voorkomen in HPV positieve cellijnen. In dit hoofdstuk bieden 
we een uitgebreid naslagwerk van hoofd - halskanker cellijnen.
In dit proefschrift heb ik meerdere mechanismen beschreven die hoofd - halskankercellen 
gebruiken om hypoxie en bestraling te overwinnen maar dat deze mechanismen ook een 
kans bieden om ze te exploiteren. Hierin maak ik een onderscheid tussen HPV positieve 






Ruim 4 jaar nadat ik aan mijn promotie begon, schrijf ik nu de laatste woorden van dit 
proefschrift. Omdat dit proefschrift nooit tot stand zou zijn gekomen zonder de hulp van 
anderen, zou ik graag deze laatste pagina’s willen opdragen aan iedereen die mij geholpen 
of bijgestaan heeft afgelopen jaren.
Professor Bussink, beste Jan, jij zorgde ervoor dat we samen nooit uit het oog verloren 
waar het uiteindelijk allemaal om draait: de patiënt. Ik kon altijd putten uit jouw eindeloze 
kennis van klinische trials, radiotherapie en hypoxie.
Professor Hammond, dear Ester, it’s hard to put into words how much of an inspiration you 
have been to me. You’ve taught me the fundamentals of thorough experiment design, the 
molecular biology of hypoxia, and how much fun conferences can be. Thanks for letting 
me be a part of the Hammond lab.
Dr. Span, beste Paul, in 2012 heb jij tijdens mijn allereerste stage mijn interesse voor 
radiobiologie gewekt. Wie had toen gedacht dat we vier jaar later samen aan een 
promotietraject zouden beginnen? Ik wil je graag bedanken voor al je steun en begeleiding. 
Experimenten van voor tot achter doorspreken, urenlange discussies over statistiek of 
ethische dilemma’s, papers schrijven, maar juist ook de flauwe woordgrappen, Star Trek 
vs. Star Wars, en een gezamenlijke voorliefde voor slowcookergerechten. Bedankt dat je 
deur altijd openstond.
Dr. Ansems, beste Marleen, bedankt voor al je advies, goede gesprekken, en discussies 
over de combinatie van immunotherapie met radiotherapie. Menig artikel is een stuk beter 
geworden dankzij je scherpe oog voor detail en grondige analyses.
Alle coauteurs van de artikelen wil ik graag hartelijk bedanken voor de samenwerking en 
hun bijdrage aan dit proefschrift. Een aantal van hen wil ik specifiek hier noemen. Beste 
Corina, bedankt voor je harde werk met de smMIPs en de interpretatie van al die uitslagen. 
Beste William, je barstte altijd van nieuwe ideeën en nam altijd de tijd om moeilijke 
concepten goed uit te leggen. Beste Monique, je dook vol enthousiasme in ons project 
en bracht elke keer weer nieuwe inzichten in hoe we onze analyses konden verbeteren of 
interpreteren. Beste Hans Kaanders, ik heb ontzettend veel van je geleerd over de klinische 
kant van hoofd-halskankers. Bedankt dat je al deze kennis hierover met mij wilde delen.
Dr. Post, beste Annemarie, jij hebt vanaf dag één voor me klaar gestaan toen ik aan mijn 
promotie begon. Maandagochtend samen drie uur lang in de kweek zitten was inmiddels 
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al vaste prik geworden. Niet voor niets waren we al snel de Jut en Jul van het lab. Alleen 
blijft de vraag wie Jut was, en wie Jul. We hebben samen heel wat congressen gezien 
(inclusief champagneontbijt!) en samen prijzen gewonnen. Daarnaast hebben we ook heel 
wat af gekookt, gefietst en gezwommen. Wat is het fijn dat je nu naast mij staat, zoals ik 
naast jou heb mogen staan.
Joost, met jou is er nooit een saai moment! Ik ben inmiddels de tel kwijtgeraakt hoeveel 
weekendjes weg, IG vergaderingen en -diners, en uitstapjes we wel niet gehad hebben. 
Af en toe moesten we elkaar maar weer eens een half jaar missen als er weer één van ons 
in het buitenland zat. Dat mocht de pret niet drukken, want je kwam gewoon langs met 
alle co - co’s. Bedankt voor al die keren slappe lach, bijzondere IG momenten, fantastische 
feestjes en natuurlijk dat je nu mijn paranimf wilt zijn.
Wenny, Renske, Tonke, Katrin, Hans, Jasper, Paul, Fokko, Pieter en alle andere collega’s 
van Radiotherapie, bedankt voor alle mooie momenten afgelopen jaren. We begonnen 
als een relatief klein Radiotherapie lab, maar zijn nu uitgegroeid tot een enorme groep 
Radiotherapie & OncoImmunologie. Bedankt voor al jullie hulp bij experimenten, zonder 
jullie (met name Wenny, Hans, Jasper en Paul) waren er een hoop experimenten minder 
goed afgelopen. Geef Herman maar een knuffel van mij!
My dear Oxonian friends and colleagues Kasia, Sam, Nat, Juan, Athena, Shaliny, Ming, Sarah, 
Ishna, Jen, Joe and a whole other bunch from the OIRO: thanks for making Oxford my 
home away from home. I must have spent about a full month with that cesium irradiator 
in the basement and we’ve worked some crazy hours but it was totally worth it. I have so 
many great memories from that summer: going punting with three labs, that epic BBQ 
party, accidentally breaking doors at conferences and building castles with colony plates. 
Kasia, I would like to specifically mention you and thank you for everything you have taught 
me (managing 500 western blots per week). This little master student has grown up to 
become a PhD student, also thanks to you.
Annelieke en Lieke, al bijna tien jaar vriendinnen door dik en dun. Door jullie ben ik heel 
wat armer geraakt aan de pool- en airhockeytafel. Het Goffertpark onveilig maken, elkaar 
virtueel onderuit schoffelen, Lord of the Rings en Hobbit marathons doen, noem maar op. 
Op naar de volgende tien? Bij voorkeur zonder lekke banden halverwege DTRH.
Lein, jij was mijn allereerste roomie toen ik op mijn 17e in Nijmegen kwam wonen en dat 
heeft Hoogeveldt, en daarna de Vossenlaan, geweten ook. Al die avondjes LUX, Stardust 
kijken, Singstar en metalconcerten zitten nog vers in mijn geheugen. Bedankt dat ik het 




Ilona, Jody, Tim W, Tim S, Gianne, Jordy, Patricia, en alle andere (ex) IGers, ik heb er 
ontzettend van genoten om zo veel jaren samen met jullie in de IG te zitten. Eindeloze 
vergaderingen werden afgewisseld met eindeloze borrels, en de trainingsweekenden 
waren altijd het hoogtepunt van mijn jaar.
Betty, Anne, Daisy en Lieke, we zijn vanaf dag één op de universiteit vriendinnen geweest. 
We hebben met werkgroep 56 heel wat af gestudeerd, maar ook met de hysterische 
heldinnen heel vaak de zon op zien komen. Ondanks dat we inmiddels door heel het land 
verspreid zijn, ben ik er trots op jullie nog steeds als vriendinnen te hebben.
Landgraafjes, Pelzertjes, Inglunder, Notebornsjer, Biezen en alles wat erbij hoort. Het maakt 
niet uit of het in het mooie Zuiden of in de Achterhoek is, het is altijd thuiskomen als ik 
bij jullie ben.
Lieve pap en mam, een paar regels in het eind van mijn proefschrift kunnen bij lange 
na geen recht doen aan hoeveel jullie voor mij betekend hebben afgelopen jaren maar 
toch wil ik een poging wagen. We hebben veel meegemaakt afgelopen jaren en ik heb 
bewondering voor hoe jullie in het leven staan. Bedankt voor jullie onvoorwaardelijke 
steun, liefde, aanmoediging, interesse en kansen die ik dankzij jullie heb gekregen. 
Lieve Lidian, het valt niet te ontkennen dat jij ook hard hebt moeten werken voor dit 
proefschrift. Dan was ik weer avonden bezig met experimenten, weekenden lang artikelen 
aan het schrijven of maanden weg naar Oxford. Ondanks dat alles hebben we natuurlijk 
samen ook de mooie momenten gevierd en steunde je me als het even niet ging zoals 
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In 2016 begon Eva - Leonne een promotietraject bij het Radiotherapy and OncoImmunology 
Laboratory van het Radboudumc. Tijdens dit traject werd zij begeleid door prof. Jan 
Bussink, prof. Ester Hammond, dr. Paul Span en dr. Marleen Ansems. Ze volgde verschillende 
cursussen op het gebied van microscopie en presentatievaardigheden, begeleidde 
drie bachelor- en masterstudenten en droeg bij aan het geven van onderwijs aan 
geneeskundestudenten. Ook bezocht ze in totaal acht (inter)nationale congressen waar 
ze haar onderzoek presenteerde. Gedurende deze periode heeft zij diverse reisbeurzen, 
beste sprekersprijzen, en een ‘Young Investigator award’ gewonnen. De resultaten van 
haar werk zijn verzameld in dit proefschrift, waarvan vijf hoofdstukken gepubliceerd zijn 
in verschillende wetenschappelijke tijdschriften.
Op dit moment is Eva - Leonne werkzaam als klinisch chemicus in opleiding bij het Amphia 
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b) Seminars & Lectures
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- RIMLS seminars
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c) (Inter)national Symposia & Congresses
- Radboud Science Day
- 42nd Conference of the European Radiation Research Society#
- 9th EORTC Pathobiology group meeting*
- New frontiers symposium
- 15th International Wolfsberg meeting on Molecular Radiation 
Biology/Oncology#
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- Annual Association for Radiation Research Meeting#
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- Journal clubs department of Radiation Oncology*
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The primary data generated between 2016 and 2017 have been recorded in a digital 
lab book, which is backed up using a WD Elements Time Machine hard disk drive at 
the department of Radiation Oncology at the Radboud university medical center. 
Data generated after 2017 are stored on LabGuru in English, and in native file formats 
(FlowJo, Excel, SPSS, Graphpad Prism, etc). The use of widely used software contribute 
to Intraoperability and Reusability. LabGuru is a certified digital lab book client which is 
centrally stored and daily backed - up on the local Radboudumc server, and is accessible via 
any internet browser. All experiments and associated results are given unique identifiers, 
and include references to standard operating procedures (also in English) and materials 
used, ensuring Findability and Accessibility. The data files on Labguru and the local server 
are accessible by the specific researchers and associated scientific staff members only. 
The data in Chapters 2, 3, 4, and 5 in this thesis are part of published articles and its 
supplementary files are available at request from Paul Span, PhD, at the department of 
Radiation Oncology of the Radboud university medical center.

